Columns: General -- Sales -- Acquisition -- WAC
| OSHPD ID | Manufacturer Name | Date Reported | Description | NDC Number | Drug Intro to Market | Patent Expire | Drug Source Type | Supporting Documents | General Comments |
|---|---|---|---|---|---|---|---|---|---|
| Rx0000077 | AbbVie | 04/29/2024 | CREON 12000USP DELAYED-RELEASE 100CAP | 00032121201 | 02/07/2030 | Single Source Drug | |||
| Rx0000077 | AbbVie | 04/29/2024 | CREON 12000USP DELAYED-RELEASE 250CAP | 00032121207 | 02/07/2030 | Single Source Drug | |||
| Rx0000077 | AbbVie | 04/29/2024 | CREON 24000USP DELAYED-RELEASE 100CAP | 00032122401 | 02/07/2030 | Single Source Drug | |||
| Rx0000077 | AbbVie | 04/29/2024 | CREON 24000USP DELAYED-RELEASE 250CAP | 00032122407 | 02/07/2030 | Single Source Drug | |||
| Rx0000077 | AbbVie | 04/29/2024 | CREON 3000USP DELAYED-RELEASE 70CAP | 00032120370 | 02/07/2030 | Single Source Drug | |||
| Rx0000077 | AbbVie | 04/29/2024 | CREON 36000USP DELAYED-RELEASE 100CAP | 00032301613 | 02/07/2030 | Single Source Drug | |||
| Rx0000077 | AbbVie | 04/29/2024 | CREON 36000USP DELAYED-RELEASE 250CAP | 00032301628 | 02/07/2030 | Single Source Drug | |||
| Rx0000077 | AbbVie | 04/29/2024 | CREON 6000USP DELAYED-RELEASE 100CAP | 00032120601 | 02/07/2030 | Single Source Drug | |||
| Rx0000077 | AbbVie | 04/29/2024 | IMBRUVICA 140 mg Capsules, 120-count | 57962014012 | 04/24/2035 | Single Source Drug | |||
| Rx0000077 | AbbVie | 04/29/2024 | IMBRUVICA 140 mg Tablets, 28-count | 57962001428 | 09/03/2036 | Single Source Drug | |||
| Rx0000077 | AbbVie | 04/29/2024 | IMBRUVICA 280 mg Tablets, 28-count | 57962028028 | 09/03/2036 | Single Source Drug | |||
| Rx0000077 | AbbVie | 04/29/2024 | IMBRUVICA 420 mg Tablets, 28-count | 57962042028 | 09/03/2036 | Single Source Drug | |||
| Rx0000077 | AbbVie | 04/29/2024 | IMBRUVICA 70 mg Capsules, 28-count | 57962007028 | 04/24/2035 | Single Source Drug | |||
| Rx0000077 | AbbVie | 04/29/2024 | IMBRUVICA140 mg Capsules, 90-count | 57962014009 | 04/24/2035 | Single Source Drug | |||
| Rx0000077 | AbbVie | 04/29/2024 | ORIAHNN CAPSULES 300MG/1MG/0.5MG; 4x14 | 00074101756 | 08/27/2040 | Single Source Drug | |||
| Rx0000077 | AbbVie | 04/29/2024 | ORILISSA 150MG TABS, 4X7 PACK | 00074003828 | 08/27/2040 | Single Source Drug | |||
| Rx0000077 | AbbVie | 04/29/2024 | ORILISSA 200MG TABS, 4X14 PACK | 00074003956 | 08/27/2040 | Single Source Drug | |||
| Rx0000077 | AbbVie | 04/29/2024 | RINVOQ 15MG 30 DAY BOTTLE | 00074230630 | 03/09/2038 | Single Source Drug | |||
| Rx0000077 | AbbVie | 04/29/2024 | SKYRIZI INJ 150MG/ML SINGLE-DOSE PEN | 00074210001 | 02/04/2034 | Single Source Drug | |||
| Rx0000077 | AbbVie | 04/29/2024 | SKYRIZI INJ 150MG/ML SINGLE-DOSE PREFILLED SYRINGE | 00074105001 | 02/04/2034 | Single Source Drug | |||
| Rx0000077 | AbbVie | 04/29/2024 | VENCLEXTA 100MG BOTTLE 180 TABLETS | 00074057634 | 09/06/2033 | Single Source Drug | |||
| Rx0000077 | AbbVie | 10/29/2024 | VENCLEXTA 100MG BOTTLE 180 TABLETS | 00074057634 | 09/06/2033 | Single Source Drug | |||
| Rx0000077 | AbbVie | 04/29/2024 | VENCLEXTA 100MG BOTTLE, 120 TABLETS | 00074057622 | 09/06/2033 | Single Source Drug | |||
| Rx0000077 | AbbVie | 10/29/2024 | VENCLEXTA 100MG BOTTLE, 120 TABLETS | 00074057622 | 09/06/2033 | Single Source Drug | |||
| Rx0000077 | AbbVie | 04/29/2024 | VENCLEXTA 100MG UNIT DOSE, 1 TABLET | 00074057611 | 09/06/2033 | Single Source Drug | |||
| Rx0000077 | AbbVie | 10/29/2024 | VENCLEXTA 100MG UNIT DOSE, 1 TABLET | 00074057611 | 09/06/2033 | Single Source Drug | |||
| Rx0000077 | AbbVie | 04/29/2024 | VENCLEXTA 10MG UNIT DOSE, 2 TABLETS | 00074056111 | 09/06/2033 | Single Source Drug | |||
| Rx0000077 | AbbVie | 10/29/2024 | VENCLEXTA 10MG UNIT DOSE, 2 TABLETS | 00074056111 | 09/06/2033 | Single Source Drug | |||
| Rx0000077 | AbbVie | 04/29/2024 | VENCLEXTA 10MG WALLET, 2 TABLETS X 7 | 00074056114 | 09/06/2033 | Single Source Drug | |||
| Rx0000077 | AbbVie | 10/29/2024 | VENCLEXTA 10MG WALLET, 2 TABLETS X 7 | 00074056114 | 09/06/2033 | Single Source Drug | |||
| Rx0000077 | AbbVie | 04/29/2024 | VENCLEXTA 50MG UNIT DOSE, 1 TABLET | 00074056611 | 09/06/2033 | Single Source Drug | |||
| Rx0000077 | AbbVie | 10/29/2024 | VENCLEXTA 50MG UNIT DOSE, 1 TABLET | 00074056611 | 09/06/2033 | Single Source Drug | |||
| Rx0000077 | AbbVie | 04/29/2024 | VENCLEXTA 50MG WALLET, 1 TABLET X 7 | 00074056607 | 09/06/2033 | Single Source Drug | |||
| Rx0000077 | AbbVie | 10/29/2024 | VENCLEXTA 50MG WALLET, 1 TABLET X 7 | 00074056607 | 09/06/2033 | Single Source Drug | |||
| Rx0000077 | AbbVie | 04/29/2024 | VENCLEXTA START PACK, 4X7 DAY WALLET | 00074057928 | 09/06/2033 | Single Source Drug | |||
| Rx0000077 | AbbVie | 10/29/2024 | VENCLEXTA START PACK, 4X7 DAY WALLET | 00074057928 | 09/06/2033 | Single Source Drug | |||
| Rx0000021 | Acorda Therapeutics, Inc. | 04/05/2024 | Ampyra Oral Tablet Extended Release 12 Hour 10 MG Package Size 60 - 1 Bottle | 10144042760 | Innovator Multiple Source Drug | ||||
| Rx0000021 | Acorda Therapeutics, Inc. | 04/05/2024 | Inbrija Inhalation Capsule 42 MG Package Size 60 - 1 Box | 10144034260 | 11/16/2032 | Single Source Drug | |||
| Rx0000251 | Actelion Pharmaceuticals US, Inc | 04/26/2024 | OPSUMIT® (macitentan)Strength:10 mg Package Size:15 Form:Tablet | 66215050115 | 04/18/2029 | Single Source Drug | Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 15, 2024. | ||
| Rx0000251 | Actelion Pharmaceuticals US, Inc | 04/26/2024 | OPSUMIT® (macitentan)Strength:10 mg Package Size:30 Form:Tablet | 66215050130 | 04/18/2029 | Single Source Drug | Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 15, 2024. | ||
| Rx0000251 | Actelion Pharmaceuticals US, Inc | 04/26/2024 | UPTRAVI® (selexipag) Strength:1000 mcg Package Size:60 Form:Tablet | 66215061006 | 12/01/2036 | Innovator Multiple Source Drug | Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 15, 2024. | ||
| Rx0000251 | Actelion Pharmaceuticals US, Inc | 04/26/2024 | UPTRAVI® (selexipag) Strength:1200 mcg Package Size:60 Form:Tablet | 66215061206 | 12/01/2036 | Innovator Multiple Source Drug | Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 15, 2024. | ||
| Rx0000251 | Actelion Pharmaceuticals US, Inc | 04/26/2024 | UPTRAVI® (selexipag) Strength:1400 mcg Package Size:60 Form:Tablet | 66215061406 | 12/01/2036 | Innovator Multiple Source Drug | Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 15, 2024. | ||
| Rx0000251 | Actelion Pharmaceuticals US, Inc | 04/26/2024 | UPTRAVI® (selexipag) Strength:1600 mcg Package Size:60 Form:Tablet | 66215061606 | 12/01/2036 | Innovator Multiple Source Drug | Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 15, 2024. | ||
| Rx0000251 | Actelion Pharmaceuticals US, Inc | 04/26/2024 | UPTRAVI® (selexipag) Strength:1800mcg Package Size:1 Form:Vial | 66215071801 | 08/01/2030 | Single Source Drug | Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 15, 2024. | ||
| Rx0000251 | Actelion Pharmaceuticals US, Inc | 04/26/2024 | UPTRAVI® (selexipag) Strength:200 mcg Package Size:140 Form:Tablet | 66215060214 | 12/01/2036 | Innovator Multiple Source Drug | Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 15, 2024. | ||
| Rx0000251 | Actelion Pharmaceuticals US, Inc | 04/26/2024 | UPTRAVI® (selexipag) Strength:200 mcg Package Size:60 Form:Tablet | 66215060206 | 12/01/2036 | Innovator Multiple Source Drug | Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 15, 2024. | ||
| Rx0000251 | Actelion Pharmaceuticals US, Inc | 04/26/2024 | UPTRAVI® (selexipag) Strength:200+800 mcg Package Size:200 Form:Tablet | 66215062820 | 12/01/2036 | Innovator Multiple Source Drug | Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 15, 2024. | ||
| Rx0000251 | Actelion Pharmaceuticals US, Inc | 04/26/2024 | UPTRAVI® (selexipag) Strength:400 mcg Package Size:60 Form:Tablet | 66215060406 | 12/01/2036 | Innovator Multiple Source Drug | Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 15, 2024. | ||
| Rx0000251 | Actelion Pharmaceuticals US, Inc | 04/26/2024 | UPTRAVI® (selexipag) Strength:600 mcg Package Size:60 Form:Tablet | 66215060606 | 12/01/2036 | Innovator Multiple Source Drug | Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 15, 2024. | ||
| Rx0000251 | Actelion Pharmaceuticals US, Inc | 04/26/2024 | UPTRAVI® (selexipag) Strength:800 mcg Package Size:60 Form:Tablet | 66215060806 | 12/01/2036 | Innovator Multiple Source Drug | Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 15, 2024. | ||
| Rx0000222 | Aimmune Therapeutics | 07/24/2024 | PALFORZIA - Capsule - 100mg - 2 Capsules per blister pack - 30 capsules per blister pack | 71881010930 | 03/12/2034 | Single Source Drug | |||
| Rx0000222 | Aimmune Therapeutics | 07/24/2024 | PALFORZIA - Capsule - 1mg - 3 Capsules per blister pack - 45 capsules per blister pack | 71881010145 | 03/12/2034 | Single Source Drug | |||
| Rx0000222 | Aimmune Therapeutics | 07/24/2024 | PALFORZIA - Capsule - 1mg - 6 Capsules per blister pack - 90 capsules per blister pack | 71881010290 | 03/12/2034 | Single Source Drug | |||
| Rx0000222 | Aimmune Therapeutics | 07/24/2024 | PALFORZIA - Capsule - 1mg-3 & 10mg-1 Capsules per blister pack - 45 capsules per blister pack | 71881010345 | 03/12/2034 | Single Source Drug | |||
| Rx0000222 | Aimmune Therapeutics | 07/24/2024 | PALFORZIA - Capsule - 20mg - 1 Capsule per blister pack - 15 capsules per blister pack | 71881010415 | 03/12/2034 | Single Source Drug | |||
| Rx0000222 | Aimmune Therapeutics | 07/24/2024 | PALFORZIA - Capsule - 20mg - 2 Capsules per blister pack - 30 capsules per blister pack | 71881010530 | 03/12/2034 | Single Source Drug | |||
| Rx0000222 | Aimmune Therapeutics | 07/24/2024 | PALFORZIA - Capsule - 20mg - 4 Capsules per blister pack - 60 capsules per blister pack | 71881010660 | 03/12/2034 | Single Source Drug | |||
| Rx0000222 | Aimmune Therapeutics | 07/24/2024 | PALFORZIA - Capsule - 20mg-1 & 100mg - 1 Capsules per blister pack - 30 capsules per blister pack | 71881010730 | 03/12/2034 | Single Source Drug | |||
| Rx0000222 | Aimmune Therapeutics | 07/24/2024 | PALFORZIA - Capsule - 20mg-2 & 100mg - 2 Capsules per blister pack - 60 capsules per blister pack | 71881011060 | 03/12/2034 | Single Source Drug | |||
| Rx0000222 | Aimmune Therapeutics | 07/24/2024 | PALFORZIA - Capsule - 20mg-3 & 100mg - 1 Capsules per blister pack - 60 capsules per blister pack | 71881010860 | 03/12/2034 | Single Source Drug | |||
| Rx0000222 | Aimmune Therapeutics | 07/24/2024 | PALFORZIA - Sachet - 300mg - 15 Sachet | 71881011115 | 03/12/2034 | Single Source Drug | |||
| Rx0000222 | Aimmune Therapeutics | 07/24/2024 | PALFORZIA - Sachet - 300mg - 30 Sachet | 71881011130 | 03/12/2034 | Single Source Drug | |||
| Rx0000400 | AkaRx, Inc., a Sobi Company | 04/12/2024 | DOPTELET, 1 BLISTER PACK in 1 CARTON > 10 TABLET, EQ 20MG BASE | 71369002010 | 07/28/2027 | Single Source Drug | |||
| Rx0000400 | AkaRx, Inc., a Sobi Company | 04/12/2024 | DOPTELET, 1 BLISTER PACK in 1 CARTON > 15 TABLET, EQ 20MG BASE | 71369002015 | 07/28/2027 | Single Source Drug | |||
| Rx0000400 | AkaRx, Inc., a Sobi Company | 04/12/2024 | DOPTELET, 2 BLISTER PACK in 1 CARTON / 15 TABLET, FILM COATED in 1 BLISTER PACK, EQ 20MG BASE | 71369002030 | 07/28/2027 | Single Source Drug | |||
| Rx0000417 | Akebia Therapeutics, Inc. | 03/31/2024 | Auryxia (Ferric Citrate) 210 mg, 200 Tablets per Bottle | 59922063101 | 12/21/2030 | Single Source Drug | |||
| Rx0000246 | Alcon Laboratories Inc | 04/30/2024 | Alcaine Ophthalmic Solution 0.5 % 15ml per package | 00998001615 | Non-innovator Multiple Source Drug | Please note, the WAC reflected in these reports is the course of therapy WAC for all products. The full WAC of the product is reflected in MediSpan | |||
| Rx0000246 | Alcon Laboratories Inc | 04/30/2024 | BSS Plus Intraocular Solution 500ml per package, Flex cont | 00065080094 | Single Source Drug | Please note, the WAC reflected in these reports is the course of therapy WAC for all products. The full WAC of the product is reflected in MediSpan | |||
| Rx0000246 | Alcon Laboratories Inc | 04/30/2024 | BSS Plus Intraocular Solution 500ml per package, Flex cont | 00065080094 | Single Source Drug | Please note, the WAC reflected in these reports is the course of therapy WAC for all products. The full WAC of the product is reflected in MediSpan | |||
| Rx0000246 | Alcon Laboratories Inc | 04/30/2024 | BSS Plus Intraocular Solution 500ml per package, Glass Cont | 00065080050 | Single Source Drug | Please note, the WAC reflected in these reports is the course of therapy WAC for all products. The full WAC of the product is reflected in MediSpan | |||
| Rx0000246 | Alcon Laboratories Inc | 04/30/2024 | BSS Plus Intraocular Solution 500ml per package, Glass Cont | 00065080050 | Single Source Drug | Please note, the WAC reflected in these reports is the course of therapy WAC for all products. The full WAC of the product is reflected in MediSpan | |||
| Rx0000246 | Alcon Laboratories Inc | 04/30/2024 | Cyclogyl Ophthalmic Solution 0.5 % 15ml per package | 00065039515 | Non-innovator Multiple Source Drug | Please note, the WAC reflected in these reports is the course of therapy WAC for all products. The full WAC of the product is reflected in MediSpan | |||
| Rx0000246 | Alcon Laboratories Inc | 04/30/2024 | Cyclogyl Ophthalmic Solution 1 % 5ml per package | 00065039605 | Non-innovator Multiple Source Drug | Please note, the WAC reflected in these reports is the course of therapy WAC for all products. The full WAC of the product is reflected in MediSpan | |||
| Rx0000246 | Alcon Laboratories Inc | 04/30/2024 | Cyclogyl Ophthalmic Solution 2 % 15ml per package | 00065039715 | Non-innovator Multiple Source Drug | Please note, the WAC reflected in these reports is the course of therapy WAC for all products. The full WAC of the product is reflected in MediSpan | |||
| Rx0000246 | Alcon Laboratories Inc | 04/30/2024 | Cyclogyl Ophthalmic Solution 2 % 2ml per package | 00065039702 | Non-innovator Multiple Source Drug | Please note, the WAC reflected in these reports is the course of therapy WAC for all products. The full WAC of the product is reflected in MediSpan | |||
| Rx0000246 | Alcon Laboratories Inc | 04/30/2024 | Cyclogyl Ophthalmic Solution 2 % 5ml per package | 00065039705 | Non-innovator Multiple Source Drug | Please note, the WAC reflected in these reports is the course of therapy WAC for all products. The full WAC of the product is reflected in MediSpan | |||
| Rx0000246 | Alcon Laboratories Inc | 04/30/2024 | Cyclomydril Ophthalmic Solution 0.2-1 % 5ml per package | 00065035905 | Non-innovator Multiple Source Drug | Please note, the WAC reflected in these reports is the course of therapy WAC for all products. The full WAC of the product is reflected in MediSpan | |||
| Rx0000246 | Alcon Laboratories Inc | 04/30/2024 | Isopto Atropine Ophthalmic Solution 1 % 5ml per package | 00065030355 | Non-innovator Multiple Source Drug | Please note, the WAC reflected in these reports is the course of therapy WAC for all products. The full WAC of the product is reflected in MediSpan | |||
| Rx0000246 | Alcon Laboratories Inc | 04/30/2024 | Miostat Intraocular Solution 0.01 % 12 vials per package | 00065002315 | Single Source Drug | Please note, the WAC reflected in these reports is the course of therapy WAC for all products. The full WAC of the product is reflected in MediSpan | |||
| Rx0000246 | Alcon Laboratories Inc | 04/30/2024 | Mydriacyl Ophthalmic Solution 1 % 15ml per package | 00998035515 | Non-innovator Multiple Source Drug | Please note, the WAC reflected in these reports is the course of therapy WAC for all products. The full WAC of the product is reflected in MediSpan | |||
| Rx0000272 | Alexion Pharmaceuticals | 04/30/2024 | CAPSULE 10MG 28 COUNT | 00310061028 | 03/26/2029 | Single Source Drug | |||
| Rx0000272 | Alexion Pharmaceuticals | 04/30/2024 | CAPSULE 10MG 60 COUNT | 00310061060 | 03/26/2029 | Single Source Drug | |||
| Rx0000272 | Alexion Pharmaceuticals | 04/30/2024 | CAPSULE 25MG 28 COUNT | 00310062528 | 03/26/2029 | Single Source Drug | |||
| Rx0000272 | Alexion Pharmaceuticals | 04/30/2024 | CAPSULE 25MG 60 COUNT | 00310062560 | 03/26/2029 | Single Source Drug | |||
| Rx0000459 | AltaThera Pharmaceuticals LLC | 03/31/2024 | Sotalol hydrochloride - Injection: 10-mL vial containing sotalol hydrochloride 150 mg | 69724011210 | 04/05/2039 | Single Source Drug | At AltaThera, we are committed to upholding the highest standards of confidentiality and integrity. We want to emphasize that information related to our unit sales volume and cost increase factors is deemed nonpublic and proprietary. This includes, but is not limited to, detailed sales figures, production costs, and any associated sensitive data. We strictly prohibit the disclosure of such information to external parties without explicit authorization. This commitment is integral to maintaining a competitive edge in the market and safeguarding our business interests. | ||
| Rx0000436 | Amdipharm Limited | 07/25/2024 | Alfuzosin HCl Tab ER 24HR 10 MG, 100 Each, Bottle | 59212020010 | Innovator Multiple Source Drug | ||||
| Rx0000436 | Amdipharm Limited | 07/25/2024 | Alitretinoin Gel 0.1%, 60 GM, Unit-of-Use, Tube | 59212060122 | Innovator Multiple Source Drug | ||||
| Rx0000436 | Amdipharm Limited | 07/25/2024 | Digoxin Tab 125 MCG (0.125 MG), 100 Each, Bottle | 59212024255 | Innovator Multiple Source Drug | ||||
| Rx0000436 | Amdipharm Limited | 07/25/2024 | Digoxin Tab 125 MCG (0.125 MG), 100 Each, Unit-Dose, Box | 59212024256 | Innovator Multiple Source Drug | ||||
| Rx0000436 | Amdipharm Limited | 07/25/2024 | Digoxin Tab 250 MCG (0.25 MG), 100 Each, Bottle | 59212024955 | Innovator Multiple Source Drug | ||||
| Rx0000436 | Amdipharm Limited | 07/25/2024 | Digoxin Tab 62.5 MCG (0.0625 MG), 100 Each, Bottle | 59212024055 | Innovator Multiple Source Drug | ||||
| Rx0000436 | Amdipharm Limited | 07/25/2024 | Donnatal Oral Elixir 16.2 MG/5ML 16.2-0.1037-0.0194-0.0065 MG/5ML, 480 ML, Bottle | 59212042316 | Innovator Multiple Source Drug | ||||
| Rx0000436 | Amdipharm Limited | 07/25/2024 | Donnatal Oral Elixir 16.2 MG/5ML PB-Hyoscy-Atrop-Scopol Elix 16.2-0.1037-0.0194-0.0065 MG/5ML, 120 ML, Bottle | 59212042304 | Innovator Multiple Source Drug | ||||
| Rx0000436 | Amdipharm Limited | 07/25/2024 | PB-Hyoscy-Atrop-Scopol Elix 16.2-0.1037-0.0194-0.0065 MG/5ML, 120 ML, Bottle | 59212042204 | Innovator Multiple Source Drug | ||||
| Rx0000436 | Amdipharm Limited | 07/25/2024 | PB-Hyoscy-Atrop-Scopol Elix 16.2-0.1037-0.0194-0.0065 MG/5ML, 480 ML, Bottle | 59212042216 | Innovator Multiple Source Drug | ||||
| Rx0000436 | Amdipharm Limited | 07/25/2024 | PB-Hyoscy-Atrop-Scopol Tab 16.2-0.1037-0.0194-0.0065 MG, 100 Each, Bottle | 59212042510 | Innovator Multiple Source Drug | ||||
| Rx0000436 | Amdipharm Limited | 07/25/2024 | Prednisolone Sod Phos Orally Disintegr Tab 10 MG (Base Eq), 12 Each, Unit-Dose, Box | 59212070012 | Innovator Multiple Source Drug | ||||
| Rx0000436 | Amdipharm Limited | 07/25/2024 | Prednisolone Sod Phos Orally Disintegr Tab 15 MG (Base Eq), 12 Each, Unit-Dose, Box | 59212070112 | Innovator Multiple Source Drug | ||||
| Rx0000436 | Amdipharm Limited | 07/25/2024 | Prednisolone Sod Phos Orally Disintegr Tab 30 MG (Base Eq), 12 Each, Unit-Dose, Box | 59212070212 | Innovator Multiple Source Drug | ||||
| Rx0000436 | Amdipharm Limited | 07/25/2024 | Tranylcypromine Sulfate Tab 10 MG, 100 Each, Bottle | 59212044710 | Innovator Multiple Source Drug | ||||
| Rx0000436 | Amdipharm Limited | 07/25/2024 | Triamterene Cap 100 MG, 100 Each, Bottle | 59212000301 | Innovator Multiple Source Drug | ||||
| Rx0000436 | Amdipharm Limited | 07/25/2024 | Triamterene Cap 50 MG, 100 Each, Bottle | 59212000201 | Innovator Multiple Source Drug | ||||
| Rx0000436 | Amdipharm Limited | 07/25/2024 | Zonisamide Cap 100 MG, 100 Each, Bottle | 59212068010 | Innovator Multiple Source Drug | ||||
| Rx0000436 | Amdipharm Limited | 07/25/2024 | Zonisamide Cap 25 MG, 100 Each, Bottle | 59212068110 | Innovator Multiple Source Drug | ||||
| Rx0000231 | American Health Packaging | 05/10/2024 | DOXYCYCLINE TABLET 100MG 30UD | 60687034425 | Non-innovator Multiple Source Drug | ||||
| Rx0000231 | American Health Packaging | 05/10/2024 | MESALAMINE DR CAP 400MG 20UD | 60687055632 | Non-innovator Multiple Source Drug | ||||
| Rx0000231 | American Health Packaging | 06/17/2024 | METHYLPHENIDATE HCL TABLET CII 5MG 30UD | 68084080521 | Non-innovator Multiple Source Drug | ||||
| Rx0000231 | American Health Packaging | 05/10/2024 | RIFAMPIN CAPS 150MG 30UD | 60687057521 | Non-innovator Multiple Source Drug | ||||
| Rx0000231 | American Health Packaging | 05/10/2024 | RIFAMPIN CAPSULE 300MG 100UD | 60687058601 | Non-innovator Multiple Source Drug | ||||
| Rx0000128 | American Regent | 04/18/2024 | ACETYLCYSTEINE SOLUTION 10%, 4ML, PKG OF 25 | 00517750425 | Non-innovator Multiple Source Drug | ||||
| Rx0000128 | American Regent | 10/15/2024 | ACETYLCYSTEINE SOLUTION 10%, 4ML, PKG OF 25 | 00517750425 | Non-innovator Multiple Source Drug | ||||
| Rx0000128 | American Regent | 04/02/2024 | Caffeine & Sodium Benzoate, 250mg/ml 2mL SDV, 10pk | 00517250210 | Non-innovator Multiple Source Drug | ||||
| Rx0000128 | American Regent | 10/15/2024 | Caffeine & Sodium Benzoate, 250mg/ml 2mL SDV, 10pk | 00517250210 | Non-innovator Multiple Source Drug | ||||
| Rx0000128 | American Regent | 10/15/2024 | Drug Product Description HYDROXYZINE HCL, 50MG/ML, 1ML SDV, PKG. OF 25 | 00517560125 | Non-innovator Multiple Source Drug | ||||
| Rx0000128 | American Regent | 04/18/2024 | HYDROXYZINE HCL, 25MG/ML, 1ML SDV, PKG. OF 25 | 00517420125 | Non-innovator Multiple Source Drug | ||||
| Rx0000128 | American Regent | 10/15/2024 | HYDROXYZINE HCL, 25MG/ML, 1ML SDV, PKG. OF 25 | 00517420125 | Non-innovator Multiple Source Drug | ||||
| Rx0000128 | American Regent | 04/18/2024 | HYDROXYZINE HCL, 50MG/ML, 1ML SDV, PKG. OF 25 | 00517560125 | Non-innovator Multiple Source Drug | ||||
| Rx0000128 | American Regent | 10/15/2024 | Injectafer Intravenous Solution 750 MG/15ML | 00517065001 | 02/15/2028 | Single Source Drug | Injectafer is not an acquired product. The licensor has granted American Regent the right to develop, manufacture, distribute and sell the product in the United States. American Regent is the NDA holder of this NDC but markets the drug through our parent company, Daiichi Sankyo, Inc. | ||
| Rx0000128 | American Regent | 10/15/2024 | MULTRYS (TRACE ELEMENTS INJECTION 4, USP, PKG. OF 25 | 00517930225 | 07/01/2041 | Single Source Drug | |||
| Rx0000128 | American Regent | 10/15/2024 | Tralement (TRACE ELEMENTS INJECTION 4, USP, PKG. OF 25 | 00517930525 | 07/01/2041 | Single Source Drug | |||
| Rx0000069 | Amgen | 04/30/2024 | Aimovig, 140 mg/mL single-dose prefilled SureClick autoinjector | 55513084301 | 04/01/2039 | Single Source Drug | Total Volume of Gross Sales and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Aimovig reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. | ||
| Rx0000069 | Amgen | 04/30/2024 | Aimovig, 70 mg/mL single-dose prefilled SureClick autoinjector | 55513084101 | 04/01/2039 | Single Source Drug | Total Volume of Gross Sales and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Aimovig reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. | ||
| Rx0000069 | Amgen | 04/30/2024 | Blincyto, 35 mcg lyophilized vial, 1 pk | 55513016001 | 04/06/2030 | Single Source Drug | Total Volume of Gross Sales and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Blincyto reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. | ||
| Rx0000069 | Amgen | 04/30/2024 | Corlanor, 5mg oral solution AMP, 28 pk | 55513081328 | Single Source Drug | Total Volume of Gross Sales and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. | |||
| Rx0000069 | Amgen | 04/30/2024 | Corlanor, 5mg tablet, 60 pk | 55513080060 | 06/12/2027 | Single Source Drug | Total Volume of Gross Sales and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Corlanor reflects the date for the latest-expiring patents publicly disclosed in the Orange Book for the approved product, including any pediatric exclusivities. | ||
| Rx0000069 | Amgen | 04/30/2024 | Corlanor, 7.5mg tablet, 60 pk | 55513081060 | 06/12/2027 | Single Source Drug | Total Volume of Gross Sales and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Corlanor reflects the date for the latest-expiring patents publicly disclosed in the Orange Book for the approved product, including any pediatric exclusivities. | ||
| Rx0000069 | Amgen | 04/30/2024 | Enbrel Mini, 50mg/mL, Cartridge (ML), 1 pack | 58406004401 | 10/19/2037 | Single Source Drug | Total Volume of Gross Sales and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. | ||
| Rx0000069 | Amgen | 09/20/2024 | Enbrel Mini, 50mg/mL, Cartridge (ML), 1 pack | 58406004401 | 10/19/2037 | Single Source Drug | Total Volume of Gross Sales and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. Patent Expiration Date: The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. | ||
| Rx0000069 | Amgen | 04/30/2024 | Enbrel Mini, 50mg/mL, Cartridge (ML), 4 pack | 58406004404 | 10/19/2037 | Single Source Drug | Total Volume of Gross Sales and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. | ||
| Rx0000069 | Amgen | 09/20/2024 | Enbrel Mini, 50mg/mL, Cartridge (ML), 4 pack | 58406004404 | 10/19/2037 | Single Source Drug | Total Volume of Gross Sales and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. Patent Expiration Date: The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. | ||
| Rx0000069 | Amgen | 04/30/2024 | Enbrel Sureclick, 50mg/mL, Pen Injector (ML), 1 pack | 58406003201 | 10/19/2037 | Single Source Drug | Total Volume of Gross Sales and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. | ||
| Rx0000069 | Amgen | 09/20/2024 | Enbrel Sureclick, 50mg/mL, Pen Injector (ML), 1 pack | 58406003201 | 10/19/2037 | Single Source Drug | Total Volume of Gross Sales and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. Patent Expiration Date: The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. | ||
| Rx0000069 | Amgen | 04/30/2024 | Enbrel Sureclick, 50mg/mL, Pen Injector (ML), 4 pack | 58406003204 | 10/19/2037 | Single Source Drug | Total Volume of Gross Sales and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. | ||
| Rx0000069 | Amgen | 09/20/2024 | Enbrel Sureclick, 50mg/mL, Pen Injector (ML), 4 pack | 58406003204 | 10/19/2037 | Single Source Drug | Total Volume of Gross Sales and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. Patent Expiration Date: The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. | ||
| Rx0000069 | Amgen | 04/30/2024 | Enbrel, 25mg (1 mL), Vial (EA), 4 pack | 58406042534 | 10/19/2037 | Single Source Drug | Total Volume of Gross Sales and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. | ||
| Rx0000069 | Amgen | 04/30/2024 | Enbrel, 25mg (1mL), Vial (EA), 1 pack | 58406042541 | 10/19/2037 | Single Source Drug | Total Volume of Gross Sales and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. | ||
| Rx0000069 | Amgen | 04/30/2024 | Enbrel, 25mg/0.5mL, Syringe (ML), 1 pack | 58406001001 | 10/19/2037 | Single Source Drug | Total Volume of Gross Sales and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. | ||
| Rx0000069 | Amgen | 09/20/2024 | Enbrel, 25mg/0.5mL, Syringe (ML), 1 pack | 58406001001 | 10/19/2037 | Single Source Drug | Total Volume of Gross Sales and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. Patent Expiration Date: The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. | ||
| Rx0000069 | Amgen | 04/30/2024 | Enbrel, 25mg/0.5mL, Syringe (ML), 4 pack | 58406001004 | 10/19/2037 | Single Source Drug | Total Volume of Gross Sales and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. | ||
| Rx0000069 | Amgen | 09/20/2024 | Enbrel, 25mg/0.5mL, Syringe (ML), 4 pack | 58406001004 | 10/19/2037 | Single Source Drug | Total Volume of Gross Sales and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. Patent Expiration Date: The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. | ||
| Rx0000069 | Amgen | 04/30/2024 | Enbrel, 25mg/0.5mL, Vial (EA), 1 pack | 58406005501 | 10/19/2037 | Single Source Drug | Total Volume of Gross Sales and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. | ||
| Rx0000069 | Amgen | 09/20/2024 | Enbrel, 25mg/0.5mL, Vial (EA), 1 pack | 58406005501 | 10/19/2037 | Single Source Drug | Total Volume of Gross Sales and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. Patent Expiration Date: The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. | ||
| Rx0000069 | Amgen | 04/30/2024 | Enbrel, 25mg/0.5mL, Vial (EA), 4 pack | 58406005504 | 10/19/2037 | Single Source Drug | Total Volume of Gross Sales and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. | ||
| Rx0000069 | Amgen | 09/20/2024 | Enbrel, 25mg/0.5mL, Vial (EA), 4 pack | 58406005504 | 10/19/2037 | Single Source Drug | Total Volume of Gross Sales and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. Patent Expiration Date: The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. | ||
| Rx0000069 | Amgen | 04/30/2024 | Enbrel, 50mg/mL, Syringe (ML), 1 pack | 58406002101 | 10/19/2037 | Single Source Drug | Total Volume of Gross Sales and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. | ||
| Rx0000069 | Amgen | 09/20/2024 | Enbrel, 50mg/mL, Syringe (ML), 1 pack | 58406002101 | 10/19/2037 | Single Source Drug | Total Volume of Gross Sales and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. Patent Expiration Date: The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. | ||
| Rx0000069 | Amgen | 04/30/2024 | Enbrel, 50mg/mL, Syringe (ML), 4 pack | 58406002104 | 10/19/2037 | Single Source Drug | Total Volume of Gross Sales and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. | ||
| Rx0000069 | Amgen | 09/20/2024 | Enbrel, 50mg/mL, Syringe (ML), 4 pack | 58406002104 | 10/19/2037 | Single Source Drug | Total Volume of Gross Sales and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. Patent Expiration Date: The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. | ||
| Rx0000069 | Amgen | 04/30/2024 | Evenity, 105mg, 1.17mL prefilled syringe, 1 pk | 55513088001 | 04/09/2033 | Single Source Drug | Total Volume of Gross Sales and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Evenity reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. | ||
| Rx0000069 | Amgen | 07/25/2024 | Evenity, 105mg, 1.17mL prefilled syringe, 1 pk | 55513088001 | 04/09/2033 | Single Source Drug | Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Evenity reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. | ||
| Rx0000069 | Amgen | 04/30/2024 | Evenity, 105mg, 1.17mL prefilled syringe, 2 pk | 55513088002 | 04/09/2033 | Single Source Drug | Total Volume of Gross Sales and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Evenity reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. | ||
| Rx0000069 | Amgen | 07/25/2024 | Evenity, 105mg, 1.17mL prefilled syringe, 2 pk | 55513088002 | 04/09/2033 | Single Source Drug | Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Evenity reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. | ||
| Rx0000069 | Amgen | 04/30/2024 | Imlygic, 106 (1 million) PFU/mL (1.0 mL) single-use vial | 55513007801 | 11/23/2025 | Single Source Drug | Total Volume of Gross Sales and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Imlygic reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. | ||
| Rx0000069 | Amgen | 04/30/2024 | Imlygic, 108 (100 million) PFU/mL (1.0 mL) single-use vial | 55513007901 | 11/23/2025 | Single Source Drug | Total Volume of Gross Sales and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Imlygic reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. | ||
| Rx0000069 | Amgen | 04/30/2024 | Kyprolis, 10 mg (2mg/mL) lyophilized vial, 1 pk | 76075010301 | 05/08/2033 | Single Source Drug | Total Volume of Gross Sales and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Kyprolis reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. | ||
| Rx0000069 | Amgen | 07/25/2024 | Kyprolis, 10 mg (2mg/mL) lyophilized vial, 1 pk | 76075010301 | 05/08/2033 | Single Source Drug | Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Kyprolis reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. | ||
| Rx0000069 | Amgen | 04/30/2024 | Kyprolis, 30 mg (2mg/mL) lyophilized vial, 1 pk | 76075010201 | 05/08/2033 | Single Source Drug | Total Volume of Gross Sales and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Kyprolis reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. | ||
| Rx0000069 | Amgen | 07/25/2024 | Kyprolis, 30 mg (2mg/mL) lyophilized vial, 1 pk | 76075010201 | 05/08/2033 | Single Source Drug | Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Kyprolis reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. | ||
| Rx0000069 | Amgen | 04/30/2024 | Kyprolis, 60 mg lyophilized vial, 1 pk | 76075010101 | 05/08/2033 | Single Source Drug | Total Volume of Gross Sales and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Kyprolis reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. | ||
| Rx0000069 | Amgen | 07/25/2024 | Kyprolis, 60 mg lyophilized vial, 1 pk | 76075010101 | 05/08/2033 | Single Source Drug | Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Kyprolis reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. | ||
| Rx0000069 | Amgen | 04/30/2024 | Lumakras, 120mg Tablet, 240 pack | 55513048824 | 08/11/2040 | Single Source Drug | Total Volume of Gross Sales and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Lumakras reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. | ||
| Rx0000069 | Amgen | 04/30/2024 | Lumakras, 320mg Tablet, 90 pack | 55513050450 | 08/11/2040 | Single Source Drug | Total Volume of Gross Sales and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Lumakras reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. | ||
| Rx0000069 | Amgen | 04/30/2024 | Nplate, 125 mcg, 0.25mL (500 mcg/mL) single-use vial | 55513022301 | 02/12/2028 | Single Source Drug | Total Volume of Gross Sales and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Nplate reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. | ||
| Rx0000069 | Amgen | 07/25/2024 | Nplate, 125 mcg, 0.25mL (500 mcg/mL) single-use vial | 55513022301 | 02/12/2028 | Single Source Drug | Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Nplate reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. | ||
| Rx0000069 | Amgen | 04/30/2024 | Nplate, 250 mcg, 0.5mL (500 mcg/mL) single-use vial | 55513022101 | 02/12/2028 | Single Source Drug | Total Volume of Gross Sales and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Nplate reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. | ||
| Rx0000069 | Amgen | 07/25/2024 | Nplate, 250 mcg, 0.5mL (500 mcg/mL) single-use vial | 55513022101 | 02/12/2028 | Single Source Drug | Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Nplate reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. | ||
| Rx0000069 | Amgen | 04/30/2024 | Nplate, 500 mcg, 1.0mL (500 mcg/mL) single-use vial | 55513022201 | 02/12/2028 | Single Source Drug | Total Volume of Gross Sales and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Nplate reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. | ||
| Rx0000069 | Amgen | 07/25/2024 | Nplate, 500 mcg, 1.0mL (500 mcg/mL) single-use vial | 55513022201 | 02/12/2028 | Single Source Drug | Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Nplate reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. | ||
| Rx0000069 | Amgen | 04/30/2024 | Otezla, 10mg (4)-20mg (4)-30g (47), Tablet Dose Pack, 55 pack | 55513036955 | 2020 | 05/29/2034 | Single Source Drug | This is a new Amgen NDC that we are reassigning from the old Celgene NDC. Total Volume of Gross Sales and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Otezla reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. | |
| Rx0000069 | Amgen | 07/25/2024 | Otezla, 10mg (4)-20mg (4)-30g (47), Tablet Dose Pack, 55 pack | 55513036955 | 2020 | 05/29/2034 | Single Source Drug | Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Otezla reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. | |
| Rx0000069 | Amgen | 04/30/2024 | Otezla, 30mg, Tablet, 60 pack | 55513013760 | 2020 | 05/29/2034 | Single Source Drug | This is a new Amgen NDC that we are reassigning from the old Celgene NDC. Total Volume of Gross Sales and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Otezla reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. | |
| Rx0000069 | Amgen | 07/25/2024 | Otezla, 30mg, Tablet, 60 pack | 55513013760 | 2020 | 05/29/2034 | Single Source Drug | Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Otezla reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. | |
| Rx0000069 | Amgen | 04/30/2024 | Parsabiv, 10 mg/2 mL single-dose vial, 1 pack | 55513074201 | 08/09/2035 | Single Source Drug | Total Volume of Gross Sales and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Parsabiv reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. | ||
| Rx0000069 | Amgen | 04/30/2024 | Parsabiv, 10 mg/2 mL single-dose vial, 10 pack | 55513074210 | 08/09/2035 | Single Source Drug | Total Volume of Gross Sales and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Parsabiv reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. | ||
| Rx0000069 | Amgen | 04/30/2024 | Parsabiv, 2.5 mg/0.5 mL single-dose vial, 1 pack | 55513074001 | 08/09/2035 | Single Source Drug | Total Volume of Gross Sales and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Parsabiv reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. | ||
| Rx0000069 | Amgen | 04/30/2024 | Parsabiv, 2.5 mg/0.5 mL single-dose vial, 10 pack | 55513074010 | 08/09/2035 | Single Source Drug | Total Volume of Gross Sales and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Parsabiv reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. | ||
| Rx0000069 | Amgen | 04/30/2024 | Parsabiv, 5 mg/1 mL single-dose vial, 1 pack | 55513074101 | 08/09/2035 | Single Source Drug | Total Volume of Gross Sales and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Parsabiv reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. | ||
| Rx0000069 | Amgen | 04/30/2024 | Parsabiv, 5 mg/1 mL single-dose vial, 10 pack | 55513074110 | 08/09/2035 | Single Source Drug | Total Volume of Gross Sales and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Parsabiv reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. | ||
| Rx0000069 | Amgen | 04/30/2024 | Prolia, 60 mg, 1.0mL (60 mg/mL) prefilled syringe | 55513071001 | 02/19/2025 | Single Source Drug | Total Volume of Gross Sales and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Prolia reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. | ||
| Rx0000069 | Amgen | 07/25/2024 | Prolia, 60 mg, 1.0mL (60 mg/mL) prefilled syringe | 55513071001 | 02/19/2025 | Single Source Drug | Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Prolia reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. | ||
| Rx0000069 | Amgen | 04/30/2024 | Repatha, 140 mg, 1.0 mL (140 mg/mL) autoinjector, 2 pack | 72511076002 | 10/08/2030 | Single Source Drug | Total Volume of Gross Sales and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Repatha reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. | ||
| Rx0000069 | Amgen | 04/30/2024 | Repatha, 140 mg, 1.0 mL (140 mg/mL) prefilled syringe | 72511075001 | 10/08/2030 | Single Source Drug | Total Volume of Gross Sales and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Repatha reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. | ||
| Rx0000069 | Amgen | 04/30/2024 | Repatha, 420 mg, 3.5 mL (120 mg/mL) Pushtronex system | 72511077001 | 10/08/2030 | Single Source Drug | Total Volume of Gross Sales and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Repatha reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. | ||
| Rx0000069 | Amgen | 04/30/2024 | Vectibix, 100 mg, 5 mL (20 mg/mL) single-use vial | 55513095401 | Single Source Drug | Total Volume of Gross Sales and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. | |||
| Rx0000069 | Amgen | 07/25/2024 | Vectibix, 100 mg, 5 mL (20 mg/mL) single-use vial | 55513095401 | Single Source Drug | Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Vectibix reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. | |||
| Rx0000069 | Amgen | 04/30/2024 | Vectibix, 400 mg, 20 mL (20 mg/mL) single-use vial | 55513095601 | Single Source Drug | Total Volume of Gross Sales and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. | |||
| Rx0000069 | Amgen | 07/25/2024 | Vectibix, 400 mg, 20 mL (20 mg/mL) single-use vial | 55513095601 | Single Source Drug | Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Vectibix reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. | |||
| Rx0000069 | Amgen | 04/30/2024 | Xgeva, 120 mg /1.7 mL (70 mg/mL) single-use vial | 55513073001 | 02/19/2025 | Single Source Drug | Total Volume of Gross Sales and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Xgeva reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. | ||
| Rx0000069 | Amgen | 07/25/2024 | Xgeva, 120 mg /1.7 mL (70 mg/mL) single-use vial | 55513073001 | 02/19/2025 | Single Source Drug | Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Xgeva reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents. | ||
| Rx0000122 | Amneal Pharmaceuticals | 07/02/2024 | Budesonide Inhalation Suspension 0.25 MG/2ML 30 ampules | 00115168774 | Non-innovator Multiple Source Drug | Increased product cost | |||
| Rx0000122 | Amneal Pharmaceuticals | 07/02/2024 | Budesonide Inhalation Suspension 0.5 MG/2ML 30 ampules | 00115168974 | Non-innovator Multiple Source Drug | Increased product cost | |||
| Rx0000132 | Arbor Pharmaceuticals, LLC | 03/31/2024 | BiDil 20mg/37.5mg 90 (Isosorbide Dinitrate/Hydralazine HCl Tablets) | 24338001009 | Single Source Drug | ||||
| Rx0000132 | Arbor Pharmaceuticals, LLC | 03/31/2024 | EDARBI 40mg (azilsartan medoxomil) 30 tablets | 60631004030 | 03/26/2028 | Single Source Drug | |||
| Rx0000132 | Arbor Pharmaceuticals, LLC | 03/31/2024 | EDARBI 80mg (azilsartan medoxomil) 30 tablets | 60631008030 | 03/26/2028 | Single Source Drug | |||
| Rx0000132 | Arbor Pharmaceuticals, LLC | 03/31/2024 | EDARBYCLOR 40mg/12.5mg (azilsartan medoxomil / chlorthalidone) 30 tablets | 60631041230 | 07/01/2031 | Single Source Drug | |||
| Rx0000132 | Arbor Pharmaceuticals, LLC | 03/31/2024 | EDARBYCLOR 40mg/25mg (azilsartan medoxomil / chlorthalidone) 30 tablets | 60631042530 | 07/01/2031 | Single Source Drug | |||
| Rx0000132 | Arbor Pharmaceuticals, LLC | 03/31/2024 | Gliadel 7.7mg 8 Implant Wafers | 24338005008 | Single Source Drug | ||||
| Rx0000132 | Arbor Pharmaceuticals, LLC | 03/31/2024 | HORIZANT 300MG (gabapentin enacarbil) 30 extended-release tablets | 53451010301 | 06/10/2029 | Single Source Drug | |||
| Rx0000132 | Arbor Pharmaceuticals, LLC | 03/31/2024 | HORIZANT 600MG (gabapentin enacarbil) 30 extended-release tablets | 53451010101 | 06/10/2029 | Single Source Drug | |||
| Rx0000132 | Arbor Pharmaceuticals, LLC | 03/31/2024 | Nymalize 30mg/5mL prefilled oral syringe 12x5 ml | 24338023012 | 04/16/2038 | Single Source Drug | |||
| Rx0000132 | Arbor Pharmaceuticals, LLC | 03/31/2024 | Nymalize 60mg/10ml Oral Solution 237ml 8oz | 24338026008 | 04/16/2038 | Single Source Drug | |||
| Rx0000132 | Arbor Pharmaceuticals, LLC | 03/31/2024 | Nymalize 60mg/10mL prefilled oral syringe 12x10ml | 24338026012 | 04/16/2038 | Single Source Drug | |||
| Rx0000132 | Arbor Pharmaceuticals, LLC | 03/31/2024 | SOTYLIZE 5mg/ml (sotalol hydrochloride) oral solution 250 ml | 24338053025 | 08/31/2035 | Innovator Multiple Source Drug | |||
| Rx0000132 | Arbor Pharmaceuticals, LLC | 03/31/2024 | SOTYLIZE 5mg/ml (sotalol hydrochloride) oral solution 480ml | 24338053048 | 08/31/2035 | Innovator Multiple Source Drug | |||
| Rx0000132 | Arbor Pharmaceuticals, LLC | 06/11/2024 | ZENZEDI C-II 10mg, 30 (Dextroamphetamine Sulfate Tablets) | 24338085303 | Non-innovator Multiple Source Drug | ||||
| Rx0000132 | Arbor Pharmaceuticals, LLC | 06/11/2024 | ZENZEDI C-II 15mg, 30 (Dextroamphetamine Sulfate Tablets) | 24338085403 | Non-innovator Multiple Source Drug | ||||
| Rx0000132 | Arbor Pharmaceuticals, LLC | 06/11/2024 | ZENZEDI C-II 2.5mg, 30 (Dextroamphetamine Sulfate Tablets) | 24338085003 | Non-innovator Multiple Source Drug | ||||
| Rx0000132 | Arbor Pharmaceuticals, LLC | 06/11/2024 | ZENZEDI C-II 20mg, 30 (Dextroamphetamine Sulfate Tablets) | 24338085503 | Non-innovator Multiple Source Drug | ||||
| Rx0000132 | Arbor Pharmaceuticals, LLC | 06/11/2024 | ZENZEDI C-II 30mg, 30 (Dextroamphetamine Sulfate Tablets) | 24338085603 | Non-innovator Multiple Source Drug | ||||
| Rx0000132 | Arbor Pharmaceuticals, LLC | 06/11/2024 | ZENZEDI C-II 5mg, 30 (Dextroamphetamine Sulfate Tablets) | 24338085103 | Non-innovator Multiple Source Drug | ||||
| Rx0000132 | Arbor Pharmaceuticals, LLC | 06/11/2024 | ZENZEDI C-II 7.5mg, 30 (Dextroamphetamine Sulfate Tablets) | 24338085203 | Non-innovator Multiple Source Drug | ||||
| Rx0000359 | Ardelyx, Inc. | 04/23/2024 | Ibsrela Oral Tablet 50 MG, 60 Each, Unit-of-Use, Bottle | 73154005060 | 08/01/2033 | Single Source Drug | |||
| Rx0000048 | Astellas Pharma US, Inc. | 03/31/2024 | Cresemba, 186 mg / 14 capsules per blister pack | 00469052002 | 10/31/2025 | Single Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Astellas believes is otherwise in the public domain or publicly available. As such, columns 8, 10 and 12 are intentionally left blank. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administrations Orange Book, as of March 31, 2024. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) This product was not acquired, therefore columns 14-22 are intentionally left blank. | ||
| Rx0000048 | Astellas Pharma US, Inc. | 03/31/2024 | Cresemba, 372 mg / 1 vial | 00469042001 | 10/31/2025 | Single Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Astellas believes is otherwise in the public domain or publicly available. As such, columns 8, 10 and 12 are intentionally left blank. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administrations Orange Book, as of March 31, 2024. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) This product was not acquired, therefore columns 14-22 are intentionally left blank. | ||
| Rx0000048 | Astellas Pharma US, Inc. | 03/31/2024 | Xtandi, 40 mg / 120 capsules per bottle | 00469012599 | 08/13/2027 | Single Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Astellas believes is otherwise in the public domain or publicly available. As such, columns 8, 10 and 12 are intentionally left blank. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administrations Orange Book, as of March 31, 2024. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) This product was not acquired, therefore columns 14-22 are intentionally left blank. | ||
| Rx0000048 | Astellas Pharma US, Inc. | 03/31/2024 | Xtandi, 40 mg / 120 tablets per bottle | 00469062599 | 08/13/2027 | Single Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Astellas believes is otherwise in the public domain or publicly available. As such, columns 8, 10 and 12 are intentionally left blank. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administrations Orange Book, as of March 31, 2024. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) This product was not acquired, therefore columns 14-22 are intentionally left blank. | ||
| Rx0000048 | Astellas Pharma US, Inc. | 03/31/2024 | Xtandi, 80 mg / 60 tablets per bottle | 00469072560 | 08/13/2027 | Single Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Astellas believes is otherwise in the public domain or publicly available. As such, columns 8, 10 and 12 are intentionally left blank. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administrations Orange Book, as of March 31, 2024. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) This product was not acquired, therefore columns 14-22 are intentionally left blank. | ||
| Rx0000015 | AstraZeneca | 07/25/2024 | LYNPARZA 120ct TABLET 100MG | 00310066812 | 10/25/2041 | Single Source Drug | Patent Expiration based on FDA Orange Book estimate; Gross Sales shared across brand | ||
| Rx0000015 | AstraZeneca | 07/25/2024 | LYNPARZA 120ct TABLET 150MG | 00310067912 | 10/25/2041 | Single Source Drug | Patent Expiration based on FDA Orange Book estimate; Gross Sales shared across brand | ||
| Rx0000015 | AstraZeneca | 07/25/2024 | LYNPARZA 60ct TABLET 100MG | 00310066860 | 10/25/2041 | Single Source Drug | Patent Expiration based on FDA Orange Book estimate; Gross Sales shared across brand | ||
| Rx0000015 | AstraZeneca | 07/25/2024 | LYNPARZA 60ct TABLET 150MG | 00310067960 | 10/25/2041 | Single Source Drug | Patent Expiration based on FDA Orange Book estimate; Gross Sales shared across brand | ||
| Rx0000354 | AVEO Pharmaceuticals, Inc. | 04/24/2024 | Fotivda Oral Capsule 0.89 MG, 21 Each, Bottle | 45629008901 | 11/05/2039 | Single Source Drug | As listed in the FDA Orange Book, the therapeutic use of tivozanib that has been approved by the FDA is presently protected by three granted United States patents. The latest to expire is US 11504365, which is scheduled to expire on November 5, 2039. Patent Data for Tivozanib [sourced from: FDA Orange Book] Product 001 TIVOZANIB HYDROCHLORIDE (FOTIVDA) CAPSULE Product No.: 001 Patent No.: 6821987 Patent Expiration: 04/26/2024* Drug Substance: DS Drug Product: DP Patent Use Code: U-3100 Delist Requested: Submission Date: 04/06/2021 Product No.: 001 Patent No: 7166722 Patent Expiration: 11/16/2024* Drug Substance: DS Drug Product: DP Patent Use Code: Delist Requested: Submission Date: 04/06/2021 Product No.: 001 Patent No.: 11504365 Patent Expiration: 11/05/2039 Drug Substance: Drug Product: Patent Use Code: U-3476 Submission Date: 12/01/2022 U-3100: A METHOD OF TREATING ADULTS WITH RELAPSED OR REFRACTORY ADVANCED RENAL CELL CARCINOMA FOLLOWING TWO OR MORE PRIOR SYSTEMIC THERAPIES BY INHIBITING THE ANGIOGENESIS OF BLOOD VESSELS WITH A VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITOR U-3476: TREATMENT OF ADULTS WITH MODERATE HEPATIC IMPAIRMENT AND RELAPSED OR REFRACTORY ADVANCED RENAL CELL CARCINOMA FOLLOWING TWO OR MORE PRIOR SYSTEMIC ANTI-CANCER THERAPIES WITH 1MG TIVOZANIB HCL ORALLY FOR 21 DAYS FOLLOWED BY NO DRUG FOR 7 DAYS *Note: US Patent 6821987 is in the process of being extended for an additional 1 year interim period until 4/26/2025, while we await the disposition of AVEO's patent applications for full 5 year patent term extensions for US 6821987 and 7166722. Exclusivity Data Product No.: 001 Exclusivity Code: NCE Exclusivity Expiration: 03/10/2026 | ||
| Rx0000354 | AVEO Pharmaceuticals, Inc. | 10/25/2024 | Fotivda Oral Capsule 0.89 MG, 21 Each, Bottle | 45629008901 | 11/05/2039 | Single Source Drug | As listed in the FDA Orange Book, the therapeutic use of tivozanib that has been approved by the FDA is presently protected by three granted United States patents. The latest to expire is US 11504365, which is scheduled to expire on November 5, 2039. Patent Data for Tivozanib [sourced from: FDA Orange Book] Product 001 TIVOZANIB HYDROCHLORIDE (FOTIVDA) CAPSULE Product No.: 001 Patent No.: 6821987 Patent Expiration: 04/26/2025* Drug Substance: DS Drug Product: DP Patent Use Code: U-3100 Delist Requested: Submission Date: 04/06/2021 Product No.: 001 Patent No: 7166722 Patent Expiration: 11/16/2024* Drug Substance: DS Drug Product: DP Patent Use Code: Delist Requested: Submission Date: 04/06/2021 Product No.: 001 Patent No.: 11504365 Patent Expiration: 11/05/2039 Drug Substance: Drug Product: Patent Use Code: U-3476 Submission Date: 12/01/2022 U-3100: A METHOD OF TREATING ADULTS WITH RELAPSED OR REFRACTORY ADVANCED RENAL CELL CARCINOMA FOLLOWING TWO OR MORE PRIOR SYSTEMIC THERAPIES BY INHIBITING THE ANGIOGENESIS OF BLOOD VESSELS WITH A VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITOR U-3476: TREATMENT OF ADULTS WITH MODERATE HEPATIC IMPAIRMENT AND RELAPSED OR REFRACTORY ADVANCED RENAL CELL CARCINOMA FOLLOWING TWO OR MORE PRIOR SYSTEMIC ANTI-CANCER THERAPIES WITH 1MG TIVOZANIB HCL ORALLY FOR 21 DAYS FOLLOWED BY NO DRUG FOR 7 DAYS *Note: US Patent 7166722 is in the process of being extended for an additional 1 year interim period until 11/16/2025, while we await the disposition of AVEO's applications for full 5 year patent term extensions for US 6821987 and 7166722. Exclusivity Data Product No.: 001 Exclusivity Code: NCE Exclusivity Expiration: 03/10/2026 | ||
| Rx0000354 | AVEO Pharmaceuticals, Inc. | 04/24/2024 | Fotivda Oral Capsule 1.34 MG, 21 Each, Bottle | 45629013401 | 11/05/2039 | Single Source Drug | As listed in the FDA Orange Book, the therapeutic use of tivozanib that has been approved by the FDA is presently protected by three granted United States patents. The latest to expire is US 11504365, which is scheduled to expire on November 5, 2039. Patent Data for Tivozanib [sourced from: FDA Orange Book] Product 001 TIVOZANIB HYDROCHLORIDE (FOTIVDA) CAPSULE Product No.: 001 Patent No.: 6821987 Patent Expiration: 04/26/2024* Drug Substance: DS Drug Product: DP Patent Use Code: U-3100 Delist Requested: Submission Date: 04/06/2021 Product No.: 001 Patent No: 7166722 Patent Expiration: 11/16/2024* Drug Substance: DS Drug Product: DP Patent Use Code: Delist Requested: Submission Date: 04/06/2021 Product No.: 001 Patent No.: 11504365 Patent Expiration: 11/05/2039 Drug Substance: Drug Product: Patent Use Code: U-3476 Submission Date: 12/01/2022 U-3100: A METHOD OF TREATING ADULTS WITH RELAPSED OR REFRACTORY ADVANCED RENAL CELL CARCINOMA FOLLOWING TWO OR MORE PRIOR SYSTEMIC THERAPIES BY INHIBITING THE ANGIOGENESIS OF BLOOD VESSELS WITH A VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITOR U-3476: TREATMENT OF ADULTS WITH MODERATE HEPATIC IMPAIRMENT AND RELAPSED OR REFRACTORY ADVANCED RENAL CELL CARCINOMA FOLLOWING TWO OR MORE PRIOR SYSTEMIC ANTI-CANCER THERAPIES WITH 1MG TIVOZANIB HCL ORALLY FOR 21 DAYS FOLLOWED BY NO DRUG FOR 7 DAYS *Note: US Patent 6821987 is in the process of being extended for an additional 1 year interim period until 4/26/2025, while we await the disposition of AVEO's patent applications for full 5 year patent term extensions for US 6821987 and 7166722. Exclusivity Data Product No.: 001 Exclusivity Code: NCE Exclusivity Expiration: 03/10/2027 | ||
| Rx0000354 | AVEO Pharmaceuticals, Inc. | 10/25/2024 | Fotivda Oral Capsule 1.34 MG, 21 Each, Bottle | 45629013401 | 11/05/2039 | Single Source Drug | As listed in the FDA Orange Book, the therapeutic use of tivozanib that has been approved by the FDA is presently protected by three granted United States patents. The latest to expire is US 11504365, which is scheduled to expire on November 5, 2039. Patent Data for Tivozanib [sourced from: FDA Orange Book] Product 001 TIVOZANIB HYDROCHLORIDE (FOTIVDA) CAPSULE Product No.: 001 Patent No.: 6821987 Patent Expiration: 04/26/2025* Drug Substance: DS Drug Product: DP Patent Use Code: U-3100 Delist Requested: Submission Date: 04/06/2021 Product No.: 001 Patent No: 7166722 Patent Expiration: 11/16/2024* Drug Substance: DS Drug Product: DP Patent Use Code: Delist Requested: Submission Date: 04/06/2021 Product No.: 001 Patent No.: 11504365 Patent Expiration: 11/05/2039 Drug Substance: Drug Product: Patent Use Code: U-3476 Submission Date: 12/01/2022 U-3100: A METHOD OF TREATING ADULTS WITH RELAPSED OR REFRACTORY ADVANCED RENAL CELL CARCINOMA FOLLOWING TWO OR MORE PRIOR SYSTEMIC THERAPIES BY INHIBITING THE ANGIOGENESIS OF BLOOD VESSELS WITH A VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITOR U-3476: TREATMENT OF ADULTS WITH MODERATE HEPATIC IMPAIRMENT AND RELAPSED OR REFRACTORY ADVANCED RENAL CELL CARCINOMA FOLLOWING TWO OR MORE PRIOR SYSTEMIC ANTI-CANCER THERAPIES WITH 1MG TIVOZANIB HCL ORALLY FOR 21 DAYS FOLLOWED BY NO DRUG FOR 7 DAYS *Note: US Patent 7166722 is in the process of being extended for an additional 1 year interim period until 11/16/2025, while we await the disposition of AVEO's applications for full 5 year patent term extensions for US 6821987 and 7166722. Exclusivity Data Product No.: 001 Exclusivity Code: NCE Exclusivity Expiration: 03/10/2026 | ||
| Rx0000277 | Avion Pharmaceuticals, LLC | 04/23/2024 | Balcoltra Oral Tablet 0.1 - 20 mg/mcg pkg, size 1 - Insert | 75854060228 | 06/01/2027 | Non-innovator Multiple Source Drug | Developed by Avion Pharmaceuticals | ||
| Rx0000277 | Avion Pharmaceuticals, LLC | 04/23/2024 | Balcoltra Oral Tablet 0.1 - 20 mg/mcg pkg, size 3 | 75854060203 | 06/01/2027 | Non-innovator Multiple Source Drug | Developed by Avion Pharmaceuticals | ||
| Rx0000108 | AvKare | 07/31/2024 | Ergocalciferol (vitamin D2) Capsule 1,250 mcg 100ct | 42291026601 | Non-innovator Multiple Source Drug | ||||
| Rx0000108 | AvKare | 07/31/2024 | Letrozole Tablet 2.5mg 90ct | 42291037490 | Non-innovator Multiple Source Drug | ||||
| Rx0000108 | AvKare | 07/31/2024 | losartan potassium/hydrochlorothiazide tablet 100 mg-12.5 mg 90ct | 42291050390 | Non-innovator Multiple Source Drug | ||||
| Rx0000108 | AvKare | 07/31/2024 | losartan potassium/hydrochlorothiazide tablet 100 mg-25 mg 90ct | 42291050490 | Non-innovator Multiple Source Drug | ||||
| Rx0000108 | AvKare | 07/31/2024 | Losartan potassium/hydrochlorothiazide tablet 50 mg-12.5 mg 90ct | 42291050290 | Non-innovator Multiple Source Drug | ||||
| Rx0000108 | AvKare | 07/31/2024 | Progesterone Capsule 100mg 100ct | 42291078401 | Non-innovator Multiple Source Drug | ||||
| Rx0000108 | AvKare | 07/31/2024 | Progesterone Capsule 200mg 100ct | 42291078501 | Non-innovator Multiple Source Drug | ||||
| Rx0000108 | AvKare | 07/31/2024 | Sulfamethoxazole/trimethoprim tablet 400 mg-80 mg 100ct | 42291075801 | Non-innovator Multiple Source Drug | ||||
| Rx0000108 | AvKare | 07/31/2024 | Sulfamethoxazole/trimethoprim tablet 400 mg-80 mg 500ct | 42291075850 | Non-innovator Multiple Source Drug | ||||
| Rx0000108 | AvKare | 07/31/2024 | Sulfamethoxazole/trimethoprim tablet 800 mg-160 mg 100ct | 42291075901 | Non-innovator Multiple Source Drug | ||||
| Rx0000108 | AvKare | 07/31/2024 | Sulfamethoxazole/trimethoprim tablet 800 mg-160 mg 500ct | 42291075950 | Non-innovator Multiple Source Drug | ||||
| Rx0000108 | AvKare | 04/29/2024 | URSODIOL 500MG TABLET 100ct | 42291093101 | Non-innovator Multiple Source Drug | ||||
| Rx0000429 | Axsome Therapeutics, Inc. | 04/29/2024 | Sunosi Tablets 150mg 30 | 81968035101 | 2019 | 12/30/2042 | Single Source Drug | The information contained in this report is subject to the following limitations and assumptions: Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Axsome believes is in the public domain or otherwise publicly available. Therefore, Gross Sales Volume US Dollars, Cost Increase Factors and Change Improvement Description have been left blank. | |
| Rx0000429 | Axsome Therapeutics, Inc. | 04/29/2024 | Sunosi Tablets 75mg 30 | 81968035001 | 2019 | 12/30/2042 | Single Source Drug | The information contained in this report is subject to the following limitations and assumptions: Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Axsome believes is in the public domain or otherwise publicly available. Therefore, Gross Sales Volume US Dollars, Cost Increase Factors and Change Improvement Description have been left blank. | |
| Rx0000430 | Azurity Pharmaceuticals | 04/17/2024 | QBRELIS® (lisinopril) Oral Solution, 1 mg / mL, 150 mL | 52652300101 | 11/06/2035 | Single Source Drug | |||
| Rx0000430 | Azurity Pharmaceuticals | 03/31/2024 | Xatmep 2.5/ml (methotrexate) Oral Solution 120ml | 52652200101 | Single Source Drug | ||||
| Rx0000430 | Azurity Pharmaceuticals | 03/31/2024 | Xatmep 2.5mg/ml (methotrexate) Oral Solution 60ml | 52652200106 | Single Source Drug | ||||
| Rx0000096 | Bausch + Lomb, Inc. | 04/28/2024 | ALREX® (loteprednol etabonate ophthalmic suspension 0.2%), 10mL | 24208035310 | Single Source Drug | The product was not acquired within the last 5 years. No patent expiration date listed. | |||
| Rx0000096 | Bausch + Lomb, Inc. | 04/28/2024 | ALREX® (loteprednol etabonate ophthalmic suspension 0.2%), 5mL | 24208035305 | Single Source Drug | The product was not acquired within the last 5 years. No patent expiration date listed. | |||
| Rx0000096 | Bausch + Lomb, Inc. | 04/28/2024 | BEPREVE Ophthalmic Solution USP, 1.5%, 10mL | 24208062901 | 01/13/2025 | Innovator Multiple Source Drug | The product was not acquired within the last 5 years. | ||
| Rx0000096 | Bausch + Lomb, Inc. | 04/28/2024 | BEPREVE Ophthalmic Solution USP, 1.5%, 5mL | 24208062902 | 01/13/2025 | Innovator Multiple Source Drug | The product was not acquired within the last 5 years. | ||
| Rx0000096 | Bausch + Lomb, Inc. | 04/28/2024 | BESIVANCE® (besifloxacin ophthalmic suspension 0.6%), 5mL | 24208044605 | 01/09/2031 | Single Source Drug | The product was not acquired within the last 5 years. | ||
| Rx0000096 | Bausch + Lomb, Inc. | 04/28/2024 | LOTEMAX® (loteprednol etabonate ophthalmic Gel 0.5%), 5g | 24208050307 | Single Source Drug | The product was not acquired within the last 5 years. No patent expiration date listed. | |||
| Rx0000096 | Bausch + Lomb, Inc. | 04/28/2024 | LOTEMAX® (loteprednol etabonate ophthalmic Ointment 0.5%), 3.5g | 24208044335 | Single Source Drug | The product was not acquired within the last 5 years. No patent expiration date listed. | |||
| Rx0000096 | Bausch + Lomb, Inc. | 04/28/2024 | LOTEMAX® (loteprednol etabonate ophthalmic suspension 0.5%), 10mL | 24208029910 | Innovator Multiple Source Drug | The product was not acquired within the last 5 years. No patent expiration date listed. | |||
| Rx0000096 | Bausch + Lomb, Inc. | 04/28/2024 | LOTEMAX® (loteprednol etabonate ophthalmic suspension 0.5%), 15mL | 24208029915 | Innovator Multiple Source Drug | The product was not acquired within the last 5 years. No patent expiration date listed. | |||
| Rx0000096 | Bausch + Lomb, Inc. | 04/28/2024 | LOTEMAX® (loteprednol etabonate ophthalmic suspension 0.5%), 5mL | 24208029905 | Innovator Multiple Source Drug | The product was not acquired within the last 5 years. No patent expiration date listed. | |||
| Rx0000096 | Bausch + Lomb, Inc. | 04/28/2024 | LOTEMAX® SM (loteprednol etabonate ophthalmic gel) 0.38%, 5g | 24208050707 | 12/23/2036 | Single Source Drug | The product was not acquired within the last 5 years. | ||
| Rx0000096 | Bausch + Lomb, Inc. | 04/28/2024 | MIOCHOL®-E (acetylcholine chloride intraocular solution), 20mg/2 mL, Vial | 24208053920 | Single Source Drug | The product was not acquired within the last 5 years. No patent expiration date listed. | |||
| Rx0000096 | Bausch + Lomb, Inc. | 04/28/2024 | PROLENSA (bromfenac ophthalmic solution) 0.07% 3mL | 24208060203 | 11/11/2033 | Single Source Drug | The product was not acquired within the last 5 years. | ||
| Rx0000096 | Bausch + Lomb, Inc. | 04/28/2024 | TIMOPTIC® in OCUDOSE® (TIMOLOL MALEATE OPHTHALMIC SOLUTION - New NDC), 0.50%, 0.3mL, 60ct | 24208049968 | Single Source Drug | The product was not acquired within the last 5 years. No patent expiration date listed. | |||
| Rx0000096 | Bausch + Lomb, Inc. | 04/28/2024 | TIMOPTIC® in OCUDOSE® (TIMOLOL MALEATE OPHTHALMIC SOLUTION) 0.25%, 0.3mL, 60ct | 00187149825 | Single Source Drug | The product was not acquired within the last 5 years. No patent expiration date listed. | |||
| Rx0000096 | Bausch + Lomb, Inc. | 04/28/2024 | VYZULTA (latanoprostene bunod ophthalmic solution) 0.024%, 2.5mL | 24208050402 | 02/21/2029 | Single Source Drug | The product was not acquired within the last 5 years. | ||
| Rx0000096 | Bausch + Lomb, Inc. | 04/28/2024 | VYZULTA (latanoprostene bunod ophthalmic solution) 0.024%, 5mL | 24208050405 | 02/21/2029 | Single Source Drug | The product was not acquired within the last 5 years. | ||
| Rx0000096 | Bausch + Lomb, Inc. | 04/28/2024 | XIIDRA® (lifitegrast ophthalmic solution) 5%, 60ct | 00078091112 | 2016 | 12/18/2033 | Single Source Drug | ||
| Rx0000096 | Bausch + Lomb, Inc. | 04/28/2024 | ZIRGAN (Ganciclovir Ophthalmic Gel 0.15%), 5mL | 24208053535 | Single Source Drug | The product was not acquired within the last 5 years. No patent expiration date listed. | |||
| Rx0000096 | Bausch + Lomb, Inc. | 04/28/2024 | ZYLET® (loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic Suspension), 10mL | 24208035810 | Single Source Drug | The product was not acquired within the last 5 years. No patent expiration date listed. | |||
| Rx0000096 | Bausch + Lomb, Inc. | 04/28/2024 | ZYLET® (loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic Suspension), 5mL | 24208035805 | Single Source Drug | The product was not acquired within the last 5 years. No patent expiration date listed. | |||
| Rx0000097 | Bausch Health US, LLC | 04/28/2024 | APLENZIN® (bupropion hydrobromide), Extended-Release Tablets, 174mg 30ct | 00187581030 | 06/27/2026 | Single Source Drug | The product was not acquired within the last 5 years. | ||
| Rx0000097 | Bausch Health US, LLC | 04/28/2024 | APLENZIN® (bupropion hydrobromide), Extended-Release Tablets, 348mg 30ct | 00187581130 | 06/27/2026 | Single Source Drug | The product was not acquired within the last 5 years. | ||
| Rx0000097 | Bausch Health US, LLC | 04/28/2024 | APLENZIN® (bupropion hydrobromide), Extended-Release Tablets, 522mg 30ct | 00187581230 | 06/27/2026 | Single Source Drug | The product was not acquired within the last 5 years. | ||
| Rx0000097 | Bausch Health US, LLC | 04/28/2024 | ARAZLO (tazarotene) Lotion, 0.045%, 45g | 00187209845 | 05/11/2038 | Single Source Drug | The product was not acquired within the last 5 years. | ||
| Rx0000097 | Bausch Health US, LLC | 04/28/2024 | ATIVAN® Tablets 1mg 1,000s | 00187006410 | Innovator Multiple Source Drug | The product was not acquired within the last 5 years. No patent expiration date listed. | |||
| Rx0000097 | Bausch Health US, LLC | 04/28/2024 | ATIVAN® Tablets .5mg 100s | 00187006301 | Innovator Multiple Source Drug | The product was not acquired within the last 5 years. No patent expiration date listed. | |||
| Rx0000097 | Bausch Health US, LLC | 04/28/2024 | ATIVAN® Tablets 1mg 100s | 00187006401 | Innovator Multiple Source Drug | The product was not acquired within the last 5 years. No patent expiration date listed. | |||
| Rx0000097 | Bausch Health US, LLC | 04/28/2024 | ATIVAN® Tablets 2mg 100s | 00187006501 | Innovator Multiple Source Drug | The product was not acquired within the last 5 years. No patent expiration date listed. | |||
| Rx0000097 | Bausch Health US, LLC | 04/28/2024 | BRYHALI (halobetasol propionate) Lotion 0.01%, 100g | 00187000201 | 11/02/2031 | Single Source Drug | The product was not acquired within the last 5 years. | ||
| Rx0000097 | Bausch Health US, LLC | 04/28/2024 | BRYHALI (halobetasol propionate) Lotion 0.01%, 60g | 00187000260 | 11/02/2031 | Single Source Drug | The product was not acquired within the last 5 years. | ||
| Rx0000097 | Bausch Health US, LLC | 04/28/2024 | DEMSER® (metyrosine), 250mg Capsules, 100ct | 25010030515 | Innovator Multiple Source Drug | The product was not acquired within the last 5 years. No patent expiration date listed. | |||
| Rx0000097 | Bausch Health US, LLC | 04/28/2024 | Duobrii (halobetasol propionate and tazarotene) Lotion 0.01%/0.045%, 1 | 00187065301 | 06/06/2036 | Single Source Drug | The product was not acquired within the last 5 years. | ||
| Rx0000097 | Bausch Health US, LLC | 04/28/2024 | JUBLIA® (efinaconazole) Topical Solution 10%, 4mL | 00187540004 | 04/25/2035 | Single Source Drug | The product was not acquired within the last 5 years. | ||
| Rx0000097 | Bausch Health US, LLC | 04/28/2024 | JUBLIA® (efinaconazole) Topical Solution 10%, 8mL | 00187540008 | 04/25/2035 | Single Source Drug | The product was not acquired within the last 5 years. | ||
| Rx0000097 | Bausch Health US, LLC | 04/28/2024 | MESTINON 60mg /SYRUP (pyridostigmine bromide) 473mL 1 Bottle | 00187301220 | Innovator Multiple Source Drug | The product was not acquired within the last 5 years. No patent expiration date listed. | |||
| Rx0000097 | Bausch Health US, LLC | 04/28/2024 | MESTINON 60mg TABLETS 100s (pyridostigmine bromide) | 00187301030 | Innovator Multiple Source Drug | The product was not acquired within the last 5 years. No patent expiration date listed. | |||
| Rx0000097 | Bausch Health US, LLC | 04/28/2024 | MESTINON TIMESPAN 180mg TABLETS (pyridostigmine bromide) 30 CT | 00187301330 | Innovator Multiple Source Drug | The product was not acquired within the last 5 years. No patent expiration date listed. | |||
| Rx0000097 | Bausch Health US, LLC | 04/28/2024 | MYSOLINE 250 mg TABLETS, 100s (primidone) | 66490069110 | Innovator Multiple Source Drug | The product was not acquired within the last 5 years. No patent expiration date listed. | |||
| Rx0000097 | Bausch Health US, LLC | 04/28/2024 | MYSOLINE 50 mg TABLETS, 100s (primidone) | 66490069010 | Innovator Multiple Source Drug | The product was not acquired within the last 5 years. No patent expiration date listed. | |||
| Rx0000097 | Bausch Health US, LLC | 04/28/2024 | SILIQ (brodalumab) Injection 210mg/1.5mL (1 box of 2 syringes) | 00187000402 | Single Source Drug | The product was not acquired within the last 5 years. No patent expiration date listed. | |||
| Rx0000097 | Bausch Health US, LLC | 04/28/2024 | VASOTEC® 2.5mg Tablets, 90s | 00187014090 | Innovator Multiple Source Drug | The product was not acquired within the last 5 years. No patent expiration date listed. | |||
| Rx0000097 | Bausch Health US, LLC | 04/28/2024 | VASOTEC® 10mg Tablets, 1,000s | 00187014210 | Innovator Multiple Source Drug | The product was not acquired within the last 5 years. No patent expiration date listed. | |||
| Rx0000097 | Bausch Health US, LLC | 04/28/2024 | VASOTEC® 10mg Tablets, 30s | 00187014230 | Innovator Multiple Source Drug | The product was not acquired within the last 5 years. No patent expiration date listed. | |||
| Rx0000097 | Bausch Health US, LLC | 04/28/2024 | VASOTEC® 10mg Tablets, 90s | 00187014290 | Innovator Multiple Source Drug | The product was not acquired within the last 5 years. No patent expiration date listed. | |||
| Rx0000097 | Bausch Health US, LLC | 04/28/2024 | VASOTEC® 2.5mg Tablets, 30s | 00187014030 | Innovator Multiple Source Drug | The product was not acquired within the last 5 years. No patent expiration date listed. | |||
| Rx0000097 | Bausch Health US, LLC | 04/28/2024 | VASOTEC® 20mg Tablets, 1,000s | 00187014310 | Innovator Multiple Source Drug | The product was not acquired within the last 5 years. No patent expiration date listed. | |||
| Rx0000097 | Bausch Health US, LLC | 04/28/2024 | VASOTEC® 20mg Tablets, 30s | 00187014330 | Innovator Multiple Source Drug | The product was not acquired within the last 5 years. No patent expiration date listed. | |||
| Rx0000097 | Bausch Health US, LLC | 04/28/2024 | VASOTEC® 20mg Tablets, 90s | 00187014390 | Innovator Multiple Source Drug | The product was not acquired within the last 5 years. No patent expiration date listed. | |||
| Rx0000097 | Bausch Health US, LLC | 04/28/2024 | VASOTEC® 5mg Tablets, 30s | 00187014130 | Innovator Multiple Source Drug | The product was not acquired within the last 5 years. No patent expiration date listed. | |||
| Rx0000097 | Bausch Health US, LLC | 04/28/2024 | VASOTEC® 5mg Tablets, 90s | 00187014190 | Innovator Multiple Source Drug | The product was not acquired within the last 5 years. No patent expiration date listed. | |||
| Rx0000097 | Bausch Health US, LLC | 04/28/2024 | WELLBUTRIN® XL 150mg Tablets, 30ct | 00187073030 | Innovator Multiple Source Drug | The product was not acquired within the last 5 years. No patent expiration date listed. | |||
| Rx0000097 | Bausch Health US, LLC | 04/28/2024 | WELLBUTRIN® XL 150mg Tablets, 90ct | 00187073090 | Innovator Multiple Source Drug | The product was not acquired within the last 5 years. No patent expiration date listed. | |||
| Rx0000097 | Bausch Health US, LLC | 04/28/2024 | WELLBUTRIN® XL 300mg Tablets, 30ct | 00187073130 | Innovator Multiple Source Drug | The product was not acquired within the last 5 years. No patent expiration date listed. | |||
| Rx0000097 | Bausch Health US, LLC | 04/28/2024 | ZELAPAR (selegiline HCI) 1.25mg Orally Disintegrating Tablets, 60ct | 00187045302 | Single Source Drug | The product was not acquired within the last 5 years. No patent expiration date listed. | |||
| Rx0000049 | Baxter Healthcare Corporation | 10/23/2024 | 0.45% SODIUM CHL INJ,1000ML, 14 USPVIAFLEX PLASTIC CONTAINER | 00338004304 | Non-innovator Multiple Source Drug | ||||
| Rx0000049 | Baxter Healthcare Corporation | 10/23/2024 | 0.9% NACL INJ USP 50 ML, 96 MINI-BAG TM VIAFLEX CONT. | 00338004941 | Non-innovator Multiple Source Drug | ||||
| Rx0000049 | Baxter Healthcare Corporation | 10/23/2024 | 0.9% NACL INJ USP, 100ML, 80 MINI-BAG PLUS CONT | 00338055318 | Non-innovator Multiple Source Drug | ||||
| Rx0000049 | Baxter Healthcare Corporation | 10/23/2024 | 0.9% NACL INJ. USP 100 ML, 96 MINI-BAG TM VIAFLEX CONT | 00338004948 | Non-innovator Multiple Source Drug | ||||
| Rx0000049 | Baxter Healthcare Corporation | 10/23/2024 | 0.9% SOD CHL 100ML, 96 MINI-BAG VIAFLEX CONT | 00338004938 | Non-innovator Multiple Source Drug | ||||
| Rx0000049 | Baxter Healthcare Corporation | 10/23/2024 | 0.9% SOD CHL IRRIG, USP, 3000ML ARTHROMATIC, 4 Plastic Cont. | 00338004727 | Non-innovator Multiple Source Drug | ||||
| Rx0000049 | Baxter Healthcare Corporation | 10/23/2024 | 0.9% SOD CHL IRRIG, USP, 3000ML ARTHROMATIC, 4 Plastic Cont. | 00338004727 | Non-innovator Multiple Source Drug | ||||
| Rx0000049 | Baxter Healthcare Corporation | 10/23/2024 | 0.9% SOD.CHL.IRRIG. USP 3000ML, 4 UROMATIC CONTAINER | 00338004747 | Non-innovator Multiple Source Drug | ||||
| Rx0000049 | Baxter Healthcare Corporation | 10/23/2024 | 0.9% SOD.CHL.IRRIG. USP 3000ML, 4 UROMATIC CONTAINER | 00338004747 | Non-innovator Multiple Source Drug | ||||
| Rx0000049 | Baxter Healthcare Corporation | 10/23/2024 | 10% DEXTROSE INJECTION USP 250ML MIGRATED, 36 Flex Cont. | 00338002302 | Non-innovator Multiple Source Drug | ||||
| Rx0000049 | Baxter Healthcare Corporation | 10/23/2024 | 20 MEQ POT CHL IN .9% SOD CHLINJ,USP 1000ML, 14 Flex Cont. | 00338069104 | Non-innovator Multiple Source Drug | ||||
| Rx0000049 | Baxter Healthcare Corporation | 10/23/2024 | 20MEQ POT CHL IN 5% DEX&0.9%SOD CHL INJ, USP 1000ML, 14 Flex Cont. | 00338080304 | Non-innovator Multiple Source Drug | ||||
| Rx0000049 | Baxter Healthcare Corporation | 10/23/2024 | 5% DEX AND 0.45% SOD CHL INJ,USP 1000ML, 14 Flex Cont. | 00338008504 | Non-innovator Multiple Source Drug | ||||
| Rx0000049 | Baxter Healthcare Corporation | 10/23/2024 | 5% DEX AND 0.9% SOD CHL ING,USP 1000ML, 14 Flex Cont. | 00338008904 | Non-innovator Multiple Source Drug | ||||
| Rx0000049 | Baxter Healthcare Corporation | 10/23/2024 | 5% DEX INJ, USP, 100 ML , 80 MINI-BAG PLUS CONTAINER | 00338055118 | Non-innovator Multiple Source Drug | ||||
| Rx0000049 | Baxter Healthcare Corporation | 10/23/2024 | 5% DEX INJ, USP, 50ML, 80 MINI-BAG PLUS CONTAINER | 00338055111 | Non-innovator Multiple Source Drug | ||||
| Rx0000049 | Baxter Healthcare Corporation | 10/23/2024 | DEXTROSE 5% INJECTION USP 1000ML MIGRATED, 14 flex cont. | 00338001704 | Non-innovator Multiple Source Drug | ||||
| Rx0000049 | Baxter Healthcare Corporation | 10/23/2024 | DEXTROSE 5% INJECTION USP 250ML MIGRATED, 36 Flex Cont. | 00338001702 | Non-innovator Multiple Source Drug | ||||
| Rx0000049 | Baxter Healthcare Corporation | 10/23/2024 | LACTATED RINGERS & 5% DEXTROSEINJ, USP 1000ML, 14 Flex Cont. | 00338012504 | Non-innovator Multiple Source Drug | ||||
| Rx0000049 | Baxter Healthcare Corporation | 10/23/2024 | LACTATED RINGERS IRRIG, 3000 ML ARTHROMATIC, 4 Plastic Cont. | 00338013727 | Non-innovator Multiple Source Drug | ||||
| Rx0000049 | Baxter Healthcare Corporation | 10/23/2024 | NACL 0.9% INJ USP 50ML, 96 MINI-BAG TM VIAFLEX MIGRATED | 00338004911 | Non-innovator Multiple Source Drug | ||||
| Rx0000049 | Baxter Healthcare Corporation | 10/23/2024 | PLASMA-LYTE A INJECTION PH 7.4MULTIPLE 1000ML 14 Flex Cont. | 00338022104 | Non-innovator Multiple Source Drug | ||||
| Rx0000049 | Baxter Healthcare Corporation | 10/23/2024 | SOD CHLOR 0.9% INJ USP 100ML, 96 MINI- BAG TM VIAFLEX MIGRATED | 00338004918 | Non-innovator Multiple Source Drug | ||||
| Rx0000049 | Baxter Healthcare Corporation | 10/23/2024 | SOD CHLOR 0.9% INJ USP 50ML, 80 MINI-BAG PLUS CONT MIGRATED | 00338055311 | Non-innovator Multiple Source Drug | ||||
| Rx0000049 | Baxter Healthcare Corporation | 10/23/2024 | SOD CHLOR 0.9% INJ USP250ML, 36 VIAFLEXPLASTIC MIGRATED | 00338004902 | Non-innovator Multiple Source Drug | ||||
| Rx0000049 | Baxter Healthcare Corporation | 10/23/2024 | STERILE WATER FOR INJ.USP 1000ML, 14 Flex Cont | 00338001304 | Non-innovator Multiple Source Drug | ||||
| Rx0000049 | Baxter Healthcare Corporation | 10/23/2024 | STERILE WATER FOR INJ.USP 1000ML, 14 Flex Cont | 00338001304 | Non-innovator Multiple Source Drug | ||||
| Rx0000024 | Bayer | 03/31/2024 | ADEMPAS 0.5 MG TABLET 9 count | 50419025091 | 02/18/2034 | Single Source Drug | |||
| Rx0000024 | Bayer | 03/31/2024 | ADEMPAS 0.5 MG TABLET 90 count | 50419025001 | 02/18/2034 | Single Source Drug | |||
| Rx0000024 | Bayer | 03/31/2024 | ADEMPAS 1 MG TABLET 9 count | 50419025191 | 02/18/2034 | Single Source Drug | |||
| Rx0000024 | Bayer | 03/31/2024 | ADEMPAS 1 MG TABLET 90 count | 50419025101 | 02/18/2034 | Single Source Drug | |||
| Rx0000024 | Bayer | 03/31/2024 | ADEMPAS 1.5 MG TABLET 9 count | 50419025291 | 02/18/2034 | Single Source Drug | |||
| Rx0000024 | Bayer | 03/31/2024 | ADEMPAS 1.5 MG TABLET 90 count | 50419025201 | 02/18/2034 | Single Source Drug | |||
| Rx0000024 | Bayer | 03/31/2024 | ADEMPAS 2 MG TABLET 9 count | 50419025391 | 02/18/2034 | Single Source Drug | |||
| Rx0000024 | Bayer | 03/31/2024 | ADEMPAS 2 MG TABLET 90 count | 50419025301 | 02/18/2034 | Single Source Drug | |||
| Rx0000024 | Bayer | 03/31/2024 | ADEMPAS 2.5 MG TABLET 9 count | 50419025491 | 02/18/2034 | Single Source Drug | |||
| Rx0000024 | Bayer | 03/31/2024 | ADEMPAS 2.5 MG TABLET 90 count | 50419025401 | 02/18/2034 | Single Source Drug | |||
| Rx0000024 | Bayer | 03/31/2024 | BETASERON-01 | 50419052401 | Single Source Drug | ||||
| Rx0000024 | Bayer | 03/31/2024 | BETASERON-35 | 50419052435 | Single Source Drug | ||||
| Rx0000024 | Bayer | 03/31/2024 | Nexavar 200mg 120 Tablets | 50419048858 | 09/10/2028 | Single Source Drug | |||
| Rx0000024 | Bayer | 03/31/2024 | Stivarga 40 mg tab 21 count bottle | 50419017105 | 06/02/2030 | Single Source Drug | |||
| Rx0000024 | Bayer | 03/31/2024 | Stivarga 40 mg tab 28 count bottle | 50419017101 | 07/09/2032 | Single Source Drug | |||
| Rx0000024 | Bayer | 03/31/2024 | Stivarga 40 mg tab 3x28 count bottle | 50419017103 | 07/09/2032 | Single Source Drug | |||
| Rx0000024 | Bayer | 03/31/2024 | Stivarga 40 mg tab 4x21 count bottle | 50419017106 | 06/02/2030 | Single Source Drug | |||
| Rx0000024 | Bayer | 03/31/2024 | VITRAKVI 100MG CAPS BT 1x60 | 50419039101 | Single Source Drug | ||||
| Rx0000024 | Bayer | 03/31/2024 | Vitrakvi 20 mg/mL oral solution | 50419039201 | Single Source Drug | ||||
| Rx0000024 | Bayer | 03/31/2024 | VITRAKVI 25MG CAPS BT 1x60 | 50419039001 | Single Source Drug | ||||
| Rx0000103 | Biocodex USA | 03/31/2024 | Diacomit 250mg Capsule 60ct | 68418793906 | Single Source Drug | ||||
| Rx0000103 | Biocodex USA | 08/21/2024 | Diacomit 250mg Capsule 60ct | 68418793906 | Single Source Drug | ||||
| Rx0000103 | Biocodex USA | 03/31/2024 | Diacomit 250mg Packet 60ct | 68418794106 | Single Source Drug | ||||
| Rx0000103 | Biocodex USA | 08/21/2024 | Diacomit 250mg Packet 60ct | 68418794106 | Single Source Drug | ||||
| Rx0000103 | Biocodex USA | 03/31/2024 | Diacomit 500mg Capsule 60ct | 68418794006 | Single Source Drug | ||||
| Rx0000103 | Biocodex USA | 08/21/2024 | Diacomit 500mg Capsule 60ct | 68418794006 | Single Source Drug | ||||
| Rx0000103 | Biocodex USA | 03/31/2024 | Diacomit 500mg Packet 60ct | 68418794206 | Single Source Drug | ||||
| Rx0000103 | Biocodex USA | 08/21/2024 | Diacomit 500mg Packet 60ct | 68418794206 | Single Source Drug | ||||
| Rx0000261 | BioMarin Pharmaceutical Inc | 07/15/2024 | BRINEURA 150 mg/5 mL INJ, Kit (Two 5 mL vials (30mg/ml) (IEV)-one 5ml vial) | 68135081102 | 05/05/2036 | Single Source Drug | |||
| Rx0000261 | BioMarin Pharmaceutical Inc | 07/15/2024 | NAGLAZYME 1MG/ML INJ, (5 mL vial) | 68135002001 | Single Source Drug | ||||
| Rx0000261 | BioMarin Pharmaceutical Inc | 07/15/2024 | PALYNZIQ 10MG/0.5ML INJ,SYR,0.5MLsingle-dose prefilled syringe | 68135075620 | 02/03/2031 | Single Source Drug | Inner NDC's for Palynziq: 68135005889, 68135067339, 68135075619 | ||
| Rx0000261 | BioMarin Pharmaceutical Inc | 07/15/2024 | PALYNZIQ 2.5MG/0.5ML INJ,SYR,0.5ML single-dose prefilled syringe | 68135005890 | 02/03/2031 | Single Source Drug | Inner NDC's for Palynziq: 68135005889, 68135067339, 68135075619 | ||
| Rx0000261 | BioMarin Pharmaceutical Inc | 07/15/2024 | PALYNZIQ 20MG/ML INJ,SYR,1ML single-dose prefilled syringe | 68135067340 | 02/03/2031 | Single Source Drug | Inner NDC's for Palynziq: 68135005889, 68135067339, 68135075619 | ||
| Rx0000261 | BioMarin Pharmaceutical Inc | 07/15/2024 | PALYNZIQ 20MG/ML INJ,SYR,1ML Ten 1 mL single- dose prefilled syringes | 68135067345 | 02/03/2031 | Single Source Drug | Inner NDC's for Palynziq: 68135005889, 68135067339, 68135075619 | ||
| Rx0000261 | BioMarin Pharmaceutical Inc | 07/15/2024 | VIMIZIM 1MG/ML INJ,SOLN,5ML vial | 68135010001 | 01/10/2032 | Single Source Drug | |||
| Rx0000038 | Boehringer Ingelheim | 04/26/2024 | OFEV 100MG CAPSULE 60 | 00597014360 | 12/07/2029 | Single Source Drug | For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the Orange Book), the latest patent expiration is provided. Not acquired within the last five years. | ||
| Rx0000038 | Boehringer Ingelheim | 04/26/2024 | OFEV 150MG CAPSULE 60 | 00597014560 | 12/07/2029 | Single Source Drug | For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the Orange Book), the latest patent expiration is provided. Not acquired within the last five years. | ||
| Rx0000078 | Bristol Myers Squibb | 04/29/2024 | ABECMA® 250 mL infusion bag and metal cassette | 59572051502 | 2021 | 02/09/2036 | Single Source Drug | Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets. | |
| Rx0000078 | Bristol Myers Squibb | 04/29/2024 | ABECMA® 50 mL infusion bag and metal cassette | 59572051501 | 2021 | 02/09/2036 | Single Source Drug | Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets. | |
| Rx0000078 | Bristol Myers Squibb | 04/29/2024 | ABECMA® 500 mL infusion bag and metal cassette | 59572051503 | 2021 | 02/09/2036 | Single Source Drug | Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets. | |
| Rx0000078 | Bristol Myers Squibb | 04/29/2024 | BREYANZI® Carton up to 4 vials of cryopreserved CAR-positive T cells | 73153090001 | 2021 | 08/20/2033 | Single Source Drug | Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets. | |
| Rx0000078 | Bristol Myers Squibb | 04/29/2024 | ELIQUIS® 2.5 mg tablet 60 count bottle | 00003089321 | 02/24/2031 | Single Source Drug | This product was developed by BMS. Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years | ||
| Rx0000078 | Bristol Myers Squibb | 04/29/2024 | ELIQUIS® 2.5 mg tablet pack of 100 | 00003089331 | 02/24/2031 | Single Source Drug | This product was developed by BMS. Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years | ||
| Rx0000078 | Bristol Myers Squibb | 04/29/2024 | ELIQUIS® 5 mg tablet 60 count bottle | 00003089421 | 02/24/2031 | Single Source Drug | This product was developed by BMS. Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years | ||
| Rx0000078 | Bristol Myers Squibb | 04/29/2024 | ELIQUIS® 5 mg tablet 74 count bottle | 00003089470 | 02/24/2031 | Single Source Drug | This product was developed by BMS. Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years | ||
| Rx0000078 | Bristol Myers Squibb | 04/29/2024 | ELIQUIS® 5 mg tablet pack of 100 | 00003089431 | 02/24/2031 | Single Source Drug | This product was developed by BMS. Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years | ||
| Rx0000078 | Bristol Myers Squibb | 04/29/2024 | ELIQUIS® 5 mg tablet pack of 74 | 00003376474 | 02/24/2031 | Single Source Drug | This product was developed by BMS. Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years | ||
| Rx0000078 | Bristol Myers Squibb | 04/29/2024 | IDHIFA® 100mg, 30 Tablets/Bottle | 59572071030 | 2017 | 09/16/2034 | Single Source Drug | Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets. | |
| Rx0000078 | Bristol Myers Squibb | 04/29/2024 | IDHIFA® 50mg, 30 Tablets/Bottle | 59572070530 | 2017 | 09/16/2034 | Single Source Drug | Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets. | |
| Rx0000078 | Bristol Myers Squibb | 04/29/2024 | INREBIC® 100mg, 120 Capsules/Bottle | 59572072012 | 2019 | 12/16/2026 | Single Source Drug | Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets. | |
| Rx0000078 | Bristol Myers Squibb | 04/29/2024 | ONUREG® 200 mg tablet pack of 7 | 59572073007 | 2021 | 06/03/2030 | Single Source Drug | Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets. | |
| Rx0000078 | Bristol Myers Squibb | 04/29/2024 | ONUREG® 300 mg tablet pack of 7 | 59572074007 | 2021 | 06/03/2030 | Single Source Drug | Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets. | |
| Rx0000078 | Bristol Myers Squibb | 04/29/2024 | ORENCIA® 125 mg Solution, 1ml Single Dose Prefilled Auto-injector, pack of 4 Auto-Injectors | 00003218851 | 02/18/2028 | Single Source Drug | This product was developed by BMS. Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years | ||
| Rx0000078 | Bristol Myers Squibb | 04/29/2024 | ORENCIA® 125 mg Solution, 1ml Single Dose Prefilled Syringe, pack of 4 Syringes | 00003218811 | 02/18/2028 | Single Source Drug | This product was developed by BMS. Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years | ||
| Rx0000078 | Bristol Myers Squibb | 04/29/2024 | ORENCIA® 250 mg lyophilized powder | 00003218713 | 12/19/2026 | Single Source Drug | This product was developed by BMS. Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years | ||
| Rx0000078 | Bristol Myers Squibb | 10/15/2024 | ORENCIA® 250 mg lyophilized powder | 00003218713 | 12/19/2026 | Single Source Drug | This product was developed by BMS. Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years | ||
| Rx0000078 | Bristol Myers Squibb | 04/29/2024 | ORENCIA® 50 mg/0.4ml Solution, 0.4ml Single Dose Prefilled Syringe, pack of 4 Syringes | 00003281411 | 02/18/2028 | Single Source Drug | This product was developed by BMS. Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years | ||
| Rx0000078 | Bristol Myers Squibb | 04/29/2024 | ORENCIA® 87.5 mg/0.7ml Solution, 0.7ml Single Dose Prefilled Syringe, pack of 4 Syringes | 00003281811 | 02/18/2028 | Single Source Drug | This product was developed by BMS. Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years | ||
| Rx0000078 | Bristol Myers Squibb | 04/29/2024 | POMALYST® 1 mg capsule pack of 100 | 59572050100 | 2013 | 12/21/2031 | Single Source Drug | Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets. | |
| Rx0000078 | Bristol Myers Squibb | 04/29/2024 | POMALYST® 1 mg capsule pack of 21 | 59572050121 | 2013 | 12/21/2031 | Single Source Drug | Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets. | |
| Rx0000078 | Bristol Myers Squibb | 04/29/2024 | POMALYST® 2 mg capsule pack of 100 | 59572050200 | 2013 | 12/21/2031 | Single Source Drug | Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets. | |
| Rx0000078 | Bristol Myers Squibb | 04/29/2024 | POMALYST® 2 mg capsule pack of 21 | 59572050221 | 2013 | 12/21/2031 | Single Source Drug | Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets. | |
| Rx0000078 | Bristol Myers Squibb | 04/29/2024 | POMALYST® 3 mg capsule pack of 100 | 59572050300 | 2013 | 12/21/2031 | Single Source Drug | Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets. | |
| Rx0000078 | Bristol Myers Squibb | 04/29/2024 | POMALYST® 3 mg capsule pack of 21 | 59572050321 | 2013 | 12/21/2031 | Single Source Drug | Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets. | |
| Rx0000078 | Bristol Myers Squibb | 04/29/2024 | POMALYST® 4 mg capsule pack of 100 | 59572050400 | 2013 | 12/21/2031 | Single Source Drug | Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets. | |
| Rx0000078 | Bristol Myers Squibb | 04/29/2024 | POMALYST® 4 mg capsule pack of 21 | 59572050421 | 2013 | 12/21/2031 | Single Source Drug | Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets. | |
| Rx0000078 | Bristol Myers Squibb | 04/29/2024 | SPRYCEL® 100 mg tablet, bottle of 30 | 00003085222 | 09/28/2026 | Single Source Drug | This product was developed by BMS. Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years | ||
| Rx0000078 | Bristol Myers Squibb | 04/29/2024 | SPRYCEL® 140 mg tablet, bottle of 30 | 00003085722 | 09/28/2026 | Single Source Drug | This product was developed by BMS. Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years | ||
| Rx0000078 | Bristol Myers Squibb | 04/29/2024 | SPRYCEL® 20 mg tablet, bottle of 60 | 00003052711 | 09/28/2026 | Single Source Drug | This product was developed by BMS. Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years | ||
| Rx0000078 | Bristol Myers Squibb | 04/29/2024 | SPRYCEL® 50 mg tablet, bottle of 60 | 00003052811 | 09/28/2026 | Single Source Drug | This product was developed by BMS. Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years | ||
| Rx0000078 | Bristol Myers Squibb | 04/29/2024 | SPRYCEL® 70 mg tablet, bottle of 60 | 00003052411 | 09/28/2026 | Single Source Drug | This product was developed by BMS. Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years | ||
| Rx0000078 | Bristol Myers Squibb | 04/29/2024 | SPRYCEL® 80 mg tablet, bottle of 30 | 00003085522 | 09/28/2026 | Single Source Drug | This product was developed by BMS. Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years | ||
| Rx0000078 | Bristol Myers Squibb | 04/29/2024 | ZEPOSIA® 0.23, 0.46MG TITR STR PCK 7CT US (Wallet) | 59572081007 | 2020 | 05/14/2029 | Single Source Drug | Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets. | |
| Rx0000078 | Bristol Myers Squibb | 04/29/2024 | ZEPOSIA® 0.23,0.46,0.92MG 28CT KIT US | 59572089028 | 2023 | 05/14/2029 | Single Source Drug | Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $74,000,000,000. This acquisition did not consist of costs for individual assets. | |
| Rx0000078 | Bristol Myers Squibb | 04/29/2024 | ZEPOSIA® 0.92MG CAP 30CT BTL US | 59572082030 | 2020 | 05/14/2029 | Single Source Drug | Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets. | |
| Rx0000498 | Catalyst Pharmaceuticals Inc | 04/09/2024 | Firdapse 10mg Tablet 240/Bottle | 69616021103 | 02/25/2037 | Single Source Drug | |||
| Rx0000498 | Catalyst Pharmaceuticals Inc | 04/09/2024 | Firdapse Blister shelf pack of 120 - 10mg tablets | 69616021106 | 02/25/2037 | Single Source Drug | |||
| Rx0000498 | Catalyst Pharmaceuticals Inc | 04/09/2024 | Fycompa 0.05MG/ML Oral Suspension | 62856029038 | 2016 | 05/22/2025 | Single Source Drug | ||
| Rx0000498 | Catalyst Pharmaceuticals Inc | 04/09/2024 | Fycompa 0.05MG/ML Oral Suspension 340 | 69616029038 | 05/22/2025 | Single Source Drug | |||
| Rx0000498 | Catalyst Pharmaceuticals Inc | 04/09/2024 | Fycompa 10mg Tablet | 62856028030 | 2014 | 05/22/2025 | Single Source Drug | ||
| Rx0000498 | Catalyst Pharmaceuticals Inc | 04/09/2024 | Fycompa 10mg Tablet 30 | 69616028030 | 05/22/2025 | Single Source Drug | |||
| Rx0000498 | Catalyst Pharmaceuticals Inc | 04/09/2024 | Fycompa 12mg Tablet | 62856028230 | 2013 | 05/22/2025 | Single Source Drug | ||
| Rx0000498 | Catalyst Pharmaceuticals Inc | 04/09/2024 | Fycompa 12mg Tablet 30 | 69616028230 | 05/22/2025 | Single Source Drug | |||
| Rx0000498 | Catalyst Pharmaceuticals Inc | 04/09/2024 | Fycompa 2mg Tablet | 62856027230 | 2013 | 05/22/2025 | Single Source Drug | ||
| Rx0000498 | Catalyst Pharmaceuticals Inc | 04/09/2024 | Fycompa 2mg Tablet 30 | 69616027230 | 05/22/2025 | Single Source Drug | |||
| Rx0000498 | Catalyst Pharmaceuticals Inc | 04/09/2024 | Fycompa 4mg Tablet | 62856027430 | 2013 | 05/22/2025 | Single Source Drug | ||
| Rx0000498 | Catalyst Pharmaceuticals Inc | 04/09/2024 | Fycompa 4mg Tablet 30 | 69616027430 | 05/22/2025 | Single Source Drug | |||
| Rx0000498 | Catalyst Pharmaceuticals Inc | 04/09/2024 | Fycompa 6mg Tablet | 62856027630 | 2013 | 05/22/2025 | Single Source Drug | ||
| Rx0000498 | Catalyst Pharmaceuticals Inc | 04/09/2024 | Fycompa 6mg Tablet 30 | 69616027630 | 05/22/2025 | Single Source Drug | |||
| Rx0000498 | Catalyst Pharmaceuticals Inc | 04/09/2024 | Fycompa 8mg Tablet | 62856027830 | 2013 | 05/22/2025 | Single Source Drug | ||
| Rx0000498 | Catalyst Pharmaceuticals Inc | 04/09/2024 | Fycompa 8mg Tablet 30 | 69616027830 | 05/22/2025 | Single Source Drug | |||
| Rx0000139 | Chiesi USA | 04/11/2024 | Cleviprex injectable emulsion 25mg/50mL 10 vials in 1 box - Emulsion | 10122061010 | 2008 | 10/10/2031 | Single Source Drug | ||
| Rx0000139 | Chiesi USA | 04/11/2024 | Cleviprex injectable emulsion 50mg/100mL 10 vials in 1 box - Emulsion | 10122061110 | 2008 | 10/10/2031 | Single Source Drug | ||
| Rx0000139 | Chiesi USA | 04/09/2024 | Curosurf® 1.5ml 80mg/mL 1 1.5mL vial - Suspension | 10122051001 | Single Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Chieisi USA believes is otherwise in the public domain or publicly available. (2) Columns 14-22 were intentionally left blank for this submission, as the drug was not acquired. | |||
| Rx0000139 | Chiesi USA | 04/09/2024 | Curosurf® 3.0ml 80mg/mL 1 3.0mL vial - Suspension | 10122051003 | Single Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Chieisi USA believes is otherwise in the public domain or publicly available. (2) Columns 14-22 were intentionally left blank for this submission, as the drug was not acquired. | |||
| Rx0000139 | Chiesi USA | 04/08/2024 | Ferriprox ORAL SOLUTION 100mg/1mL 1 bottle of 500 mL - Solution | 10122010150 | 2015 | 10/26/2029 | Single Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Chieisi USA believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administrations Orange Book, as of April 3, 2024. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. | |
| Rx0000139 | Chiesi USA | 04/08/2024 | Ferriprox TD 1000mg FILM COATED TABLETS 1000mg 1 carton of 5 blister packs - Tablet | 10122010401 | 10/25/2038 | Single Source Drug | Acquired while in development. Approved while owned by Chiesi USA. | ||
| Rx0000139 | Chiesi USA | 04/12/2024 | Juxtapid Oral Capsule 10 MG 1 package of 28 capsules - Capsule | 76431011001 | 2012 | 08/19/2027 | Single Source Drug | ||
| Rx0000139 | Chiesi USA | 04/12/2024 | Juxtapid Oral Capsule 20 MG 1 package of 28 capsules - Capsule | 76431012001 | 2012 | 08/19/2027 | Single Source Drug | ||
| Rx0000139 | Chiesi USA | 04/12/2024 | Juxtapid Oral Capsule 30 MG 1 package of 28 capsules - Capsule | 76431013001 | 2015 | 08/19/2027 | Single Source Drug | ||
| Rx0000139 | Chiesi USA | 04/12/2024 | Juxtapid Oral Capsule 5 MG 1 package of 28 capsules - Capsule | 76431010501 | 2012 | 08/19/2027 | Single Source Drug | ||
| Rx0000139 | Chiesi USA | 04/08/2024 | Kengreal for injection 50mg/10ML 50mg 1 box of 28 ampules - Solution | 10122062010 | 07/10/2035 | Single Source Drug | |||
| Rx0000139 | Chiesi USA | 04/11/2024 | Myalept Subcutaneous Soltution Reconsituted 11.3 MG 1 vial - Injectable | 76431021001 | 2014 | Single Source Drug | |||
| Rx0000139 | Chiesi USA | 04/10/2024 | Mycapssa 20mg 1 package of 28 capsules - Capsule | 69880012028 | 2020 | 12/28/2040 | Single Source Drug | ||
| Rx0000139 | Chiesi USA | 04/08/2024 | Revcovi® (elapegademase-IvIr 1.6mg/ml) Injection 1 vial 2.4mg/1.5mL - Solution | 10122050201 | 2018 | Single Source Drug | |||
| Rx0000080 | Cipla USA, Inc. | 07/15/2024 | Griseofulvin Oral Suspension USP (microsize) 125mg/5ml, 120ml | 69097036108 | Non-innovator Multiple Source Drug | ||||
| Rx0000320 | CMP Pharma | 03/31/2024 | Sodium Polystyrene Sulfonate, suspension, 15g/60ml, 10 BOTTLE in 1 CARTON 60 mL in 1 BOTTLE, | 46287000660 | Non-innovator Multiple Source Drug | ||||
| Rx0000320 | CMP Pharma | 03/31/2024 | Sodium Polystyrene Sulfonate, suspension, 15g/60mL, 120 mL in 1 BOTTLE | 46287000604 | Non-innovator Multiple Source Drug | ||||
| Rx0000320 | CMP Pharma | 03/31/2024 | Sodium Polystyrene Sulfonate, suspension, 15g/60ml, 473 mL in 1 BOTTLE | 46287000601 | Non-innovator Multiple Source Drug | ||||
| Rx0000200 | Collegium Pharmaceuticals | 04/19/2024 | Belbuca 150mg, 1 box of 60 films | 59385002260 | 2015 | 12/21/2032 | Innovator Multiple Source Drug | na | |
| Rx0000200 | Collegium Pharmaceuticals | 04/19/2024 | Belbuca 300mg 1 box of 60 films | 59385002360 | 2015 | 12/21/2032 | Innovator Multiple Source Drug | na | |
| Rx0000200 | Collegium Pharmaceuticals | 04/19/2024 | Belbuca 450mg, 1 box of 60 films | 59385002460 | 2015 | 12/21/2032 | Innovator Multiple Source Drug | na | |
| Rx0000200 | Collegium Pharmaceuticals | 04/19/2024 | Belbuca 600mg, 1 box of 60 films | 59385002560 | 2015 | 12/21/2032 | Innovator Multiple Source Drug | na | |
| Rx0000200 | Collegium Pharmaceuticals | 04/19/2024 | Belbuca 750mg, 1 box of 60 films | 59385002660 | 2015 | 12/21/2032 | Innovator Multiple Source Drug | na | |
| Rx0000200 | Collegium Pharmaceuticals | 04/19/2024 | Belbuca 900mg, 1 box of 60 films | 59385002760 | 2015 | 12/21/2032 | Innovator Multiple Source Drug | na | |
| Rx0000200 | Collegium Pharmaceuticals | 04/19/2024 | Belbuca, 75mg, 1 box of 60 films | 59385002160 | 2015 | 12/21/2032 | Innovator Multiple Source Drug | na | |
| Rx0000200 | Collegium Pharmaceuticals | 04/19/2024 | Nucynta 100mg, tablet, 100 pack | 24510010010 | 2009 | 06/27/2025 | Innovator Multiple Source Drug | na | |
| Rx0000200 | Collegium Pharmaceuticals | 04/19/2024 | Nucynta 50mg, tablet, 100 pack | 24510005010 | 2009 | 06/27/2025 | Innovator Multiple Source Drug | na | |
| Rx0000200 | Collegium Pharmaceuticals | 04/19/2024 | Nucynta 75mg, tablet, 100 pack | 24510007510 | 2009 | 06/27/2025 | Innovator Multiple Source Drug | na | |
| Rx0000200 | Collegium Pharmaceuticals | 04/19/2024 | Nucynta ER 100mg, tablet, 60 pack | 24510011660 | 2011 | 09/22/2028 | Innovator Multiple Source Drug | na | |
| Rx0000200 | Collegium Pharmaceuticals | 04/19/2024 | Nucynta ER 150 mg, tablet, 60 pack | 24510017460 | 2011 | 09/22/2028 | Innovator Multiple Source Drug | na | |
| Rx0000200 | Collegium Pharmaceuticals | 04/19/2024 | Nucynta ER 200 mg, tablet, 60 pack | 24510023260 | 2011 | 09/22/2028 | Innovator Multiple Source Drug | na | |
| Rx0000200 | Collegium Pharmaceuticals | 04/19/2024 | Nucynta ER 250 mg, tablet, 60 pack | 24510029160 | 2011 | 09/22/2028 | Innovator Multiple Source Drug | na | |
| Rx0000200 | Collegium Pharmaceuticals | 04/19/2024 | Nucynta ER 50mg, tablet, 60 pack | 24510005860 | 2011 | 09/22/2028 | Innovator Multiple Source Drug | na | |
| Rx0000200 | Collegium Pharmaceuticals | 04/19/2024 | Symproic 0.2 mg, 1 bottle of 30 tablets | 59385004130 | 2017 | 05/13/2033 | Innovator Multiple Source Drug | na | |
| Rx0000200 | Collegium Pharmaceuticals | 04/19/2024 | Xtampza ER 13.5mg, capsule, 100 pack | 24510011510 | 09/02/2036 | Innovator Multiple Source Drug | na | ||
| Rx0000200 | Collegium Pharmaceuticals | 04/19/2024 | Xtampza ER 18mg, capsule, 100 pack | 24510012010 | 09/02/2036 | Innovator Multiple Source Drug | na | ||
| Rx0000200 | Collegium Pharmaceuticals | 04/19/2024 | Xtampza ER 27mg, capsule, 100 pack | 24510013010 | 09/02/2036 | Innovator Multiple Source Drug | na | ||
| Rx0000200 | Collegium Pharmaceuticals | 04/19/2024 | Xtampza ER 36mg, capsule, 100 pack | 24510014010 | 09/02/2036 | Innovator Multiple Source Drug | na | ||
| Rx0000200 | Collegium Pharmaceuticals | 04/19/2024 | Xtampza ER 9mg, capsule, 100 pack | 24510011010 | 09/02/2036 | Innovator Multiple Source Drug | na | ||
| Rx0000154 | Corcept Therapeutics Incorporated | 04/29/2024 | Korlym (mifepristone) 300mg Tablet (Bottle of 28) | 76346007301 | 08/22/2038 | Innovator Multiple Source Drug | WAC is reported at the package level. The information provided herein is provided to the best of our knowledge as of submission and based on our interpretation of applicable statutory and regulatory provisions. Information designated as confidential has been designated as such based on our understanding and belief that the subject information is non-public. Our provision of information shall not be interpreted as a waiver of any of our rights available under state, federal, or other applicable law with respect to the information contained herein or with respect to California SB 17, all of which we expressly reserve. Patent expiration dates do not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. | ||
| Rx0000154 | Corcept Therapeutics Incorporated | 04/29/2024 | Korlym (mifepristone) 300mg Tablet (Bottle of 280) | 76346007302 | 08/22/2038 | Innovator Multiple Source Drug | WAC is reported at the package level. The information provided herein is provided to the best of our knowledge as of submission and based on our interpretation of applicable statutory and regulatory provisions. Information designated as confidential has been designated as such based on our understanding and belief that the subject information is non-public. Our provision of information shall not be interpreted as a waiver of any of our rights available under state, federal, or other applicable law with respect to the information contained herein or with respect to California SB 17, all of which we expressly reserve. Patent expiration dates do not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. | ||
| Rx0000184 | Cosette Pharmaceuticals, Inc. | 10/24/2024 | Azor Tablets 10 mg/20 mg | 00713087130 | 2007 | Innovator Multiple Source Drug | |||
| Rx0000184 | Cosette Pharmaceuticals, Inc. | 10/24/2024 | Azor Tablets 10 mg/40 mg | 00713087330 | 2007 | Innovator Multiple Source Drug | |||
| Rx0000184 | Cosette Pharmaceuticals, Inc. | 10/24/2024 | Azor Tablets 5 mg/20 mg | 00713087030 | 2007 | Innovator Multiple Source Drug | |||
| Rx0000184 | Cosette Pharmaceuticals, Inc. | 10/24/2024 | Azor Tablets 5 mg/40 mg | 00713087230 | 2007 | Innovator Multiple Source Drug | |||
| Rx0000184 | Cosette Pharmaceuticals, Inc. | 10/24/2024 | Benicar HCT Tablets 20 mg/12.5 mg | 00713086330 | 2003 | Innovator Multiple Source Drug | |||
| Rx0000184 | Cosette Pharmaceuticals, Inc. | 10/24/2024 | Benicar HCT Tablets 40 mg/12.5 mg | 00713086430 | 2003 | Innovator Multiple Source Drug | |||
| Rx0000184 | Cosette Pharmaceuticals, Inc. | 10/24/2024 | Benicar HCT Tablets 40 mg/25 mg | 00713086530 | 2003 | Innovator Multiple Source Drug | |||
| Rx0000184 | Cosette Pharmaceuticals, Inc. | 10/24/2024 | Benicar Tablets 20 mg | 00713086130 | 2002 | Innovator Multiple Source Drug | |||
| Rx0000184 | Cosette Pharmaceuticals, Inc. | 10/24/2024 | Benicar Tablets 40 mg | 00713086230 | 2002 | Innovator Multiple Source Drug | |||
| Rx0000184 | Cosette Pharmaceuticals, Inc. | 10/24/2024 | Benicar Tablets 5 mg | 00713086030 | 2002 | Innovator Multiple Source Drug | |||
| Rx0000184 | Cosette Pharmaceuticals, Inc. | 04/11/2024 | Clomid Tablets 50 mg 30-ct box | 00713088530 | 2022 | Single Source Drug | |||
| Rx0000184 | Cosette Pharmaceuticals, Inc. | 04/11/2024 | Clomid Tablets 50 ng 10-ct box | 00713088509 | 2022 | Single Source Drug | |||
| Rx0000184 | Cosette Pharmaceuticals, Inc. | 10/24/2024 | Effient Tablets 10 mg | 00713088230 | 2012 | Innovator Multiple Source Drug | |||
| Rx0000184 | Cosette Pharmaceuticals, Inc. | 10/24/2024 | Effient Tablets 5 mg | 00713088130 | 2012 | Innovator Multiple Source Drug | |||
| Rx0000184 | Cosette Pharmaceuticals, Inc. | 04/11/2024 | Migergot Suppositories 2-100 mg 12-ct box | 00713016612 | Single Source Drug | ||||
| Rx0000184 | Cosette Pharmaceuticals, Inc. | 10/24/2024 | Tribenzor Tablets 20 mg/5 mg/12.5 mg | 00713087430 | 2010 | Innovator Multiple Source Drug | |||
| Rx0000184 | Cosette Pharmaceuticals, Inc. | 10/24/2024 | Tribenzor Tablets 40 mg/10 mg/12.5 mg | 00713087730 | 2010 | Innovator Multiple Source Drug | |||
| Rx0000184 | Cosette Pharmaceuticals, Inc. | 10/24/2024 | Tribenzor Tablets 40 mg/10 mg/25 mg | 00713087830 | 2010 | Innovator Multiple Source Drug | |||
| Rx0000184 | Cosette Pharmaceuticals, Inc. | 10/24/2024 | Tribenzor Tablets 40 mg/5 mg/12.5 mg | 00713087530 | 2010 | Innovator Multiple Source Drug | |||
| Rx0000184 | Cosette Pharmaceuticals, Inc. | 10/24/2024 | Tribenzor Tablets 40 mg/5 mg/25 mg | 00713087630 | 2010 | Innovator Multiple Source Drug | |||
| Rx0000184 | Cosette Pharmaceuticals, Inc. | 10/24/2024 | Welchol for Oral Suspension 3.75 g | 00713088030 | 2010 | Innovator Multiple Source Drug | |||
| Rx0000184 | Cosette Pharmaceuticals, Inc. | 10/24/2024 | Welchol Tablets 625 mg | 00713087981 | 2000 | Innovator Multiple Source Drug | |||
| Rx0000425 | CSL Behring LLC | 04/10/2024 | Berinert 500 units (500 IU / Solution / Pkg Size 1) | 63833082502 | Single Source Drug | Please note that Berinert® is supplied with a Mix2Vial filter transfer set that is under patent until October 9, 2024 | |||
| Rx0000425 | CSL Behring LLC | 09/20/2024 | Berinert 500 units (500 IU / Solution / Pkg Size 1) | 63833082502 | Single Source Drug | CSL Behring supports patient access to our lifesaving medicines which is reflected in our responsible approach to drug pricing consistent with the value our therapies deliver. | |||
| Rx0000425 | CSL Behring LLC | 09/20/2024 | Haegarda 2000iu / 2000iu Solution / UOM EA = 1 vial | 63833082802 | Single Source Drug | CSL Behring supports patient access to our lifesaving medicines which is reflected in our responsible approach to drug pricing consistent with the value our therapies deliver. | |||
| Rx0000425 | CSL Behring LLC | 09/20/2024 | Haegarda 3000iu / 3000iu Solution / UOM EA = 1 vial | 63833082902 | Single Source Drug | CSL Behring supports patient access to our lifesaving medicines which is reflected in our responsible approach to drug pricing consistent with the value our therapies deliver. | |||
| Rx0000425 | CSL Behring LLC | 09/13/2024 | Hizentra 10 ml (2g) - inner / 2gm Solution / UOM EA = 1 vial | 44206045291 | 06/09/2032 | Single Source Drug | CSL Behring supports patient access to our lifesaving medicines which is reflected in our responsible approach to drug pricing consistent with the value our therapies deliver. | ||
| Rx0000425 | CSL Behring LLC | 09/13/2024 | Hizentra 10 ml (2g) PFS - inner / 2gm Solution / UOM EA = 1 vial | 44206045795 | 06/09/2032 | Single Source Drug | CSL Behring supports patient access to our lifesaving medicines which is reflected in our responsible approach to drug pricing consistent with the value our therapies deliver. | ||
| Rx0000425 | CSL Behring LLC | 09/13/2024 | Hizentra 10 ml (2g) PFS / 2gm Solution / UOM EA = 1 vial | 44206045722 | 06/09/2032 | Single Source Drug | CSL Behring supports patient access to our lifesaving medicines which is reflected in our responsible approach to drug pricing consistent with the value our therapies deliver. | ||
| Rx0000425 | CSL Behring LLC | 09/13/2024 | Hizentra 10 ml (2g) / 2gm Solution / UOM EA = 1 vial | 44206045202 | 06/09/2032 | Single Source Drug | CSL Behring supports patient access to our lifesaving medicines which is reflected in our responsible approach to drug pricing consistent with the value our therapies deliver. | ||
| Rx0000425 | CSL Behring LLC | 09/13/2024 | Hizentra 20 ml (4g) - inner / 4gm Solution / UOM EA = 1 vial | 44206045492 | 06/09/2032 | Single Source Drug | CSL Behring supports patient access to our lifesaving medicines which is reflected in our responsible approach to drug pricing consistent with the value our therapies deliver. | ||
| Rx0000425 | CSL Behring LLC | 09/13/2024 | Hizentra 20 ml (4g) PFS - inner / 4gm Solution / UOM EA = 1 vial | 44206045896 | 06/09/2032 | Single Source Drug | CSL Behring supports patient access to our lifesaving medicines which is reflected in our responsible approach to drug pricing consistent with the value our therapies deliver. | ||
| Rx0000425 | CSL Behring LLC | 09/13/2024 | Hizentra 20 ml (4g) PFS / 4gm Solution / UOM EA = 1 vial | 44206045824 | 06/09/2032 | Single Source Drug | CSL Behring supports patient access to our lifesaving medicines which is reflected in our responsible approach to drug pricing consistent with the value our therapies deliver. | ||
| Rx0000425 | CSL Behring LLC | 09/13/2024 | Hizentra 20 ml (4g) / 4gm Solution / UOM EA = 1 vial | 44206045404 | 06/09/2032 | Single Source Drug | CSL Behring supports patient access to our lifesaving medicines which is reflected in our responsible approach to drug pricing consistent with the value our therapies deliver. | ||
| Rx0000425 | CSL Behring LLC | 09/13/2024 | Hizentra 5 ml (1g) - inner / 1gm Solution / UOM EA = 1 vial | 44206045190 | 06/09/2032 | Single Source Drug | CSL Behring supports patient access to our lifesaving medicines which is reflected in our responsible approach to drug pricing consistent with the value our therapies deliver. | ||
| Rx0000425 | CSL Behring LLC | 09/13/2024 | Hizentra 5 ml (1g) / 1gm Solution / UOM EA = 1 vial | 44206045101 | 06/09/2032 | Single Source Drug | CSL Behring supports patient access to our lifesaving medicines which is reflected in our responsible approach to drug pricing consistent with the value our therapies deliver. | ||
| Rx0000425 | CSL Behring LLC | 09/13/2024 | Hizentra 5 ml (1g) PFS - inner / 1gm Solution / UOM EA = 1 vial | 44206045694 | 06/09/2032 | Single Source Drug | CSL Behring supports patient access to our lifesaving medicines which is reflected in our responsible approach to drug pricing consistent with the value our therapies deliver. | ||
| Rx0000425 | CSL Behring LLC | 09/13/2024 | Hizentra 5 ml (1g) PFS / 1gm Solution / UOM EA = 1 vial | 44206045621 | 06/09/2032 | Single Source Drug | CSL Behring supports patient access to our lifesaving medicines which is reflected in our responsible approach to drug pricing consistent with the value our therapies deliver. | ||
| Rx0000425 | CSL Behring LLC | 09/13/2024 | Hizentra 50 ml (10g) - inner / 10gm Solution / UOM EA = 1 vial | 44206045593 | 06/09/2032 | Single Source Drug | CSL Behring supports patient access to our lifesaving medicines which is reflected in our responsible approach to drug pricing consistent with the value our therapies deliver. | ||
| Rx0000425 | CSL Behring LLC | 09/13/2024 | Hizentra 50 ml (10g) / 10gm Solution / UOM EA = 1 vial | 44206045510 | 06/09/2032 | Single Source Drug | CSL Behring supports patient access to our lifesaving medicines which is reflected in our responsible approach to drug pricing consistent with the value our therapies deliver. | ||
| Rx0000425 | CSL Behring LLC | 09/13/2024 | Hizentra 50 ml (10g) PFS - inner / 10gm Solution / UOM EA = 1 vial | 44206045597 | 06/09/2032 | Single Source Drug | CSL Behring supports patient access to our lifesaving medicines which is reflected in our responsible approach to drug pricing consistent with the value our therapies deliver. | ||
| Rx0000425 | CSL Behring LLC | 09/13/2024 | Hizentra 50 ml (10g) PFS / 10gm Solution / UOM EA = 1 vial | 44206045525 | 06/09/2032 | Single Source Drug | CSL Behring supports patient access to our lifesaving medicines which is reflected in our responsible approach to drug pricing consistent with the value our therapies deliver. | ||
| Rx0000425 | CSL Behring LLC | 09/13/2024 | Privigen 100ml (10g) - Inner / 10gm Solution / UOM EA = 1 vial | 44206043791 | 08/03/2028 | Single Source Drug | CSL Behring supports patient access to our lifesaving medicines which is reflected in our responsible approach to drug pricing consistent with the value our therapies deliver. | ||
| Rx0000425 | CSL Behring LLC | 09/13/2024 | Privigen 100ml (10g) / 10gm Solution / UOM EA = 1 vial | 44206043710 | 08/03/2028 | Single Source Drug | CSL Behring supports patient access to our lifesaving medicines which is reflected in our responsible approach to drug pricing consistent with the value our therapies deliver. | ||
| Rx0000425 | CSL Behring LLC | 09/13/2024 | Privigen 200ml (20g) - Inner / 20gm Solution / UOM EA = 1 vial | 44206043892 | 08/03/2028 | Single Source Drug | CSL Behring supports patient access to our lifesaving medicines which is reflected in our responsible approach to drug pricing consistent with the value our therapies deliver. | ||
| Rx0000425 | CSL Behring LLC | 09/13/2024 | Privigen 200ml (20g) / 20gm Solution / UOM EA = 1 vial | 44206043820 | 08/03/2028 | Single Source Drug | CSL Behring supports patient access to our lifesaving medicines which is reflected in our responsible approach to drug pricing consistent with the value our therapies deliver. | ||
| Rx0000425 | CSL Behring LLC | 09/13/2024 | Privigen 400ml (40g) - Inner / 40gm Solution / UOM EA = 1 vial | 44206043993 | 08/03/2028 | Single Source Drug | CSL Behring supports patient access to our lifesaving medicines which is reflected in our responsible approach to drug pricing consistent with the value our therapies deliver. | ||
| Rx0000425 | CSL Behring LLC | 09/13/2024 | Privigen 400ml (40g) / 40gm Solution / UOM EA = 1 vial | 44206043940 | 08/03/2028 | Single Source Drug | CSL Behring supports patient access to our lifesaving medicines which is reflected in our responsible approach to drug pricing consistent with the value our therapies deliver. | ||
| Rx0000425 | CSL Behring LLC | 09/13/2024 | Privigen 50ml (5g) - Inner / 5gm Solution / UOM EA = 1 vial | 44206043690 | 08/03/2028 | Single Source Drug | CSL Behring supports patient access to our lifesaving medicines which is reflected in our responsible approach to drug pricing consistent with the value our therapies deliver. | ||
| Rx0000425 | CSL Behring LLC | 09/13/2024 | Privigen 50ml (5g) / 5gm Solution / UOM EA = 1 vial | 44206043605 | 08/03/2028 | Single Source Drug | CSL Behring supports patient access to our lifesaving medicines which is reflected in our responsible approach to drug pricing consistent with the value our therapies deliver. | ||
| Rx0000230 | Cumberland Pharmaceuticals | 05/01/2024 | CALDOLOR VIALS 25 5mL VIA. | 66220028708 | 09/14/2030 | Single Source Drug | |||
| Rx0000230 | Cumberland Pharmaceuticals | 07/09/2024 | KRISTALOSE 10GM SOLD BY CASE (30 PACKETS) | 66220071930 | Single Source Drug | ||||
| Rx0000230 | Cumberland Pharmaceuticals | 07/09/2024 | KRISTALOSE 20GM SOLD BY CASE (30 PACKETS) | 66220072930 | Single Source Drug | ||||
| Rx0000230 | Cumberland Pharmaceuticals | 07/09/2024 | VIBATIV 750MG CASE OF 12 SINGLE DOSE VIALS | 66220031522 | 01/01/2027 | Single Source Drug | |||
| Rx0000216 | Deciphera Pharmaceuticals, LLC | 04/29/2024 | Qinlock Oral Tablet 50 MG, 90 Each, Bottle | 73207010130 | 10/06/2042 | Single Source Drug | |||
| Rx0000216 | Deciphera Pharmaceuticals, LLC | 10/03/2024 | Qinlock Oral Tablet 50 MG, 90 Each, Bottle | 73207010130 | Single Source Drug | ||||
| Rx0000492 | Dynavax Technologies Corporation | 03/31/2024 | HEPLISAV-B [Hepatitis B Vaccine (Recombinant)] Adjuvanted 20 MCG / 0.5 ML PFS Injection, Solution 5 SYRINGE in 1 CARTON (43528-003-05) / .5 mL in 1 SYRINGE (43528-003-01) | 43528000305 | 04/16/2032 | Innovator Multiple Source Drug | |||
| Rx0000282 | Edenbridge Pharmaceuticals, LLC | 07/03/2024 | METHENAMINE MANDELATE - 0.5g Oral Tablet, 100ct Bottle [Qty: 1] | 42799010501 | Non-innovator Multiple Source Drug | Updated WAC effective date, please remove corresponding Q2 report | |||
| Rx0000282 | Edenbridge Pharmaceuticals, LLC | 07/03/2024 | METHENAMINE MANDELATE -1g Oral Tablet, 100ct Bottle [Qty: 1] | 42799010601 | Non-innovator Multiple Source Drug | Updated WAC effective date, please remove corresponding Q2 report | |||
| Rx0000076 | Eisai Inc. | 04/30/2024 | Lenvatinib Mesylate 10 & 4 MG Capsule Therapy Pack 10 EA UU | 62856071405 | 02/23/2036 | Single Source Drug | |||
| Rx0000076 | Eisai Inc. | 04/30/2024 | Lenvatinib Mesylate 10 MG & 2 x 4 MG Capsule Therapy Pack 15 EA UU | 62856071805 | 02/23/2036 | Single Source Drug | |||
| Rx0000076 | Eisai Inc. | 04/30/2024 | Lenvatinib Mesylate 10 MG Capsule Therapy Pack 5 EA UU | 62856071005 | 02/23/2036 | Single Source Drug | |||
| Rx0000076 | Eisai Inc. | 04/30/2024 | Lenvatinib Mesylate 2 x 10 MG & 4 MG Capsule Therapy Pack 15 EA UU | 62856072405 | 02/23/2036 | Single Source Drug | |||
| Rx0000076 | Eisai Inc. | 04/30/2024 | Lenvatinib Mesylate 2 x 10 MG Capsule Therapy Pack 10 EA UU | 62856072005 | 02/23/2036 | Single Source Drug | |||
| Rx0000076 | Eisai Inc. | 04/30/2024 | Lenvatinib Mesylate 2 x 4 MG Capsule Therapy Pack 10 EA UU | 62856070805 | 02/23/2036 | Single Source Drug | |||
| Rx0000076 | Eisai Inc. | 04/30/2024 | Lenvatinib Mesylate 3 x 4 MG Capsule Therapy Pack 15 EA UU | 62856071205 | 02/23/2036 | Single Source Drug | |||
| Rx0000076 | Eisai Inc. | 04/30/2024 | Lenvatinib Mesylate 3 x 4 MG Capsule Therapy Pack 90 EA UU | 62856071230 | 02/23/2036 | Single Source Drug | |||
| Rx0000076 | Eisai Inc. | 04/30/2024 | Lenvatinib Mesylate 4 MG Capsule Therapy Pack 30 EA UU | 62856070430 | 02/23/2036 | Single Source Drug | |||
| Rx0000076 | Eisai Inc. | 04/30/2024 | Lenvatinib Mesylate 4 MG Capsule Therapy Pack 5 EA UU | 62856070405 | 02/23/2036 | Single Source Drug | |||
| Rx0000076 | Eisai Inc. | 04/30/2024 | LENVIMA (lenvatinib mesylate) 8 mg/day (4 mg x 2) 60 count | 62856070830 | 02/23/2036 | Single Source Drug | |||
| Rx0000076 | Eisai Inc. | 04/30/2024 | LENVIMA (lenvatinib mesylate)10 mg/day (10 mg x 1) 30 count | 62856071030 | 02/23/2036 | Single Source Drug | |||
| Rx0000076 | Eisai Inc. | 04/30/2024 | LENVIMA (lenvatinib mesylate)14 mg/day (10 mg x 1 and 4 mg x 1) 60 count | 62856071430 | 02/23/2036 | Single Source Drug | |||
| Rx0000076 | Eisai Inc. | 04/30/2024 | LENVIMA (lenvatinib) 18 mg/day (10 mg x 1 and 4 mg x 2) 30 day supply | 62856071830 | 02/23/2036 | Single Source Drug | |||
| Rx0000076 | Eisai Inc. | 04/30/2024 | LENVIMA (lenvatinib) 20 mg/day (10 mg x 2) 30 day supply | 62856072030 | 02/23/2036 | Single Source Drug | |||
| Rx0000076 | Eisai Inc. | 04/30/2024 | LENVIMA (lenvatinib) 24 mg/day (10 mg x 2 and 4 mg x 1) 30 day supply | 62856072430 | 02/23/2036 | Single Source Drug | |||
| Rx0000114 | Eli Lilly and Company | 03/31/2024 | Verzenio Package Size: 14 Strength: 100 mg Dosage Form: TABLET | 00002481554 | 12/15/2029 | Single Source Drug | All information is provided by Eli Lilly and Company (Lilly) to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. In determining the patent expiration date, Lilly evaluated compound patents that cover the products and/or method of use patents that, in isolation or in aggregate, cover all approved methods of using the products. Lilly did not consider pending possible patent extensions or patents, including pending patent applications, that may cover other aspects of the products, e.g., their formulation and/or delivery devices (where applicable). Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is in the public domain or otherwise publicly available. | ||
| Rx0000114 | Eli Lilly and Company | 03/31/2024 | Verzenio Package Size: 14 Strength: 150 mg Dosage Form: TABLET | 00002533754 | 12/15/2029 | Single Source Drug | All information is provided by Eli Lilly and Company (Lilly) to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. In determining the patent expiration date, Lilly evaluated compound patents that cover the products and/or method of use patents that, in isolation or in aggregate, cover all approved methods of using the products. Lilly did not consider pending possible patent extensions or patents, including pending patent applications, that may cover other aspects of the products, e.g., their formulation and/or delivery devices (where applicable). Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is in the public domain or otherwise publicly available. | ||
| Rx0000114 | Eli Lilly and Company | 03/31/2024 | Verzenio Package Size: 14 Strength: 200 mg Dosage Form: TABLET | 00002621654 | 12/15/2029 | Single Source Drug | All information is provided by Eli Lilly and Company (Lilly) to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. In determining the patent expiration date, Lilly evaluated compound patents that cover the products and/or method of use patents that, in isolation or in aggregate, cover all approved methods of using the products. Lilly did not consider pending possible patent extensions or patents, including pending patent applications, that may cover other aspects of the products, e.g., their formulation and/or delivery devices (where applicable). Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is in the public domain or otherwise publicly available. | ||
| Rx0000114 | Eli Lilly and Company | 03/31/2024 | Verzenio Package Size: 14 Strength: 50 mg Dosage Form: TABLET | 00002448354 | 12/15/2029 | Single Source Drug | All information is provided by Eli Lilly and Company (Lilly) to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. In determining the patent expiration date, Lilly evaluated compound patents that cover the products and/or method of use patents that, in isolation or in aggregate, cover all approved methods of using the products. Lilly did not consider pending possible patent extensions or patents, including pending patent applications, that may cover other aspects of the products, e.g., their formulation and/or delivery devices (where applicable). Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is in the public domain or otherwise publicly available. | ||
| Rx0000079 | EMD Serono, Inc. | 04/30/2024 | Cetrotide Subcutaneous Kit 0.25 MG, 1 Each, Box | 44087122501 | Single Source Drug | ||||
| Rx0000079 | EMD Serono, Inc. | 07/26/2024 | Mavenclad (10 Tabs) Oral Tablet Therapy Pack 10 MG, 10 Each, Unit-of-Use, Box | 44087400000 | 11/23/2038 | Single Source Drug | |||
| Rx0000079 | EMD Serono, Inc. | 07/26/2024 | Mavenclad (4 Tabs) Oral Tablet Therapy Pack 10 MG, 4 Each, Unit-of-Use, Box | 44087400004 | 11/23/2038 | Single Source Drug | |||
| Rx0000079 | EMD Serono, Inc. | 07/26/2024 | Mavenclad (5 Tabs) Oral Tablet Therapy Pack 10 MG, 5 Each, Unit-of-Use, Box | 44087400005 | 11/23/2038 | Single Source Drug | |||
| Rx0000079 | EMD Serono, Inc. | 07/26/2024 | Mavenclad (6 Tabs) Oral Tablet Therapy Pack 10 MG, 6 Each, Unit-of-Use, Box | 44087400006 | 11/23/2038 | Single Source Drug | |||
| Rx0000079 | EMD Serono, Inc. | 07/26/2024 | Mavenclad (7 Tabs) Oral Tablet Therapy Pack 10 MG, 7 Each, Unit-of-Use, Box | 44087400007 | 11/23/2038 | Single Source Drug | |||
| Rx0000079 | EMD Serono, Inc. | 07/26/2024 | Mavenclad (8 Tabs) Oral Tablet Therapy Pack 10 MG, 8 Each, Unit-of-Use, Box | 44087400008 | 11/23/2038 | Single Source Drug | |||
| Rx0000079 | EMD Serono, Inc. | 07/26/2024 | Mavenclad (9 Tabs) Oral Tablet Therapy Pack 10 MG, 9 Each, Unit-of-Use, Box | 44087400009 | 11/23/2038 | Single Source Drug | |||
| Rx0000079 | EMD Serono, Inc. | 04/30/2024 | Ovidrel Subcutaneous Injectable 250 MCG/0.5ML, .5 ML, Unit-Dose, Syringe | 44087115001 | Single Source Drug | ||||
| Rx0000079 | EMD Serono, Inc. | 04/30/2024 | Rebif Rebidose Subcutaneous Solution Auto-injector 22 MCG/0.5ML, .5 ML, Unit-Dose, Syringe Qty 12 | 44087332201 | Single Source Drug | In the advance notice, both the inner and outer pack NDCs for Rebif were submitted. The inner pack NDCs (44087002209, 44087004409, 44087332209, 44087334409) were submitted in error as they are not saleable units. This product is sold in a package quantity of 12 syringes. With this said, for the Quarterly Price Increase report, we will only be submitting the Outer pack NDCs as again they are the only saleable units. | |||
| Rx0000079 | EMD Serono, Inc. | 04/30/2024 | Rebif Rebidose Subcutaneous Solution Auto-injector 44 MCG/0.5ML, .5 ML, Unit-Dose, Syringe Qty 12 | 44087334401 | Single Source Drug | In the advance notice, both the inner and outer pack NDCs for Rebif were submitted. The inner pack NDCs (44087002209, 44087004409, 44087332209, 44087334409) were submitted in error as they are not saleable units. This product is sold in a package quantity of 12 syringes. With this said, for the Quarterly Price Increase report, we will only be submitting the Outer pack NDCs as again they are the only saleable units. | |||
| Rx0000079 | EMD Serono, Inc. | 04/30/2024 | Rebif Rebidose Titration Pack Subcutaneous Solution Auto-injector 6X8.8 & 6X22 MCG, 4.2 ML, Unit-of-Use, Box | 44087018801 | Single Source Drug | In the advance notice, both the inner and outer pack NDCs for Rebif were submitted. The inner pack NDCs (44087002209, 44087004409, 44087332209, 44087334409) were submitted in error as they are not saleable units. This product is sold in a package quantity of 12 syringes. With this said, for the Quarterly Price Increase report, we will only be submitting the Outer pack NDCs as again they are the only saleable units. | |||
| Rx0000079 | EMD Serono, Inc. | 04/30/2024 | Rebif Subcutaneous Solution Prefilled Syringe 22 MCG/0.5ML, .5 ML, Unit-Dose, Syringe Qty 12 | 44087002203 | Single Source Drug | In the advance notice, both the inner and outer pack NDCs for Rebif were submitted. The inner pack NDCs (44087002209, 44087004409, 44087332209, 44087334409) were submitted in error as they are not saleable units. This product is sold in a package quantity of 12 syringes. With this said, for the Quarterly Price Increase report, we will only be submitting the Outer pack NDCs as again they are the only saleable units. | |||
| Rx0000079 | EMD Serono, Inc. | 04/30/2024 | Rebif Subcutaneous Solution Prefilled Syringe 44 MCG/0.5ML, .5 ML, Unit-Dose, Syringe Qty 12 | 44087004403 | Single Source Drug | In the advance notice, both the inner and outer pack NDCs for Rebif were submitted. The inner pack NDCs (44087002209, 44087004409, 44087332209, 44087334409) were submitted in error as they are not saleable units. This product is sold in a package quantity of 12 syringes. With this said, for the Quarterly Price Increase report, we will only be submitting the Outer pack NDCs as again they are the only saleable units. | |||
| Rx0000079 | EMD Serono, Inc. | 04/30/2024 | Rebif Titration Pack Subcutaneous Solution Prefilled Syringe 6X8.8 & 6X22 MCG, 4.2 ML, Unit-of-Use, Box | 44087882201 | Single Source Drug | In the advance notice, both the inner and outer pack NDCs for Rebif were submitted. The inner pack NDCs (44087002209, 44087004409, 44087332209, 44087334409) were submitted in error as they are not saleable units. This product is sold in a package quantity of 12 syringes. With this said, for the Quarterly Price Increase report, we will only be submitting the Outer pack NDCs as again they are the only saleable units. | |||
| Rx0000079 | EMD Serono, Inc. | 04/30/2024 | Serostim Subcutaneous Solution Reconstituted 4 MG, 1 Each, Unit-Dose, Vial Qty 7 | 44087000407 | Single Source Drug | ||||
| Rx0000079 | EMD Serono, Inc. | 04/30/2024 | Serostim Subcutaneous Solution Reconstituted 5 MG, 1 Each, Unit-Dose, Vial Qty 7 | 44087000507 | Single Source Drug | ||||
| Rx0000079 | EMD Serono, Inc. | 04/30/2024 | Serostim Subcutaneous Solution Reconstituted 6 MG, 1 Each, Unit-Dose, Vial Qty 7 | 44087000607 | Single Source Drug | ||||
| Rx0000079 | EMD Serono, Inc. | 04/30/2024 | Tepmetko Oral Tablet 225 MG, 30 Each, Box | 44087500003 | Single Source Drug | ||||
| Rx0000079 | EMD Serono, Inc. | 04/30/2024 | Tepmetko Oral Tablet 225 MG, 60 Each, Box | 44087500006 | Single Source Drug | ||||
| Rx0000557 | Emmaus Medical, Inc. | 03/31/2024 | ENDARI [L-glutamine oral powder], 5g/1, Powder for solution, 1 powder for solution in 1 packet | 42457042001 | Single Source Drug | ||||
| Rx0000557 | Emmaus Medical, Inc. | 03/31/2024 | ENDARI [L-glutamine oral powder], 5g/1, Powder for solution, 60 packet in 1 carton | 42457042060 | Single Source Drug | ||||
| Rx0000091 | Endo Pharmaceuticals Inc. | 07/31/2024 | Aveed, 750 mg/3mL (250mg/1mL) solution, single use vial | 67979051143 | 05/08/2027 | Single Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administrations Orange Book, as of 7/22/2024. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Endo did not acquire this product from another manufacturer within the previous five years. As a result, Endo has left columns 14-22 blank because they are not applicable to this product. | ||
| Rx0000091 | Endo Pharmaceuticals Inc. | 04/30/2024 | Edex®, Alprostadil For Inj Kit 10 MCG, 2 | 52244001002 | Innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administrations Orange Book, as of 4/24/2024. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the Patent Expiration Date field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product. | |||
| Rx0000091 | Endo Pharmaceuticals Inc. | 04/30/2024 | Edex®, Alprostadil For Inj Kit 10 MCG, 6 | 52244001006 | Innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administrations Orange Book, as of 4/24/2024. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the Patent Expiration Date field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product. | |||
| Rx0000091 | Endo Pharmaceuticals Inc. | 04/30/2024 | Edex®, Alprostadil For Inj Kit 20 MCG, 2 | 52244002002 | Innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administrations Orange Book, as of 4/24/2024. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the Patent Expiration Date field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product. | |||
| Rx0000091 | Endo Pharmaceuticals Inc. | 04/30/2024 | Edex®, Alprostadil For Inj Kit 20 MCG, 6 | 52244002006 | Innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administrations Orange Book, as of 4/24/2024. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the Patent Expiration Date field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product. | |||
| Rx0000091 | Endo Pharmaceuticals Inc. | 04/30/2024 | Edex®, Alprostadil For Inj Kit 40 MCG, 2 | 52244004002 | Innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administrations Orange Book, as of 4/24/2024. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the Patent Expiration Date field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product. | |||
| Rx0000091 | Endo Pharmaceuticals Inc. | 04/30/2024 | Edex®, Alprostadil For Inj Kit 40 MCG, 6 | 52244004006 | Innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administrations Orange Book, as of 4/24/2024. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the Patent Expiration Date field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product. | |||
| Rx0000091 | Endo Pharmaceuticals Inc. | 04/30/2024 | FROVA®, Frovatriptan Succinate Tab 2.5 MG (Base Equivalent), 9 | 63481002509 | Innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administrations Orange Book, as of 4/24/2024. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the Patent Expiration Date field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product. | |||
| Rx0000091 | Endo Pharmaceuticals Inc. | 04/30/2024 | PERCOCET®, Oxycodone w/ Acetaminophen Tab 10-325 MG, 100 | 63481062970 | Non-innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administrations Orange Book, as of 4/24/2024. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the Patent Expiration Date field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product. | |||
| Rx0000091 | Endo Pharmaceuticals Inc. | 04/30/2024 | PERCOCET®, Oxycodone w/ Acetaminophen Tab 2.5-325 MG, 100 | 63481062770 | Non-innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administrations Orange Book, as of 4/24/2024. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the Patent Expiration Date field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product. | |||
| Rx0000091 | Endo Pharmaceuticals Inc. | 04/30/2024 | PERCOCET®, Oxycodone w/ Acetaminophen Tab 5-325 MG, 100 | 63481062370 | Non-innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administrations Orange Book, as of 4/24/2024. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the Patent Expiration Date field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product. | |||
| Rx0000091 | Endo Pharmaceuticals Inc. | 04/30/2024 | PERCOCET®, Oxycodone w/ Acetaminophen Tab 5-325 MG, 500 | 63481062385 | Non-innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administrations Orange Book, as of 4/24/2024. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the Patent Expiration Date field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product. | |||
| Rx0000091 | Endo Pharmaceuticals Inc. | 04/30/2024 | PERCOCET®, Oxycodone w/ Acetaminophen Tab 7.5-325 MG, 100 | 63481062870 | Non-innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administrations Orange Book, as of 4/24/2024. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the Patent Expiration Date field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product. | |||
| Rx0000091 | Endo Pharmaceuticals Inc. | 04/30/2024 | THEO-24®, Theophylline Cap ER 24HR 100 MG, 100 | 52244010010 | Non-innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administrations Orange Book, as of 4/24/2024. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the Patent Expiration Date field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product. | |||
| Rx0000091 | Endo Pharmaceuticals Inc. | 04/30/2024 | THEO-24®, Theophylline Cap ER 24HR 200 MG, 100 | 52244020010 | Non-innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administrations Orange Book, as of 4/24/2024. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the Patent Expiration Date field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product. | |||
| Rx0000091 | Endo Pharmaceuticals Inc. | 04/30/2024 | THEO-24®, Theophylline Cap ER 24HR 300 MG, 100 | 52244030010 | Non-innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administrations Orange Book, as of 4/24/2024. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the Patent Expiration Date field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product. | |||
| Rx0000091 | Endo Pharmaceuticals Inc. | 04/30/2024 | THEO-24®, Theophylline Cap ER 24HR 400 MG, 100 | 52244040010 | Non-innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administrations Orange Book, as of 4/24/2024. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the Patent Expiration Date field for this product blank. (3) Endo did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Endo has left columns N-U blank because they are not applicable to this product. | |||
| Rx0000091 | Endo Pharmaceuticals Inc. | 07/31/2024 | Valstar, 40 mg/1ml solution, 4x5mL | 67979000101 | Innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The Orange Book indicates that, as of 7/22/2024, the Orange Book database does not contain unexpired patents for this product. As a result, Endo has left the patent expiration date field for this product blank.(3) Endo did not acquire this product from another manufacturer within the previous five years. As a result, Endo has left columns 14-22 blank because they are not applicable to this product. | |||
| Rx0000091 | Endo Pharmaceuticals Inc. | 07/31/2024 | Xiaflex, 0.9mg powder for solution, single use vial | 66887000301 | Single Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The federal Food and Drug Administrations Purple Book does not require the listing of patents or their expiration dates for any product, including Xiaflex. The patent expiration date for any patent potentially associated with Xiaflex would also depend on pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten such an expiration date. As a result, Endo has left the patent expiration date field for this product blank.(3) Endo did not acquire this product from another manufacturer within the previous five years. As a result, Endo has left columns 14-22 blank because they are not applicable to this product. | |||
| Rx0000584 | Endo USA, Inc. | 07/31/2024 | BREVITAL SODIUM METHOHEXITAL SODIUM INJECTABLE 500MG/VIAL | 42023010501 | 1990 | Single Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The Orange Book indicates that, as of 7/22/2024, the Orange Book database does not contain unexpired patents for this product. As a result, Endo has left the patent expiration date field for this product blank.(3) Year Introduced: For this data element, Endo provided the market date for the product that Endo reports to the Centers for Medicare and Medicaid Services (CMS) under the Medicaid Drug Rebate Program. Consistent with CMS guidance, this date is the earliest date the product was first marketed under the application number by any labeler. (4) For the WAC at introduction Endo is reporting the earliest WAC reported to the drug pricing compendia under the product NDC. | ||
| Rx0000584 | Endo USA, Inc. | 07/31/2024 | TIGAN TRIMETHOBENZAMIDE HYDROCHLORIDE INJECTABLE 100MG/ML, 25vl | 42023011925 | 2006 | Single Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The Orange Book indicates that, as of 7/22/2024, the Orange Book database does not contain unexpired patents for this product. As a result, Endo has left the patent expiration date field for this product blank.(3) Year Introduced: For this data element, Endo provided the market date for the product that Endo reports to the Centers for Medicare and Medicaid Services (CMS) under the Medicaid Drug Rebate Program. Consistent with CMS guidance, this date is the earliest date the product was first marketed under the application number by any labeler. (4) For the WAC at introduction Endo is reporting the earliest WAC reported to the drug pricing compendia under the product NDC. | ||
| Rx0000405 | Esperion | 03/31/2024 | Nexletol 30 Tab 180 mg/1 Tablet Film Coated | 72426011803 | 06/19/2040 | Single Source Drug | |||
| Rx0000405 | Esperion | 03/31/2024 | Nexlizet 30 Tab 180 mg/1, 10 mg/1 Tablet Film Coated | 72426081803 | 06/19/2040 | Single Source Drug | |||
| Rx0000270 | Eton Pharmaceuticals, Inc. | 04/25/2024 | Alkindi Sprinkle (hydrocortisone) Oral Granules 0.5 MG, 50 Capsules, Bottle | 71863010950 | 2020 | 05/12/2034 | Single Source Drug | Alkindi was not commercialized prior to acquisition. After following up with the state we were instructed to utilize the Intro to Market WAC for the "WAC at Acquisition" and "WAC - Year Prior to Acquisition" as a work-around. | |
| Rx0000270 | Eton Pharmaceuticals, Inc. | 04/25/2024 | Alkindi Sprinkle (hydrocortisone) Oral Granules 1 MG, 50 Capsules, Bottle | 71863011050 | 2020 | 05/12/2034 | Single Source Drug | Alkindi was not commercialized prior to acquisition. After following up with the state we were instructed to utilize the Intro to Market WAC for the "WAC at Acquisition" and "WAC - Year Prior to Acquisition" as a work-around. | |
| Rx0000270 | Eton Pharmaceuticals, Inc. | 04/25/2024 | Alkindi Sprinkle (hydrocortisone) Oral Granules 2 MG, 50 Capsules, Bottle | 71863011150 | 2020 | 05/12/2034 | Single Source Drug | Alkindi was not commercialized prior to acquisition. After following up with the state we were instructed to utilize the Intro to Market WAC for the "WAC at Acquisition" and "WAC - Year Prior to Acquisition" as a work-around. | |
| Rx0000270 | Eton Pharmaceuticals, Inc. | 04/25/2024 | Alkindi Sprinkle (hydrocortisone) Oral Granules 5 MG, 50 Capsules, Bottle | 71863011250 | 2020 | 05/12/2034 | Single Source Drug | Alkindi was not commercialized prior to acquisition. After following up with the state we were instructed to utilize the Intro to Market WAC for the "WAC at Acquisition" and "WAC - Year Prior to Acquisition" as a work-around. | |
| Rx0000455 | Evofem Biosciences, Inc. | 04/30/2024 | Phexxi Vaginal Gel 1.8-1-0.4%, 5 GM, Unit-of-Use, Box Qty 12 | 69751010012 | 03/15/2033 | Single Source Drug | |||
| Rx0000010 | Exelixis, Inc. | 04/30/2024 | CABOMETYX 20MG 30 TAB BTL EACH | 42388002426 | 07/09/2033 | Single Source Drug | https://reports.siera.hcai.ca.gov/api/report/drug-pricing/attachment?id=1046 | Exelixis did not acquire this product from another manufacturer within the previous five years. As a result, Exelixis has left columns N-U blank because they are not applicable to this product. The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administrations Orange Book, as of 4/15/2024. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date | |
| Rx0000010 | Exelixis, Inc. | 04/30/2024 | CABOMETYX 40MG 30 TAB BTL EACH | 42388002526 | 07/09/2033 | Single Source Drug | https://reports.siera.hcai.ca.gov/api/report/drug-pricing/attachment?id=1047 | Exelixis did not acquire this product from another manufacturer within the previous five years. As a result, Exelixis has left columns N-U blank because they are not applicable to this product. The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administrations Orange Book, as of 4/15/2024. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date | |
| Rx0000010 | Exelixis, Inc. | 04/30/2024 | CABOMETYX 60MG 30 TAB BTL EACH | 42388002326 | 07/09/2033 | Single Source Drug | https://reports.siera.hcai.ca.gov/api/report/drug-pricing/attachment?id=1045 | Exelixis did not acquire this product from another manufacturer within the previous five years. As a result, Exelixis has left columns N-U blank because they are not applicable to this product. The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administrations Orange Book, as of 4/15/2024. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date | |
| Rx0000193 | Forte Bio-Pharma, LLC | 07/11/2024 | NALOCET TABLETS 1 PACK 100 TABS 2.5 MG/300 MG | 72245019310 | Non-innovator Multiple Source Drug | ||||
| Rx0000193 | Forte Bio-Pharma, LLC | 07/11/2024 | PROLATE TABLETS 1 PACK 100 TABS 10 MG/300 MG | 72245068310 | Non-innovator Multiple Source Drug | ||||
| Rx0000193 | Forte Bio-Pharma, LLC | 07/11/2024 | PROLATE TABLETS 1 PACK 100 TABS 5 MG/300 MG | 72245068110 | Non-innovator Multiple Source Drug | ||||
| Rx0000193 | Forte Bio-Pharma, LLC | 07/11/2024 | PROLATE TABLETS 1 PACK 100 TABS 7.5 MG/300 MG | 72245068210 | Non-innovator Multiple Source Drug | ||||
| Rx0000260 | Galderma Laboratories | 04/10/2024 | TRI-LUMA Cream 24x30g US | 00299595030 | 10/25/2022 | Single Source Drug | https://reports.siera.hcai.ca.gov/api/report/drug-pricing/attachment?id=768 | ||
| Rx0000034 | Genentech USA | 04/25/2024 | Alecensa 150 Mg - 240 Capsules | 50242013001 | 04/24/2035 | Single Source Drug | |||
| Rx0000034 | Genentech USA | 03/31/2024 | ENSPRYNG® (satralizumab-mwge) 120 mg/mL prefilled syringe | 50242000701 | Single Source Drug | Patent expiration (column 6) and Unit Sales in US (column 8) are not filled out numerically as the information is not publicly available. The acquisition fields are left blank as the drug product was not acquired from a third party. There are four drug products with a price increase but do not have a five year history. Please see the supporting documents for additional information | |||
| Rx0000034 | Genentech USA | 03/31/2024 | GAZYVA® (obinutuzumab) 1,000 mg/40 mL vial | 50242007001 | Single Source Drug | Patent expiration (column 6) and Unit Sales in US (column 8) are not filled out numerically as the information is not publicly available. The acquisition fields are left blank as the drug product was not acquired from a third party. There are four drug products with a price increase but do not have a five year history. Please see the supporting documents for additional information. | |||
| Rx0000034 | Genentech USA | 07/24/2024 | KADCYLA® (ado-trastuzumab emtansine) 100 mg vial. Lyophilized powder in single-dose vials: 100 mg per vial of ado-trastuzumab emtansine. | 50242008801 | Single Source Drug | ||||
| Rx0000034 | Genentech USA | 07/24/2024 | KADCYLA® (ado-trastuzumab emtansine) 160 mg vial. Lyophilized powder in single-dose vials: 160 mg per vial of ado-trastuzumab emtansine. | 50242008701 | Single Source Drug | ||||
| Rx0000034 | Genentech USA | 03/31/2024 | KADCYLA® (ado-trastuzumab emtansine) 100 mg vial | 50242008801 | Single Source Drug | Patent expiration (column 6) and Unit Sales in US (column 8) are not filled out numerically as the information is not publicly available. The acquisition fields are left blank as the drug product was not acquired from a third party. There are four drug products with a price increase but do not have a five year history. Please see the supporting documents for additional information | |||
| Rx0000034 | Genentech USA | 03/31/2024 | KADCYLA® (ado-trastuzumab emtansine) 160 mg vial | 50242008701 | Single Source Drug | Patent expiration (column 6) and Unit Sales in US (column 8) are not filled out numerically as the information is not publicly available. The acquisition fields are left blank as the drug product was not acquired from a third party. There are four drug products with a price increase but do not have a five year history. Please see the supporting documents for additional information | |||
| Rx0000034 | Genentech USA | 03/31/2024 | PERJETA® (pertuzumab) 420 mg/14 mL vial | 50242014501 | Single Source Drug | Patent expiration (column 6) and Unit Sales in US (column 8) are not filled out numerically as the information is not publicly available. The acquisition fields are left blank as the drug product was not acquired from a third party. There are four drug products with a price increase but do not have a five year history. Please see the supporting documents for additional information | |||
| Rx0000034 | Genentech USA | 07/24/2024 | POLIVY® (polatuzumab vedotin-piiq) 140 mg Vial. POLIVY for injection is a sterile, preservative-free, white to grayish-white lyophilized powder, which has a cake-like appearance and is supplied in 140 mg single-dose vial. | 50242010501 | Single Source Drug | ||||
| Rx0000034 | Genentech USA | 07/24/2024 | POLIVY® (polatuzumab vedotin-piiq) 30 mg vial. POLIVY for injection is a sterile, preservative-free, white to grayish-white lyophilized powder, which has a cake-like appearance and is supplied in a 30 mg single-dose vial. | 50242010301 | Single Source Drug | ||||
| Rx0000034 | Genentech USA | 03/31/2024 | POLIVY® (polatuzumab vedotin-piiq) 30 mg vial | 50242010301 | Single Source Drug | Patent expiration (column 6) and Unit Sales in US (column 8) are not filled out numerically as the information is not publicly available. The acquisition fields are left blank as the drug product was not acquired from a third party. There are four drug products with a price increase but do not have a five year history. Please see the supporting documents for additional information | |||
| Rx0000034 | Genentech USA | 03/31/2024 | POLIVY® (polatuzumab vidotin-piiq) 140 mg vial | 50242010501 | Single Source Drug | Patent expiration (column 6) and Unit Sales in US (column 8) are not filled out numerically as the information is not publicly available. The acquisition fields are left blank as the drug product was not acquired from a third party. There are four drug products with a price increase but do not have a five year history. Please see the supporting documents for additional information. | |||
| Rx0000034 | Genentech USA | 03/31/2024 | TNKase® (tenecteplase) 50 mg vial | 50242012047 | Single Source Drug | Patent expiration (column 6) and Unit Sales in US (column 8) are not filled out numerically as the information is not publicly available. The acquisition fields are left blank as the drug product was not acquired from a third party. There are four drug products with a price increase but do not have a five year history. Please see the supporting documents for additional information | |||
| Rx0000034 | Genentech USA | 07/24/2024 | TNKase® (tenecteplase) 50 mg vial. TNKase (tenecteplase for injection) is supplied as a sterile, lyophilized powder in a 50 mg, glass (20 cc) vial under partial vacuum. | 50242012047 | Single Source Drug | ||||
| Rx0000034 | Genentech USA | 03/31/2024 | XOLAIR® (omalizumab) 150 mg vial | 50242004062 | Single Source Drug | Patent expiration (column 6) and Unit Sales in US (column 8) are not filled out numerically as the information is not publicly available. The acquisition fields are left blank as the drug product was not acquired from a third party. There are four drug products with a price increase but do not have a five year history. Please see the supporting documents for additional information | |||
| Rx0000034 | Genentech USA | 03/31/2024 | XOLAIR® (omalizumab) 150 mg/mL syringe | 50242021501 | Single Source Drug | Patent expiration (column 6) and Unit Sales in US (column 8) are not filled out numerically as the information is not publicly available. The acquisition fields are left blank as the drug product was not acquired from a third party. There are four drug products with a price increase but do not have a five year history. Please see the supporting documents for additional information | |||
| Rx0000034 | Genentech USA | 03/31/2024 | XOLAIR® (omalizumab) 75 mg/0.5 mL syringe | 50242021401 | Single Source Drug | Patent expiration (column 6) and Unit Sales in US (column 8) are not filled out numerically as the information is not publicly available. The acquisition fields are left blank as the drug product was not acquired from a third party. There are four drug products with a price increase but do not have a five year history. Please see the supporting documents for additional information | |||
| Rx0000087 | Gilead Sciences, Inc. | 04/29/2024 | BIKTARVY (bictegravir sodium/emtricitabine/tenofovir alafenamide fumar 30 mg-120 mg-15 mg) tablet, 30ct bottle | 61958250501 | 02/23/2031 | Single Source Drug | The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years. | ||
| Rx0000087 | Gilead Sciences, Inc. | 04/29/2024 | BIKTARVY (bictegravir sodium/emtricitabine/tenofovir alafenamide fumar 50 mg-200 mg-25 mg) tablet, 30ct blister pack | 61958250103 | 02/23/2031 | Single Source Drug | The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years. | ||
| Rx0000087 | Gilead Sciences, Inc. | 04/29/2024 | BIKTARVY (bictegravir sodium/emtricitabine/tenofovir alafenamide fumar 50 mg-200 mg-25 mg) tablet, 30ct bottle | 61958250101 | 02/23/2031 | Single Source Drug | The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years. | ||
| Rx0000087 | Gilead Sciences, Inc. | 04/29/2024 | CAYSTON (aztreonam for inhalation solution) 75mg/vial, 84 vials/kit | 61958090101 | 12/21/2021 | Single Source Drug | The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years. | ||
| Rx0000087 | Gilead Sciences, Inc. | 04/29/2024 | COMPLERA (emtricitabine/rilpivirine HCl/tenofovir disoproxil fumarate 200 mg-25 mg-300 mg) tablet, 30ct bottle | 61958110101 | 01/14/2033 | Single Source Drug | The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years. | ||
| Rx0000087 | Gilead Sciences, Inc. | 04/29/2024 | GENVOYA (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide 150 mg-150 mg-200 mg-10 mg) tablet, 30ct bottle | 61958190101 | 10/04/2032 | Single Source Drug | The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years. | ||
| Rx0000087 | Gilead Sciences, Inc. | 04/29/2024 | LETAIRIS (ambrisentan 10 mg) tablet, 10ct bottle | 61958080205 | 10/14/2031 | Single Source Drug | The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years. | ||
| Rx0000087 | Gilead Sciences, Inc. | 04/29/2024 | LETAIRIS (ambrisentan 10 mg) tablet, 30ct bottle | 61958080201 | 10/14/2031 | Single Source Drug | The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years. | ||
| Rx0000087 | Gilead Sciences, Inc. | 04/29/2024 | LETAIRIS (ambrisentan 5 mg) tablet, 10ct bottle | 61958080105 | 10/14/2031 | Single Source Drug | The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years. | ||
| Rx0000087 | Gilead Sciences, Inc. | 04/29/2024 | LETAIRIS (ambrisentan 5 mg) tablet, 30ct bottle | 61958080101 | 10/14/2031 | Single Source Drug | The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years. | ||
| Rx0000087 | Gilead Sciences, Inc. | 04/29/2024 | ODEFSEY (emtricitabine/rilpivirine HCl/tenofovir alafenamide fumarate 200 mg-25 mg-25 mg) tablet, 30ct bottle | 61958210101 | 08/15/2032 | Single Source Drug | The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years. | ||
| Rx0000087 | Gilead Sciences, Inc. | 04/29/2024 | STRIBILD (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil 150 mg-150 mg-200 mg-300 mg) tablet, 30ct bottle | 61958120101 | 10/06/2032 | Single Source Drug | The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years. | ||
| Rx0000087 | Gilead Sciences, Inc. | 04/29/2024 | TYBOST (cobicistat 150 mg) tablet, 30ct bottle | 61958140101 | 08/22/2026 | Single Source Drug | The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years. | ||
| Rx0000087 | Gilead Sciences, Inc. | 04/29/2024 | VEMLIDY (tenofovir alafenamide 25mg) tablets, 30ct bottle | 61958230101 | 08/15/2032 | Single Source Drug | The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years. | ||
| Rx0000087 | Gilead Sciences, Inc. | 04/29/2024 | ZYDELIG (idelalisib 100 mg) tablet, 60ct bottle | 61958170101 | 09/02/2033 | Single Source Drug | The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years. | ||
| Rx0000087 | Gilead Sciences, Inc. | 04/29/2024 | ZYDELIG (idelalisib 150 mg) tablet, 60ct bottle | 61958170201 | 09/02/2033 | Single Source Drug | The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years. | ||
| Rx0000029 | GlaxoSmithKline | 04/19/2024 | Benlysta, Belimumab 200 MG/ML Solution Auto-injector 1 ML | 49401008801 | Single Source Drug | ||||
| Rx0000029 | GlaxoSmithKline | 04/19/2024 | Benlysta, Belimumab 200 MG/ML Solution Auto-injector 1 ML X4 | 49401008835 | Single Source Drug | ||||
| Rx0000029 | GlaxoSmithKline | 04/19/2024 | Benlysta, Belimumab 200 MG/ML Solution Prefilled Syringe 1 ML UD | 49401008842 | Single Source Drug | ||||
| Rx0000029 | GlaxoSmithKline | 04/19/2024 | Benlysta, Belimumab 200 MG/ML Solution Prefilled Syringe 1 ML UD X4 | 49401008847 | Single Source Drug | ||||
| Rx0000029 | GlaxoSmithKline | 04/19/2024 | Bexsero, Meningococcal Vac Group B (Recombant OMV Adjuvanted) Suspension Prefilled Syringe 0.5 ML UD | 58160097602 | Single Source Drug | ||||
| Rx0000029 | GlaxoSmithKline | 04/19/2024 | Bexsero, Meningococcal Vac Group B (Recombant OMV Adjuvanted) Suspension Prefilled Syringe 0.5 ML UD X10 | 58160097620 | Single Source Drug | ||||
| Rx0000029 | GlaxoSmithKline | 04/19/2024 | Nucala, Mepolizumab 100 MG/ML Solution Auto-injector 1 ML UD | 00173089201 | Single Source Drug | ||||
| Rx0000029 | GlaxoSmithKline | 04/19/2024 | Nucala, Mepolizumab 100 MG/ML Solution Prefilled Syringe 1 ML UD | 00173089242 | Single Source Drug | ||||
| Rx0000029 | GlaxoSmithKline | 04/19/2024 | Shingrix, Zoster Vaccine Recombinant Adjuvanted 50 MCG/0.5ML Suspension Reconstituted 1 EA UD | 58160081912 | Single Source Drug | ||||
| Rx0000029 | GlaxoSmithKline | 04/19/2024 | Shingrix, Zoster Vaccine Recombinant Adjuvanted 50 MCG/0.5ML Suspension Reconstituted 1 EA UD X10 | 58160082311 | Single Source Drug | ||||
| Rx0000164 | Harmony Biosciences, LLC | 04/24/2024 | WAKIX pitolisant HCl 17.8 mg 30 Oral Tab | 72028017803 | 02/01/2029 | Single Source Drug | |||
| Rx0000164 | Harmony Biosciences, LLC | 04/24/2024 | WAKIX pitolisant HCl 4.45 mg 30 Oral Tab | 72028004503 | 02/01/2029 | Single Source Drug | |||
| Rx0000534 | Harrow Eye, LLC | 04/24/2024 | Ilevro Ophthalmic Suspension 0.3 % | 00078074303 | 2014 | 03/31/2032 | Single Source Drug | ||
| Rx0000534 | Harrow Eye, LLC | 07/18/2024 | Natamycin Ophth Susp 5%, 15 ML, Unit-of-Use, Bottle | 71776000515 | 1989 | Single Source Drug | |||
| Rx0000534 | Harrow Eye, LLC | 04/24/2024 | Nevanac Ophthalmic Suspension 0.1 % | 00078077803 | 2005 | 01/31/2027 | Single Source Drug | ||
| Rx0000534 | Harrow Eye, LLC | 04/24/2024 | Triesence Intraocular Suspension 40 MG/ML | 00065054301 | 2008 | 12/17/2029 | Single Source Drug | ||
| Rx0000534 | Harrow Eye, LLC | 04/24/2024 | Verkazia Ophthalmic Emulsion 0.1 % | 65086000112 | 2022 | 06/02/2029 | Single Source Drug | ||
| Rx0000145 | Horizon Therapeutics USA, Inc. | 07/22/2024 | Product Name: KRYSTEXXA; Drug product strength: 1 mL sterile concentrate for dilution containing 8 mg of pegloticase protein, expressed in uricase protein amounts. Drug product dosage form: vial. Drug product package size: 8 MG/ML single use vial | 75987008010 | Single Source Drug | Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Horizon believes is otherwise in the public domain or publicly available. Please note the Patent Expiration date for Krystexxa is not publicly available. | |||
| Rx0000287 | Insmed Incorporated | 04/12/2024 | Arikayce Inhalation Suspension 590 MG/8.4ML | 71558059028 | 05/15/2035 | Single Source Drug | |||
| Rx0000266 | Intercept Pharmaceuticals, Inc. | 04/02/2024 | Ocaliva - OBETICHOLIC ACID - 10mg Oral Tablet, 30ct bottle [Qty:1] | 69516001030 | 04/26/2036 | Single Source Drug | |||
| Rx0000266 | Intercept Pharmaceuticals, Inc. | 04/02/2024 | Ocaliva - OBETICHOLIC ACID - 5mg Oral Tablet, 30ct bottle [Qty:1] | 69516000530 | 04/26/2036 | Single Source Drug | |||
| Rx0000214 | Intra-Cellular Therapies, Inc. | 04/02/2024 | Caplyta Oral Capsule 42 MG 30 Pack | 72060014230 | 12/10/2040 | Single Source Drug | |||
| Rx0000084 | Ipsen Biopharmaceuticals, Inc. | 10/02/2024 | Drug product name: Onivyde. Drug product strength: 43 mg/10 mL (4.3 mg/mL). Drug product dosage form: vial. Drug product package size: 10 mL. | 15054004301 | 10/15/2036 | Single Source Drug | |||
| Rx0000084 | Ipsen Biopharmaceuticals, Inc. | 03/31/2024 | Drug product name: Tazverik. Drug product strength: 200mg. Drug product dosage form: tablet. Drug product package size: 1 bottle (240 tablets). | 72607010000 | 2020 | 12/19/2035 | Single Source Drug | The information provided in response to 22 CCR § 96070(b)(6) is based upon patents listed in the FDA Orange Book. | |
| Rx0000248 | Janssen Biotech, Inc. | 04/26/2024 | DARZALEX FASPRO (daratumumab and hyaluronidase-fihj)Strength: 1800mg / 15 mL Package Size:1 Form:1 single vial | 57894050301 | 11/03/2036 | Single Source Drug | Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed on janssenpatents.com for this product as of April 15, 2024. | ||
| Rx0000248 | Janssen Biotech, Inc. | 10/30/2024 | DARZALEX FASPRO (daratumumab and hyaluronidase-fihj)Strength: 1800mg / 15 mL Package Size:1 Form:1 single vial | 57894050301 | 11/01/2036 | Single Source Drug | |||
| Rx0000248 | Janssen Biotech, Inc. | 04/26/2024 | DARZALEX (daratumumab)Strength:100 mg 5 mL Package Size:1 Form:1 single vial | 57894050205 | 09/25/2029 | Single Source Drug | Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed on janssenpatents.com for this product as of April 15, 2024. | ||
| Rx0000248 | Janssen Biotech, Inc. | 10/30/2024 | DARZALEX (daratumumab)Strength:100 mg 5 mL Package Size:1 Form:1 single vial | 57894050205 | 09/25/2029 | Single Source Drug | |||
| Rx0000248 | Janssen Biotech, Inc. | 04/26/2024 | DARZALEX (daratumumab)Strength:400 mg 20 mL Package Size:1 Form:1 single vial | 57894050220 | 09/25/2029 | Single Source Drug | Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed on janssenpatents.com for this product as of April 15, 2024. | ||
| Rx0000248 | Janssen Biotech, Inc. | 10/30/2024 | DARZALEX (daratumumab)Strength:400 mg 20 mL Package Size:1 Form:1 single vial | 57894050220 | 09/25/2029 | Single Source Drug | |||
| Rx0000248 | Janssen Biotech, Inc. | 04/26/2024 | RYBREVANT (amivantamab-vmjw)Strength: 350mg/7mL Package Size:1 Form:1 single vial | 57894050101 | 05/21/2035 | Single Source Drug | Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed on janssenpatents.com for this product as of April 15, 2024. | ||
| Rx0000248 | Janssen Biotech, Inc. | 07/30/2024 | RYBREVANT (amivantamab-vmjw)Strength: 350mg/7mL Package Size:1 Form:1 single vial | 57894050101 | 05/21/2035 | Single Source Drug | This date represents the expiration date of the composition of matter patent, including a pending patent term extension request. | ||
| Rx0000248 | Janssen Biotech, Inc. | 04/26/2024 | TREMFYA (guselkumab) One Press Injector Strength: 100mg / 1 mL Package Size:1 Form:1 syringe | 57894064011 | 01/18/2031 | Single Source Drug | Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed on janssenpatents.com for this product as of April 15, 2024. | ||
| Rx0000248 | Janssen Biotech, Inc. | 04/26/2024 | TREMFYA (guselkumab) prefilled syringe Strength: 100mg / 1 mL Package Size:1 Form:1 syringe | 57894064001 | 01/18/2031 | Single Source Drug | Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed on janssenpatents.com for this product as of April 15, 2024. | ||
| Rx0000253 | Janssen Pharmaceuticals, Inc. | 04/26/2024 | ELMIRON® Strength:100 mg Package Size:100 Form:Capsule | 50458009801 | Single Source Drug | No unexpired patents | |||
| Rx0000253 | Janssen Pharmaceuticals, Inc. | 04/26/2024 | INVEGA® HAFYERA® Strength:1092 mg Package Size:1 Form:Disposable Syringe/Dose Pack | 50458061101 | 11/24/2041 | Single Source Drug | Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 15, 2024. | ||
| Rx0000253 | Janssen Pharmaceuticals, Inc. | 04/26/2024 | INVEGA® HAFYERA® Strength:1560 mg Package Size:1 Form:Disposable Syringe/Dose Pack | 50458061201 | 11/24/2041 | Single Source Drug | Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 15, 2024. | ||
| Rx0000253 | Janssen Pharmaceuticals, Inc. | 04/26/2024 | INVEGA® SUSTENNA® Strength:117 mg Package Size:1 Form:Disposable Syringe/Dose Pack | 50458056201 | 01/26/2031 | Single Source Drug | Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 15, 2024. | ||
| Rx0000253 | Janssen Pharmaceuticals, Inc. | 04/26/2024 | INVEGA® SUSTENNA® Strength:156 mg Package Size:1 Form:Disposable Syringe/Dose Pack | 50458056301 | 01/26/2031 | Single Source Drug | Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 15, 2024. | ||
| Rx0000253 | Janssen Pharmaceuticals, Inc. | 04/26/2024 | INVEGA® SUSTENNA® Strength:234 mg Package Size:1 Form:Disposable Syringe/Dose Pack | 50458056401 | 01/26/2031 | Single Source Drug | Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 15, 2024. | ||
| Rx0000253 | Janssen Pharmaceuticals, Inc. | 04/26/2024 | INVEGA® SUSTENNA® Strength:39 mg Package Size:1 Form:Disposable Syringe/Dose Pack | 50458056001 | 01/26/2031 | Single Source Drug | Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 15, 2024 | ||
| Rx0000253 | Janssen Pharmaceuticals, Inc. | 04/26/2024 | INVEGA® SUSTENNA® Strength:78 mg Package Size:1 Form:Disposable Syringe/Dose Pack | 50458056101 | 01/26/2031 | Single Source Drug | Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 15, 2024. | ||
| Rx0000253 | Janssen Pharmaceuticals, Inc. | 04/26/2024 | INVEGA® TRINZA® Strength:273 mg Package Size:1 Form:Disposable Syringe/Dose Pack | 50458060601 | 04/05/2036 | Single Source Drug | Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 15, 2024. | ||
| Rx0000253 | Janssen Pharmaceuticals, Inc. | 04/26/2024 | INVEGA® TRINZA® Strength:410 mg Package Size:1 Form:Disposable Syringe/Dose Pack | 50458060701 | 04/05/2036 | Single Source Drug | Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 15, 2024. | ||
| Rx0000253 | Janssen Pharmaceuticals, Inc. | 04/26/2024 | INVEGA® TRINZA® Strength:546 mg Package Size:1 Form:Disposable Syringe/Dose Pack | 50458060801 | 04/05/2036 | Single Source Drug | Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 15, 2024. | ||
| Rx0000253 | Janssen Pharmaceuticals, Inc. | 04/26/2024 | INVEGA® TRINZA® Strength:819 mg Package Size:1 Form:Disposable Syringe/Dose Pack | 50458060901 | 04/05/2036 | Single Source Drug | Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 15, 2024. | ||
| Rx0000253 | Janssen Pharmaceuticals, Inc. | 07/30/2024 | PONVORY ® (ponesimod) Strength: 10 mg Package Size:14 Form:Tablet | 50458070714 | 10/10/2042 | Single Source Drug | This date represents that expiration date of the last to expire patent listed in the Orange Book for this product as of July 10, 2024. | ||
| Rx0000253 | Janssen Pharmaceuticals, Inc. | 07/30/2024 | PONVORY ® (ponesimod) Strength: 20 mg Package Size:30 Form:Tablet | 50458072030 | 10/10/2042 | Single Source Drug | This date represents that expiration date of the last to expire patent listed in the Orange Book for this product as of July 10, 2024. | ||
| Rx0000253 | Janssen Pharmaceuticals, Inc. | 04/26/2024 | SPRAVATO Strength:56 mg Package Size:2 Form:Nasal Spray | 50458002802 | 02/16/2040 | Single Source Drug | Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration data provided is the latest projected patent expiration date for patents listed in Orange Book as of April 15, 2024 | ||
| Rx0000253 | Janssen Pharmaceuticals, Inc. | 04/26/2024 | SPRAVATO Strength:84 mg Package Size:3 Form:Nasal Spray | 50458002803 | 02/16/2040 | Single Source Drug | Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration data provided is the latest projected patent expiration date for patents listed in Orange Book as of April 15, 2024 | ||
| Rx0000250 | Janssen Products, LP | 04/26/2024 | BALVERSA® (erdafitinib) Strength:3 MG Package Size:56 Form:Tablet | 59676003056 | 02/02/2038 | Single Source Drug | Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 15, 2024. | ||
| Rx0000250 | Janssen Products, LP | 04/26/2024 | BALVERSA® (erdafitinib) Strength:3 MG Package Size:84 Form:Tablet | 59676003084 | 02/02/2038 | Single Source Drug | Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 15, 2024. | ||
| Rx0000250 | Janssen Products, LP | 04/26/2024 | BALVERSA® (erdafitinib) Strength:4 MG Package Size:28 Form:Tablet | 59676004028 | 02/02/2038 | Single Source Drug | Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 15, 2024. | ||
| Rx0000250 | Janssen Products, LP | 04/26/2024 | BALVERSA® (erdafitinib) Strength:4 MG Package Size:56 Form:Tablet | 59676004056 | 02/02/2038 | Single Source Drug | Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 15, 2024. | ||
| Rx0000250 | Janssen Products, LP | 04/26/2024 | BALVERSA® (erdafitinib) Strength:5 MG Package Size:28 Form:Tablet | 59676005028 | 02/02/2038 | Single Source Drug | Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 15, 2024. | ||
| Rx0000250 | Janssen Products, LP | 04/26/2024 | EDURANT (rilpivirine) Strength:25mg Package Size:30 Form:Tablet | 59676027801 | 01/21/2029 | Single Source Drug | Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed on janssenpatents.com for this product as of April 15, 2024. | ||
| Rx0000250 | Janssen Products, LP | 07/30/2024 | EDURANT (rilpivirine) Strength:25mg Package Size:30 Form:Tablet | 59676027801 | 10/21/2025 | Single Source Drug | This date represents that expiration date of the last to expire patent listed in the Orange Book for this product as of July 10, 2024. | ||
| Rx0000250 | Janssen Products, LP | 04/26/2024 | ERLEADA (apalutamide) Strength:60mg Package Size:120 Form:Tablet | 59676060012 | 04/30/2038 | Single Source Drug | Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 15, 2024. | ||
| Rx0000250 | Janssen Products, LP | 04/26/2024 | PREZCOBIX (darunavir 800mg, cobicistat 150mg) Strength:800 MG/150 MG Package Size:30 Form:Tablet | 59676057530 | 10/06/2032 | Single Source Drug | Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 15, 2024. | ||
| Rx0000250 | Janssen Products, LP | 04/26/2024 | PREZISTA® Strength:150 MG Package Size:240 Form:Tablet | 59676056401 | 06/26/2027 | Single Source Drug | Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 15, 2024. | ||
| Rx0000250 | Janssen Products, LP | 04/26/2024 | PREZISTA® Strength:600 MG Package Size:60 Form:Tablet | 59676056201 | 06/26/2027 | Innovator Multiple Source Drug | Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 15, 2024. | ||
| Rx0000250 | Janssen Products, LP | 04/26/2024 | PREZISTA® Strength:75 MG Package Size:480 Form:Tablet | 59676056301 | 06/26/2027 | Single Source Drug | Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 15, 2024. | ||
| Rx0000250 | Janssen Products, LP | 04/26/2024 | PREZISTA® Strength:800 MG Package Size:30 Form:Tablet | 59676056630 | 06/26/2027 | Innovator Multiple Source Drug | Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 15, 2024. | ||
| Rx0000250 | Janssen Products, LP | 04/26/2024 | PREZISTA® ORAL SUSPENSION Strength:100MG/mL Package Size:200mL Form:Oral Suspension | 59676056501 | 06/26/2027 | Single Source Drug | Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 15, 2024. | ||
| Rx0000250 | Janssen Products, LP | 04/26/2024 | SYMTUZA (darunavir 800mg/cobicistat 150mg/emtricitabine 200mg/tenofovir alafenamide 10mg) Strength: 800 MG/150 MG/200 MG/10 MG Package Size:30 Form:Tablet | 59676080030 | 07/19/2038 | Single Source Drug | Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 15, 2024. | ||
| Rx0000008 | Jazz Pharmaceuticals, Inc. | 10/23/2024 | Defitelio (Defibrotide Sodium) Carton of 10 Vials | 68727080002 | 06/22/2032 | Single Source Drug | The current patent expiration date, as defined under the California Code of Regulations § 96070, for Defitelio in the US corresponds to the last to expire of the patents listed in the Approved Products with Therapeutic Equivalence Evaluations (the Orange Book), as published by the Federal Food and Drug Association as of Oct 23, 2024. Unit Sales Volume and Change Improvement: Per CA Health & Safety Code Section 127681(c) Jazz Pharmaceuticals respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The drug was not acquired from another manufacturer within the last five years. | ||
| Rx0000008 | Jazz Pharmaceuticals, Inc. | 04/26/2024 | Defitelio 200mg/2.5mL Solution 80mg/1mL | 68727080002 | 06/22/2032 | Single Source Drug | The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration?s Orange Book, as of April 19, 2024. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. Unit Sales Volume and Change Improvement: Per CA Health & Safety Code Section 127681(c) Jazz Pharmaceuticals respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. | ||
| Rx0000008 | Jazz Pharmaceuticals, Inc. | 10/23/2024 | RYLAZE (asparaginase erwinia chrysanthemi (recombinant)-rywn) injection - 3 vial pack | 68727090003 | 05/06/2038 | Single Source Drug | The current patent expiration date, as defined under the California Code of Regulations § 96070, for Rylaze in the US is May 6, 2038. Jazz has certain pending patent applications that, if granted, will impact the patent expiration date. Unit Sales Volume and Change Improvement: Per CA Health & Safety Code Section 127681(c) Jazz Pharmaceuticals respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The drug was not acquired from another manufacturer within the last five years. | ||
| Rx0000008 | Jazz Pharmaceuticals, Inc. | 10/23/2024 | Vyxeos daunorubicin and cytarabine liposome for injection (2 vial carton) | 68727074502 | 10/15/2032 | Single Source Drug | The current patent expiration date, as defined under the California Code of Regulations § 96070, for Vyxeos in the US corresponds to the last to expire of the patents listed in the Approved Products with Therapeutic Equivalence Evaluations (the Orange Book), as published by the Federal Food and Drug Association as of Oct 23, 2024. Unit Sales Volume and Change Improvement: Per CA Health & Safety Code Section 127681(c) Jazz Pharmaceuticals respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The drug was not acquired from another manufacturer within the last five years. | ||
| Rx0000008 | Jazz Pharmaceuticals, Inc. | 04/26/2024 | Xyrem 500 MG/ML Oral Solution 180 ml | 68727010001 | 09/15/2033 | Innovator Multiple Source Drug | The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration?s Orange Book, as of April 19, 2024. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. Unit Sales Volume and Change Improvement: Per CA Health & Safety Code Section 127681(c) Jazz Pharmaceuticals respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. | ||
| Rx0000008 | Jazz Pharmaceuticals, Inc. | 04/26/2024 | Xywav 500 MG/ML Oral Solution 180 ml | 68727015001 | 09/19/2037 | Single Source Drug | The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration?s Orange Book, as of April 19, 2024. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. Unit Sales Volume and Change Improvement: Per CA Health & Safety Code Section 127681(c) Jazz Pharmaceuticals respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. | ||
| Rx0000008 | Jazz Pharmaceuticals, Inc. | 10/23/2024 | Zepzelca (lurbinectedin) 4mg Vial | 68727071201 | 2020 | 12/13/2029 | Single Source Drug | The current patent expiration date, as defined under the California Code of Regulations § 96070, for Zepzelca in the US corresponds to the last to expire of the patents listed in the Approved Products with Therapeutic Equivalence Evaluations (the Orange Book) as published by the Federal Food and Drug Association as of Oct 23, 2024. Jazz has certain pending patent applications that, if granted, will impact the patent expiration date. Unit Sales Volume and Change Improvement: Per CA Health & Safety Code Section 127681(c) Jazz Pharmaceuticals respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. | |
| Rx0000127 | Karyopharm Therapeutics Inc. | 04/25/2024 | Xpovio (100 MG Once Weekly) Oral Tablet Therapy Pack 50 MG, 2 Each, Unit-of-Use, Disp Pack Qty 4 | 72237010305 | 08/14/2035 | Single Source Drug | |||
| Rx0000127 | Karyopharm Therapeutics Inc. | 04/25/2024 | Xpovio (40 MG Once Weekly) Oral Tablet Therapy Pack 40 MG, 1 Each, Unit-of-Use, Disp Pack Qty 4 | 72237010207 | 08/14/2035 | Single Source Drug | |||
| Rx0000127 | Karyopharm Therapeutics Inc. | 04/25/2024 | Xpovio (40 MG Twice Weekly) Oral Tablet Therapy Pack 40 MG, 2 Each, Unit-of-Use, Disp Pack Qty 4 | 72237010206 | 08/14/2035 | Single Source Drug | |||
| Rx0000127 | Karyopharm Therapeutics Inc. | 04/25/2024 | Xpovio (60 MG Once Weekly) Oral Tablet Therapy Pack 60 MG, 1 Each, Unit-of-Use, Disp Pack Qty 4 | 72237010401 | 08/14/2035 | Single Source Drug | |||
| Rx0000127 | Karyopharm Therapeutics Inc. | 04/25/2024 | Xpovio (60 MG Twice Weekly) Oral Tablet Therapy Pack 20 MG, 6 Each, Unit-of-Use, Disp Pack Qty 4 | 72237010103 | 08/14/2035 | Single Source Drug | |||
| Rx0000127 | Karyopharm Therapeutics Inc. | 04/25/2024 | Xpovio (80 MG Once Weekly) Oral Tablet Therapy Pack 40 MG, 2 Each, Unit-of-Use, Disp Pack Qty 4 | 72237010202 | 08/14/2035 | Single Source Drug | |||
| Rx0000127 | Karyopharm Therapeutics Inc. | 04/25/2024 | Xpovio (80 MG Twice Weekly) Oral Tablet Therapy Pack 20 MG, 8 Each, Unit-of-Use, Disp Pack Qty 4 | 72237010104 | 08/14/2035 | Single Source Drug | |||
| Rx0000264 | Kedrion Biopharma Inc. | 03/31/2024 | gammaked 10% carton w/ 1 x 100ml vial | 76125090010 | Single Source Drug | ||||
| Rx0000264 | Kedrion Biopharma Inc. | 03/31/2024 | gammaked 10% carton w/ 1 x 200ml vial | 76125090020 | Single Source Drug | ||||
| Rx0000264 | Kedrion Biopharma Inc. | 03/31/2024 | gammaked 10% carton w/ 1 x 50ml vial | 76125090050 | Single Source Drug | ||||
| Rx0000386 | KVK Tech, Inc. | 04/09/2024 | Lomaira Oral Tablet 8 MG 90ct | 10702000109 | Non-innovator Multiple Source Drug | ||||
| Rx0000060 | Kyowa Kirin, Inc. | 04/23/2024 | CRYSVITA (burosumab-twza) injection, for subcutaneous use, 10 mg/mL, 1 ML, single dose vial | 42747010201 | Single Source Drug | Product was relabeled from 69794-0102-01 to 42747-0102-01 in September 2023. The 5year WAC increase history is inclusive of the price increases on the previous NDC. | |||
| Rx0000060 | Kyowa Kirin, Inc. | 04/23/2024 | CRYSVITA (burosumab-twza) injection, for subcutaneous use, 20 mg/mL, 1 ML, single dose vial | 42747020301 | Single Source Drug | Product was relabeled from 69794-0203-01 to 42747-0203-01 in September 2023. The 5year WAC increase history is inclusive of the price increases on the previous NDC. | |||
| Rx0000060 | Kyowa Kirin, Inc. | 04/23/2024 | CRYSVITA (burosumab-twza) injection, for subcutaneous use, 30 mg/mL, 1 ML, single dose vial | 42747030401 | Single Source Drug | Product was relabeled from 69794-0304-01 to 42747-0304-01 in September 2023. The 5year WAC increase history is inclusive of the price increases on the previous NDC. | |||
| Rx0000060 | Kyowa Kirin, Inc. | 04/23/2024 | Nourianz Oral Tablet 20 MG, 90 Each, Bottle | 42747060290 | 01/28/2028 | Single Source Drug | |||
| Rx0000060 | Kyowa Kirin, Inc. | 04/23/2024 | Nourianz Oral Tablet 40 MG, 90 Each, Bottle | 42747060490 | 01/28/2028 | Single Source Drug | |||
| Rx0000083 | Laboratoire HRA Pharma | 06/17/2024 | Lysodren 500 mg tablets 100 count bottles | 76336008060 | Single Source Drug | ||||
| Rx0000083 | Laboratoire HRA Pharma | 06/17/2024 | Metopirone 250 mg capsules 18 count bottles | 76336045518 | Single Source Drug | ||||
| Rx0000089 | Lannett Company, Inc. | 10/30/2024 | Lisdexamfetamine Dimesylate 40mg Capsule 100 CT Bottle | 00527466437 | Non-innovator Multiple Source Drug | ||||
| Rx0000089 | Lannett Company, Inc. | 10/30/2024 | Lisdexamfetamine Dimesylate 50mg Capsule 100 CT Bottle | 00527466537 | Non-innovator Multiple Source Drug | ||||
| Rx0000089 | Lannett Company, Inc. | 10/30/2024 | Lisdexamfetamine Dimesylate 60mg Capsule 100 CT Bottle | 00527466637 | Non-innovator Multiple Source Drug | ||||
| Rx0000089 | Lannett Company, Inc. | 10/30/2024 | Lisdexamfetamine Dimesylate 70mg Capsule 100 CT Bottle | 00527466737 | Non-innovator Multiple Source Drug | ||||
| Rx0000009 | Lantheus Medical Imaging, Inc. | 04/12/2024 | DEFINITY US 16Vial KIT. INJECTION, SUSPENSION, 6.52 mg/mL. 16 VIAL, GLASS in 1 CARTON (11994-011-16) > 1.5 mL in 1 VIAL, GLASS | 11994001116 | 05/04/2037 | Single Source Drug | This information is confidential and proprietary, and not publicly available or within the public domain | ||
| Rx0000009 | Lantheus Medical Imaging, Inc. | 04/12/2024 | DEFINITY US 4Vial KIT. INJECTION, SUSPENSION, 6.52 mg/mL. 4 VIAL, GLASS in 1 CARTON (11994-011-04) > 1.5 mL in 1 VIAL, GLASS | 11994001104 | 05/04/2037 | Single Source Drug | This information is confidential and proprietary, and not publicly available or within the public domain | ||
| Rx0000009 | Lantheus Medical Imaging, Inc. | 04/12/2024 | NEUROLITE® (Kit for the Preparation of Technetium Tc99m Bicisate for Injection) | 11994000602 | Single Source Drug | This information is confidential and proprietary, and not publicly available or within the public domain | |||
| Rx0000413 | Leadiant Biosciences, Inc. | 04/29/2024 | Cystaran Ophthalmic Solution 0.44 % | 54482002002 | Single Source Drug | ||||
| Rx0000025 | Lundbeck LLC | 04/23/2024 | Northera 100mg. 90 Capsules | 67386082019 | 02/18/2021 | Innovator Multiple Source Drug | Acquisition fields not completed as product was not acquired in the last 5 years. | ||
| Rx0000025 | Lundbeck LLC | 04/23/2024 | Northera 200mg. 90 Capsules | 67386082119 | 02/18/2021 | Innovator Multiple Source Drug | Acquisition fields not completed as product was not acquired in the last 5 years. | ||
| Rx0000025 | Lundbeck LLC | 04/23/2024 | Northera 300mg. 90 Capsules | 67386082219 | 02/18/2021 | Innovator Multiple Source Drug | Acquisition fields not completed as product was not acquired in the last 5 years. | ||
| Rx0000025 | Lundbeck LLC | 04/23/2024 | Onfi 10mg. 100 Tablets | 67386031401 | Innovator Multiple Source Drug | Acquisition fields not completed as product was not acquired in the last 5 years. | |||
| Rx0000025 | Lundbeck LLC | 04/23/2024 | Onfi 20mg. 100 Tablets | 67386031501 | Innovator Multiple Source Drug | Acquisition fields not completed as product was not acquired in the last 5 years. | |||
| Rx0000025 | Lundbeck LLC | 04/23/2024 | Onfi Oral Suspension 2.5mg/mL 120mL Bottle | 67386031321 | Innovator Multiple Source Drug | Acquisition fields not completed as product was not acquired in the last 5 years. | |||
| Rx0000025 | Lundbeck LLC | 10/24/2024 | Vyepti 100mg/ml single dose vial | 67386013051 | Single Source Drug | ||||
| Rx0000025 | Lundbeck LLC | 04/23/2024 | Xenazine 12.5mg. 112 Tablets | 67386042101 | Innovator Multiple Source Drug | Acquisition fields not completed as product was not acquired in the last 5 years. | |||
| Rx0000025 | Lundbeck LLC | 04/23/2024 | Xenazine 25.0mg. 112 Tablets | 67386042201 | Innovator Multiple Source Drug | Acquisition fields not completed as product was not acquired in the last 5 years. | |||
| Rx0000072 | Mayne Pharma Inc | 07/26/2024 | Rhofade External Cream 1 %, 30 g, Unit-of-Use, Tube | 71403000330 | 2017 | 06/11/2035 | Single Source Drug | Mayne Pharma Commercial LLC (Mayne Pharma) acquired Rhofade from EPI Health LLC following its bankruptcy. Mayne currently controls all pricing and distribution rights for this NDC and is reporting on pricing actions. | |
| Rx0000382 | Melinta Therapeutics, LLC | 04/30/2024 | MINOCIN (Minocycline-Hydrochloride) is administered via intravenous form and packaged as 10 VIAL in 1 CARTON > 1 INJECTION in 1 VIAL (100 mg dose) | 70842016010 | 10/16/2032 | Single Source Drug | |||
| Rx0000138 | Merck Sharp & Dohme LLC | 04/23/2024 | BRIDION 10 200 mg/2 mL Vial (ML) | 00006542312 | 01/27/2026 | Single Source Drug | Mercks submission to HCAi is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677) (collectively, SB 17), the information provided is limited to information Merck believes is in the public domain; (2) the columns requiring information relating to product acquisition are left blank because the product does not meet the criteria set forth in SB 17 (i.e., disclosure required if acquired by a manufacturer in the previous five years). The WAC price does not include the Federal Excise Tax (FET); (3) the listed expiration date reflects the expiration of the key patent or exclusivity period for the pharmaceutical product, which often results in a loss of market exclusivity. The key patent(s) for a product typically covers the products active pharmaceutical ingredient. Later-expiring patents directed to other innovations associated with the product, including for example, formulations, manufacturing processes or uses of the product, may provide additional commercial benefits and/or varying degrees of additional protection. Regulatory exclusivity tied to the protection of clinical data is complementary to patent protection and, in some cases, may provide more effective or longer lasting marketing exclusivity than a products patent portfolio. In the U.S., the data protection term generally runs five years from first marketing approval of a new chemical entity, extended to seven years for an orphan drug indication, and twelve years from first marketing approval of a biological product. | ||
| Rx0000138 | Merck Sharp & Dohme LLC | 04/23/2024 | BRIDION 10 500 mg/5 mL Vial (ML) | 00006542515 | 01/27/2026 | Single Source Drug | Mercks submission to HCAi is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677) (collectively, SB 17), the information provided is limited to information Merck believes is in the public domain; (2) the columns requiring information relating to product acquisition are left blank because the product does not meet the criteria set forth in SB 17 (i.e., disclosure required if acquired by a manufacturer in the previous five years). The WAC price does not include the Federal Excise Tax (FET); (3) the listed expiration date reflects the expiration of the key patent or exclusivity period for the pharmaceutical product, which often results in a loss of market exclusivity. The key patent(s) for a product typically covers the products active pharmaceutical ingredient. Later-expiring patents directed to other innovations associated with the product, including for example, formulations, manufacturing processes or uses of the product, may provide additional commercial benefits and/or varying degrees of additional protection. Regulatory exclusivity tied to the protection of clinical data is complementary to patent protection and, in some cases, may provide more effective or longer lasting marketing exclusivity than a products patent portfolio. In the U.S., the data protection term generally runs five years from first marketing approval of a new chemical entity, extended to seven years for an orphan drug indication, and twelve years from first marketing approval of a biological product. | ||
| Rx0000138 | Merck Sharp & Dohme LLC | 04/23/2024 | DIFICID 1 packet granules (40mg/mL final concentration) Suspension-Reconsitituted-Oral (EA) | 52015070022 | 11/28/2034 | Single Source Drug | Mercks submission to HCAi is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677) (collectively, SB 17), the information provided is limited to information Merck believes is in the public domain; (2) the columns requiring information relating to product acquisition are left blank because the product does not meet the criteria set forth in SB 17 (i.e., disclosure required if acquired by a manufacturer in the previous five years). The WAC price does not include the Federal Excise Tax (FET); (3) the listed expiration date reflects the expiration of the key patent or exclusivity period for the pharmaceutical product, which often results in a loss of market exclusivity. The key patent(s) for a product typically covers the products active pharmaceutical ingredient. Later-expiring patents directed to other innovations associated with the product, including for example, formulations, manufacturing processes or uses of the product, may provide additional commercial benefits and/or varying degrees of additional protection. Regulatory exclusivity tied to the protection of clinical data is complementary to patent protection and, in some cases, may provide more effective or longer lasting marketing exclusivity than a products patent portfolio. In the U.S., the data protection term generally runs five years from first marketing approval of a new chemical entity, extended to seven years for an orphan drug indication, and twelve years from first marketing approval of a biological product. | ||
| Rx0000138 | Merck Sharp & Dohme LLC | 04/23/2024 | DIFICID 20 200 mg Tablets | 52015008001 | 01/31/2028 | Single Source Drug | Mercks submission to HCAi is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677) (collectively, SB 17), the information provided is limited to information Merck believes is in the public domain; (2) the columns requiring information relating to product acquisition are left blank because the product does not meet the criteria set forth in SB 17 (i.e., disclosure required if acquired by a manufacturer in the previous five years). The WAC price does not include the Federal Excise Tax (FET); (3) the listed expiration date reflects the expiration of the key patent or exclusivity period for the pharmaceutical product, which often results in a loss of market exclusivity. The key patent(s) for a product typically covers the products active pharmaceutical ingredient. Later-expiring patents directed to other innovations associated with the product, including for example, formulations, manufacturing processes or uses of the product, may provide additional commercial benefits and/or varying degrees of additional protection. Regulatory exclusivity tied to the protection of clinical data is complementary to patent protection and, in some cases, may provide more effective or longer lasting marketing exclusivity than a products patent portfolio. In the U.S., the data protection term generally runs five years from first marketing approval of a new chemical entity, extended to seven years for an orphan drug indication, and twelve years from first marketing approval of a biological product. | ||
| Rx0000138 | Merck Sharp & Dohme LLC | 09/26/2024 | GARDASIL 9 0.5 mL Syringes 10 | 00006412102 | 12/10/2028 | Single Source Drug | Mercks submission to HCAi is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677) (collectively, SB 17), the information provided is limited to information Merck believes is in the public domain; (2) the columns requiring information relating to product acquisition are left blank because the product does not meet the criteria set forth in SB 17 (i.e., disclosure required if acquired by a manufacturer in the previous five years). (3) The WAC price does not include the Federal Excise Tax (FET); (4) The listed expiration date reflects the expiration of the key patent or exclusivity period for the pharmaceutical product, which often results in a loss of market exclusivity. The key patent(s) for a product typically covers the products active pharmaceutical ingredient. Later-expiring patents directed to other innovations associated with the product, including for example, formulations, manufacturing processes or uses of the product, may provide additional commercial benefits and/or varying degrees of additional protection. Regulatory exclusivity tied to the protection of clinical data is complementary to patent protection and, in some cases, may provide more effective or longer lasting marketing exclusivity than a products patent portfolio. In the U.S., the data protection term generally runs five years from first marketing approval of a new chemical entity, extended to seven years for an orphan drug indication, and twelve years from first marketing approval of a biological product. | ||
| Rx0000138 | Merck Sharp & Dohme LLC | 09/26/2024 | GARDASIL 9 0.5 mL Vials 10 | 00006411903 | 12/10/2028 | Single Source Drug | Mercks submission to HCAi is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677) (collectively, SB 17), the information provided is limited to information Merck believes is in the public domain; (2) the columns requiring information relating to product acquisition are left blank because the product does not meet the criteria set forth in SB 17 (i.e., disclosure required if acquired by a manufacturer in the previous five years). (3) The WAC price does not include the Federal Excise Tax (FET); (4) The listed expiration date reflects the expiration of the key patent or exclusivity period for the pharmaceutical product, which often results in a loss of market exclusivity. The key patent(s) for a product typically covers the products active pharmaceutical ingredient. Later-expiring patents directed to other innovations associated with the product, including for example, formulations, manufacturing processes or uses of the product, may provide additional commercial benefits and/or varying degrees of additional protection. Regulatory exclusivity tied to the protection of clinical data is complementary to patent protection and, in some cases, may provide more effective or longer lasting marketing exclusivity than a products patent portfolio. In the U.S., the data protection term generally runs five years from first marketing approval of a new chemical entity, extended to seven years for an orphan drug indication, and twelve years from first marketing approval of a biological product. | ||
| Rx0000138 | Merck Sharp & Dohme LLC | 09/26/2024 | VARIVAX 0.5 mL Vials 10 | 00006482700 | Single Source Drug | Mercks submission to HCAi is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677) (collectively, SB 17), the information provided is limited to information Merck believes is in the public domain; (2) the columns requiring information relating to product acquisition are left blank because the product does not meet the criteria set forth in SB 17 (i.e., disclosure required if acquired by a manufacturer in the previous five years). (3) The WAC Price does not include the Federal Excise Tax (FET). | |||
| Rx0000138 | Merck Sharp & Dohme LLC | 04/23/2024 | ZERBAXA 10 1.5 gram Vial (EA) | 67919003001 | 08/14/2035 | Single Source Drug | Mercks submission to HCAi is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677) (collectively, SB 17), the information provided is limited to information Merck believes is in the public domain; (2) the columns requiring information relating to product acquisition are left blank because the product does not meet the criteria set forth in SB 17 (i.e., disclosure required if acquired by a manufacturer in the previous five years). The WAC price does not include the Federal Excise Tax (FET); (3) the listed expiration date reflects the expiration of the key patent or exclusivity period for the pharmaceutical product, which often results in a loss of market exclusivity. The key patent(s) for a product typically covers the products active pharmaceutical ingredient. Later-expiring patents directed to other innovations associated with the product, including for example, formulations, manufacturing processes or uses of the product, may provide additional commercial benefits and/or varying degrees of additional protection. Regulatory exclusivity tied to the protection of clinical data is complementary to patent protection and, in some cases, may provide more effective or longer lasting marketing exclusivity than a products patent portfolio. In the U.S., the data protection term generally runs five years from first marketing approval of a new chemical entity, extended to seven years for an orphan drug indication, and twelve years from first marketing approval of a biological product. | ||
| Rx0000051 | MILLICENT U.S., INC. | 04/25/2024 | Femring (estradiol acetate vaginal ring) 0.1 mg/day, 1 Box | 72495020210 | Single Source Drug | ||||
| Rx0000051 | MILLICENT U.S., INC. | 04/25/2024 | Femring (estradiol acetate vaginal ring) 0.05 mg/day, 1 Box | 72495020105 | Single Source Drug | ||||
| Rx0000051 | MILLICENT U.S., INC. | 04/25/2024 | Intrarosa Prasterone Vaginal Inserts 6.5 mg per insert, 28 inserts per box | 72495040128 | 2017 | 03/19/2031 | Single Source Drug | ||
| Rx0000046 | Mylan Specialty LP | 04/30/2024 | Cimduo Tabs 300mg/300mg 30s | 49502045093 | Single Source Drug | ||||
| Rx0000046 | Mylan Specialty LP | 04/30/2024 | Depen (Penicillamine Tabs) 250mg 1s | 00037440101 | Innovator Multiple Source Drug | ||||
| Rx0000046 | Mylan Specialty LP | 04/30/2024 | Edluar 10mg Sublingual T 3x10 | 00037601030 | 02/25/2031 | Innovator Multiple Source Drug | 00037-6010-30 is a discontinued NDC effective May 31, 2023 and would typically not appear on Viatris analysis for NDCs to report. Viatris is reporting this NDC on this report in response to Californias Notice of Potential Wholesale Acquisition Cost Increase Report in an abundance of caution and in the interest of supporting Californias Drug Price Transparency Program. Viatris reserves the right on future reports to reassess this reporting obligation for discontinued NDCs. | ||
| Rx0000046 | Mylan Specialty LP | 04/30/2024 | Edluar 10mg Sublingual T 5x6 | 00037601093 | 02/25/2031 | Innovator Multiple Source Drug | |||
| Rx0000046 | Mylan Specialty LP | 04/30/2024 | Edluar 5mg Sublingual T 3x10 | 00037605030 | 02/25/2031 | Innovator Multiple Source Drug | 00037-6050-30 is a discontinued NDC effective January 31, 2023 and would typically not appear on Viatris analysis for NDCs to report. Viatris is reporting this NDC on this report in response to Californias Notice of Potential Wholesale Acquisition Cost Increase Report in an abundance of caution and in the interest of supporting Californias Drug Price Transparency Program. Viatris reserves the right on future reports to reassess this reporting obligation for discontinued NDCs. | ||
| Rx0000046 | Mylan Specialty LP | 04/30/2024 | Edluar 5mg Sublingual T 5x6 | 00037605093 | 02/25/2031 | Innovator Multiple Source Drug | |||
| Rx0000046 | Mylan Specialty LP | 04/30/2024 | EMSAM TDS 12mg/day Bx30 | 49502090230 | Single Source Drug | ||||
| Rx0000046 | Mylan Specialty LP | 04/30/2024 | EMSAM TDS 6mg/day Bx30 | 49502090030 | Single Source Drug | ||||
| Rx0000046 | Mylan Specialty LP | 04/30/2024 | EMSAM TDS 9mg/day Bx30 | 49502090130 | Single Source Drug | ||||
| Rx0000046 | Mylan Specialty LP | 04/30/2024 | Epifoam 1% 10g 1PK | 00037682410 | Non-innovator Multiple Source Drug | ||||
| Rx0000046 | Mylan Specialty LP | 04/30/2024 | Gastrocrom Oral Concentrate 20mg/mL 5mL 96s | 00037067896 | Innovator Multiple Source Drug | ||||
| Rx0000046 | Mylan Specialty LP | 04/30/2024 | Levsin Tabs 0.125mg 100s | 68220011210 | Non-innovator Multiple Source Drug | ||||
| Rx0000046 | Mylan Specialty LP | 04/30/2024 | Levsin/SL Tabs 0.125mg 100s | 68220011310 | Non-innovator Multiple Source Drug | ||||
| Rx0000046 | Mylan Specialty LP | 04/30/2024 | NuLev Chewable Melt Tabs 0.125mg 100s | 68220011810 | Non-innovator Multiple Source Drug | ||||
| Rx0000046 | Mylan Specialty LP | 04/30/2024 | Pretomanid Tabs 200mg 26s | 49502047626 | Single Source Drug | ||||
| Rx0000046 | Mylan Specialty LP | 04/30/2024 | Proctofoam HC 1% 10g 1PK | 00037682210 | Non-innovator Multiple Source Drug | ||||
| Rx0000046 | Mylan Specialty LP | 04/30/2024 | Proctofoam NS 1% 15g | 00037682315 | Non-innovator Multiple Source Drug | ||||
| Rx0000046 | Mylan Specialty LP | 04/30/2024 | Rowasa Kit Rectal Suspension 4g/60mL 28PK | 00037006603 | Innovator Multiple Source Drug | ||||
| Rx0000046 | Mylan Specialty LP | 04/30/2024 | Rowasa Kit Rectal Suspension 4g/60mL 7PK | 00037006605 | Innovator Multiple Source Drug | ||||
| Rx0000046 | Mylan Specialty LP | 04/30/2024 | Soma Tabs 250mg 30s | 00037225030 | Innovator Multiple Source Drug | ||||
| Rx0000046 | Mylan Specialty LP | 04/30/2024 | Soma Tabs 250mg100s | 00037225010 | Innovator Multiple Source Drug | ||||
| Rx0000046 | Mylan Specialty LP | 04/30/2024 | Soma Tabs 350mg 100s | 00037200101 | Innovator Multiple Source Drug | ||||
| Rx0000046 | Mylan Specialty LP | 04/30/2024 | Symfi Lo Tabs 400mg/300mg/300mg 30s | 49502042593 | Innovator Multiple Source Drug | ||||
| Rx0000046 | Mylan Specialty LP | 04/30/2024 | Symfi Tabs 600mg/300mg/300mg 30s | 49502047593 | Innovator Multiple Source Drug | ||||
| Rx0000046 | Mylan Specialty LP | 04/30/2024 | Tobramycin Inhalation Solution (Tobi) 300mg/5mL 56s | 49502034573 | 11/04/2030 | Innovator Multiple Source Drug | |||
| Rx0000046 | Mylan Specialty LP | 04/30/2024 | Urelle Tabs 0.12mg/81mg/10.8mg/32.4mg/40.8mg 90s | 00037632190 | Non-innovator Multiple Source Drug | ||||
| Rx0000046 | Mylan Specialty LP | 10/31/2024 | YUPELRI (Revefenacin) Inhalation Solution 175mcg/3mL 30PK | 49502080693 | 10/23/2039 | Single Source Drug | |||
| Rx0000046 | Mylan Specialty LP | 04/30/2024 | YUPELRI Inhalation Solution 175mcg/3mL | 49502080693 | 10/23/2039 | Single Source Drug | |||
| Rx0000476 | Neurelis | 03/31/2024 | 1 VALTOCO CARTON .5mg/.1ml VIAL, 1 Each, Unit-of-Use, Box Qty 2 | 72252050502 | 03/27/2029 | Single Source Drug | |||
| Rx0000476 | Neurelis | 03/31/2024 | 1 VALTOCO CARTON 10mg/.1ml VIAL, 1 Each, Unit-of-Use, Box Qty 2 | 72252051002 | 03/27/2029 | Single Source Drug | |||
| Rx0000476 | Neurelis | 03/31/2024 | VALTOCO CARTON with 10mg/.1ml VIALS, 1 Each, Unit-of-Use, Box Qty 2 | 72252052004 | 03/27/2029 | Single Source Drug | |||
| Rx0000476 | Neurelis | 03/31/2024 | VALTOCO CARTON with 7.5mg/.1ml VIALS, 1 Each, Unit-of-Use, Box Qty 2 | 72252051504 | 03/27/2029 | Single Source Drug | |||
| Rx0000420 | Nielsen BioSciences, Inc. | 03/31/2024 | Candin Injection Solution/1U in 0.1mL Intradermally/1mL Vial | 59584013801 | Single Source Drug | Nielsen Biosciences price increase factors, costs and revenue constitute trade secret information and are exempt from disclosure. | |||
| Rx0000420 | Nielsen BioSciences, Inc. | 03/31/2024 | Spherusol Injection Solution/Coccidioides immitis Spherule-Derived Skin Test Antigen - 1.27mcg/0.1mL/1mL Vial/0.1mL Intradermally/1ml multidose vial | 59584014001 | Single Source Drug | Nielsen Biosciences price increase factors, costs and revenue constitute trade secret information and are exempt from disclosure. | |||
| Rx0000204 | Noden Pharma USA, Inc. | 03/31/2024 | TEKTURNA 150MG TAB 30/EA | 70839015030 | 08/19/2026 | Single Source Drug | |||
| Rx0000204 | Noden Pharma USA, Inc. | 03/31/2024 | TEKTURNA 300MG TAB 30/EA | 70839030030 | 08/19/2026 | Single Source Drug | |||
| Rx0000073 | Novartis | 04/26/2024 | AFINITOR DISPERZ TABLET FOR SUSPENSION 2 mg 28 | 00078062651 | 03/27/2023 | Innovator Multiple Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | AFINITOR DISPERZ TABLET FOR SUSPENSION 3 mg 28 | 00078062751 | 03/27/2023 | Innovator Multiple Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | AFINITOR DISPERZ TABLET FOR SUSPENSION 5 mg 28 | 00078062851 | 03/27/2023 | Innovator Multiple Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | AFINITOR TABLET 10 mg 28 | 00078056751 | 07/01/2028 | Innovator Multiple Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | AFINITOR TABLET 2.5 mg 28 | 00078059451 | 07/01/2028 | Innovator Multiple Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | AFINITOR TABLET 5 mg 28 | 00078056651 | 07/01/2028 | Innovator Multiple Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | AFINITOR TABLET 7.5 mg 28 | 00078062051 | 07/01/2028 | Innovator Multiple Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | COSENTYX (2 SYRINGES) SYRINGE (ML) 150 mg/mL 1 | 00078063998 | 12/21/2035 | Single Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | COSENTYX SENSOREADY (2 PENS) PEN INJECTOR (ML) 150 mg/mL 1 | 00078063941 | 12/21/2035 | Single Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | COSENTYX SENSOREADY PEN PEN INJECTOR (ML) 150 mg/mL 1 | 00078063968 | 12/21/2035 | Single Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | COSENTYX SYRINGE SYRINGE (ML) 150 mg/mL 1 | 00078063997 | 12/21/2035 | Single Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | COSENTYX SYRINGE SYRINGE (ML) 75 mg/0.5 mL 0.5 | 00078105697 | 12/21/2035 | Single Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | DIOVAN HCT TABLET 160 mg-12.5 mg 90 | 00078031534 | 12/18/2017 | Innovator Multiple Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | DIOVAN HCT TABLET 160 mg-25 mg 90 | 00078038334 | 12/18/2017 | Innovator Multiple Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | DIOVAN HCT TABLET 320 mg-12.5 mg 90 | 00078047134 | 12/18/2017 | Innovator Multiple Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | DIOVAN HCT TABLET 320 mg-25 mg 90 | 00078047234 | 12/18/2017 | Innovator Multiple Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | DIOVAN HCT TABLET 80 mg-12.5 mg 90 | 00078031434 | 12/18/2017 | Innovator Multiple Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | DIOVAN TABLET 160 mg 90 | 00078035934 | 12/18/2017 | Innovator Multiple Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | DIOVAN TABLET 320 mg 90 | 00078036034 | 12/18/2017 | Innovator Multiple Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | DIOVAN TABLET 40 mg 30 | 00078042315 | 12/18/2017 | Innovator Multiple Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | DIOVAN TABLET 80 mg 90 | 00078035834 | 12/18/2017 | Innovator Multiple Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | ENTRESTO TABLET 24 mg-26 mg 180 | 00078065967 | 05/09/2036 | Single Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | ENTRESTO TABLET 24 mg-26 mg 60 | 00078065920 | 05/09/2036 | Single Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | ENTRESTO TABLET 49 mg-51 mg 180 | 00078077767 | 05/09/2036 | Single Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | ENTRESTO TABLET 49 mg-51 mg 60 | 00078077720 | 05/09/2036 | Single Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | ENTRESTO TABLET 97 mg-103 mg 180 | 00078069667 | 05/09/2036 | Single Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | ENTRESTO TABLET 97 mg-103 mg 60 | 00078069620 | 05/09/2036 | Single Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | EXFORGE HCT TABLET 10 mg-160 mg-12.5 mg 30 | 00078056115 | 11/16/2023 | Innovator Multiple Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | EXFORGE HCT TABLET 10 mg-160 mg-25 mg 30 | 00078056215 | 11/16/2023 | Innovator Multiple Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | EXFORGE HCT TABLET 10 mg-320 mg-25 mg 30 | 00078056315 | 11/16/2023 | Innovator Multiple Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | EXFORGE HCT TABLET 5 mg-160 mg-12.5 mg 30 | 00078055915 | 11/16/2023 | Innovator Multiple Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | EXFORGE HCT TABLET 5 mg-160 mg-25 mg 30 | 00078056015 | 11/16/2023 | Innovator Multiple Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | EXFORGE TABLET 10 mg-160 mg 30 | 00078048915 | 07/08/2019 | Innovator Multiple Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | EXFORGE TABLET 10 mg-320 mg 30 | 00078049115 | 07/08/2019 | Innovator Multiple Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | EXFORGE TABLET 5 mg-160 mg 30 | 00078048815 | 07/08/2019 | Innovator Multiple Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | EXFORGE TABLET 5 mg-320 mg 30 | 00078049015 | 07/08/2019 | Innovator Multiple Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | EXJADE TABLET, DISPERSIBLE 125 mg 30 | 00078046815 | 04/05/2019 | Innovator Multiple Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | EXJADE TABLET, DISPERSIBLE 250 mg 30 | 00078046915 | 04/05/2019 | Innovator Multiple Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | EXJADE TABLET, DISPERSIBLE 500 mg 30 | 00078047015 | 04/05/2019 | Innovator Multiple Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | EXTAVIA KIT 0.3 mg 15 | 00078056912 | 05/17/2013 | Innovator Multiple Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | GILENYA CAPSULE 0.5 mg 30 | 00078060715 | 12/25/2027 | Innovator Multiple Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 10/31/2024 | ILARIS VIAL (ML) 150 mg/mL 1 VIAL | 00078073461 | 12/09/2029 | Single Source Drug | The product was not acquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | JADENU SPRINKLE GRANULES IN PACKET (EA) 180 mg 30 | 00078071315 | 04/05/2019 | Innovator Multiple Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | JADENU SPRINKLE GRANULES IN PACKET (EA) 360 mg 30 | 00078072015 | 04/05/2019 | Innovator Multiple Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | JADENU SPRINKLE GRANULES IN PACKET (EA) 90 mg 30 | 00078072715 | 04/05/2019 | Innovator Multiple Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | JADENU TABLET 180 mg 30 | 00078065515 | 11/21/2034 | Innovator Multiple Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | JADENU TABLET 360 mg 30 | 00078065615 | 11/21/2034 | Innovator Multiple Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | JADENU TABLET 90 mg 30 | 00078065415 | 11/21/2034 | Innovator Multiple Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | KESIMPTA PEN PEN INJECTOR (ML) 20 mg/0.4 mL 0.4 | 00078100768 | 12/30/2037 | Single Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | KISQALI FEMARA CO-PACK TABLET 200 mg/day (200 mg x 1)-2.5 mg 49 | 00078090961 | 04/14/2036 | Single Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | KISQALI FEMARA CO-PACK TABLET 400 mg/day (200 mg x 2)-2.5 mg 70 | 00078091661 | 04/14/2036 | Single Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | KISQALI FEMARA CO-PACK TABLET 600 mg/day (200 mg x 3)-2.5 mg 91 | 00078092361 | 04/14/2036 | Single Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | KISQALI TABLET 200 mg/day (200 mg x 1) 21 | 00078086001 | 04/14/2036 | Single Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | KISQALI TABLET 400 mg/day (200 mg x 2) 42 | 00078086742 | 04/14/2036 | Single Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | KISQALI TABLET 600 mg/day (200 mg x 3) 63 | 00078087463 | 04/14/2036 | Single Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 07/31/2024 | KYMRIAH PLASTIC BAG, INJECTION (EA) 0.2 x 10exp6 to 2.5 x 10exp8 cell 1 | 00078084619 | 07/12/3033 | Single Source Drug | The product was not acquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 07/31/2024 | KYMRIAH PLASTIC BAG, INJECTION (EA) 0.6 x 10exp8 to 6 x 10exp8 cell 1 | 00078095819 | 07/12/2033 | Single Source Drug | The product was not acquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | MAYZENT TABLET 0.25 mg 28 | 00078097950 | 11/30/2030 | Single Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | MAYZENT TABLET 2 mg 30 | 00078098615 | 11/30/2030 | Single Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | MAYZENT TABLET, DOSE PACK 0.25 mg (12 tabs) 12 | 00078097912 | 11/30/2030 | Single Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | MEKINIST TABLET 0.5 mg 30 | 00078110515 | 03/02/2034 | Single Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | MEKINIST TABLET 2 mg 30 | 00078111215 | 03/02/2034 | Single Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | MYFORTIC TABLET, DELAYED RELEASE (ENTERIC COATED) 180 mg 120 | 00078038566 | 02/27/2018 | Innovator Multiple Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | MYFORTIC TABLET, DELAYED RELEASE (ENTERIC COATED) 360 mg 120 | 00078038666 | 02/27/2018 | Innovator Multiple Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | NEORAL CAPSULE 100 mg 30 | 00078024815 | 09/26/2014 | Innovator Multiple Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | NEORAL CAPSULE 25 mg 30 | 00078024615 | 09/26/2014 | Innovator Multiple Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | NEORAL SOLUTION, ORAL 100 mg/mL 50 | 00078027422 | 09/26/2014 | Innovator Multiple Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | PIQRAY TABLET 200 mg/day (200 mg x 1) 28 | 00078070184 | 04/29/2033 | Single Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | PIQRAY TABLET 250 mg/day (200 mg x 1 and 50 mg x 1) 56 | 00078071502 | 04/29/2033 | Single Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | PIQRAY TABLET 300 mg/day (150 mg x 2) 56 | 00078070802 | 04/29/2033 | Single Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | PROMACTA POWDER IN PACKET (EA) 12.5 mg 30 | 00078097261 | 01/12/2026 | Single Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | PROMACTA POWDER IN PACKET (EA) 25 mg 30 | 00078069761 | 01/13/2026 | Single Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | PROMACTA TABLET 12.5 mg 30 | 00078068415 | 02/01/2028 | Single Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | PROMACTA TABLET 25 mg 30 | 00078068515 | 02/01/2028 | Single Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | PROMACTA TABLET 50 mg 14 | 00078068655 | 02/01/2028 | Single Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | PROMACTA TABLET 50 mg 30 | 00078068615 | 02/01/2028 | Single Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | PROMACTA TABLET 75 mg 30 | 00078068715 | 02/01/2028 | Single Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | RYDAPT CAPSULE 25 mg 112 | 00078069819 | 12/02/2030 | Single Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | RYDAPT CAPSULE 25 mg 56 | 00078069899 | 12/02/2030 | Single Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | SCEMBLIX TABLET 20 mg 60 | 00078109120 | 05/14/2040 | Single Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | SCEMBLIX TABLET 40 mg 60 | 00078109820 | 05/14/2040 | Single Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | TABRECTA TABLET 150 mg 56 | 00078070956 | 07/22/2035 | Single Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | TABRECTA TABLET 200 mg 56 | 00078071656 | 07/22/2035 | Single Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | TAFINLAR CAPSULE 50 mg 120 | 00078068266 | 03/02/2034 | Single Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | TAFINLAR CAPSULE 75 mg 120 | 00078068166 | 03/02/2034 | Single Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | TASIGNA CAPSULE 150 mg 28 | 00078059287 | 10/07/2032 | Single Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | TASIGNA CAPSULE 200 mg 28 | 00078052687 | 10/07/2032 | Single Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | TASIGNA CAPSULE 50 mg 120 | 00078095166 | 10/07/2032 | Single Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | TEGRETOL SUSPENSION, ORAL (FINAL DOSE FORM) 100 mg/5 mL 450 | 00078050883 | 10/11/2000 | Innovator Multiple Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | TEGRETOL TABLET 200 mg 100 | 00078050905 | 10/11/2000 | Innovator Multiple Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | TEGRETOL XR TABLET, EXTENDED RELEASE 12 HR 100 mg 100 | 00078051005 | 02/08/2011 | Innovator Multiple Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | TEGRETOL XR TABLET, EXTENDED RELEASE 12 HR 200 mg 100 | 00078051105 | 02/08/2011 | Innovator Multiple Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | TEGRETOL XR TABLET, EXTENDED RELEASE 12 HR 400 mg 100 | 00078051205 | 02/08/2011 | Innovator Multiple Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | TOBRADEX OINTMENT (GRAM) 0.3 %-0.1 % 3.5 | 00078087601 | 03/09/3008 | Single Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | TRILEPTAL SUSPENSION, ORAL (FINAL DOSE FORM) 300 mg/5 mL (60 mg/mL) 250 | 00078035752 | 12/19/2020 | Innovator Multiple Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | TRILEPTAL TABLET 150 mg 100 | 00078045605 | 02/12/2018 | Innovator Multiple Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | TRILEPTAL TABLET 300 mg 100 | 00078033705 | 02/12/2018 | Innovator Multiple Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | TRILEPTAL TABLET 600 mg 100 | 00078045705 | 02/12/2018 | Innovator Multiple Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | TYKERB TABLET 250 mg 150 | 00078067119 | 09/18/2029 | Innovator Multiple Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000073 | Novartis | 04/26/2024 | ZYKADIA TABLET 150 mg 84 | 00078069484 | 02/02/2032 | Single Source Drug | The product was not aquired. All information is provided by Novartis to the best of our knowledge at the time of submission. WAC is reported at the package level not the unit level. Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 ? 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 ? 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Novartis related information herein is confidential and proprietary, commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that the confidentiality of this submission and of all Novartis? related information herein be maintained to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure. | ||
| Rx0000249 | Octapharma USA, Inc. | 07/31/2024 | Panzyga 10 gm/100 mL single use vial | 68982082204 | Innovator Multiple Source Drug | ||||
| Rx0000249 | Octapharma USA, Inc. | 07/31/2024 | Panzyga 2.5 gm/ 25 mL single use vial | 68982082202 | Innovator Multiple Source Drug | ||||
| Rx0000249 | Octapharma USA, Inc. | 07/31/2024 | Panzyga 20 gm/200 mL single use vial | 68982082205 | Innovator Multiple Source Drug | ||||
| Rx0000249 | Octapharma USA, Inc. | 07/31/2024 | Panzyga 30 gm/300 mL single use vial | 68982082206 | Innovator Multiple Source Drug | ||||
| Rx0000249 | Octapharma USA, Inc. | 07/31/2024 | Panzyga 5 gm/50 mL single use vial | 68982082203 | Innovator Multiple Source Drug | ||||
| Rx0000375 | Organon | 07/18/2024 | Pregnyl Intramuscular Solution Reconstituted 10000 Unit Package of 1 Vial | 78206015001 | Innovator Multiple Source Drug | Pregnyl no longer under patent, no date to report. Organon is the resulting organization from the divesture of Merck's women's health division, biosimilars, and select legacy products. For clarity, this product being sold under the Organon label are not new to market products as they existed previously under Merck but are being sold now under the Organon label. | |||
| Rx0000067 | Otsuka America Pharmaceutical, Inc. | 04/30/2024 | Abilify Asimtufii 720mg Kit | 59148010280 | 04/23/2033 | Single Source Drug | |||
| Rx0000067 | Otsuka America Pharmaceutical, Inc. | 04/30/2024 | Abilify Asimtufii 960mg Kit | 59148011480 | 04/23/2033 | Single Source Drug | |||
| Rx0000067 | Otsuka America Pharmaceutical, Inc. | 04/30/2024 | Abilify Maintena 300mg Dual Chamber Syringe | 59148004580 | 04/06/2034 | Single Source Drug | |||
| Rx0000067 | Otsuka America Pharmaceutical, Inc. | 04/30/2024 | Abilify Maintena 300mg Kit | 59148001871 | 04/06/2034 | Single Source Drug | |||
| Rx0000067 | Otsuka America Pharmaceutical, Inc. | 04/30/2024 | Abilify Maintena 400mg Dual Chamber Syringe | 59148007280 | 04/06/2034 | Single Source Drug | |||
| Rx0000067 | Otsuka America Pharmaceutical, Inc. | 04/30/2024 | Abilify Maintena 400mg Kit | 59148001971 | 04/06/2034 | Single Source Drug | |||
| Rx0000067 | Otsuka America Pharmaceutical, Inc. | 04/30/2024 | Jynarque 15mg tablets, 30 count bottle | 59148008213 | 04/07/2030 | Single Source Drug | |||
| Rx0000067 | Otsuka America Pharmaceutical, Inc. | 04/30/2024 | Jynarque 15mg/15mg tablets, 4x weekly blister cards | 59148007928 | 04/07/2030 | Single Source Drug | |||
| Rx0000067 | Otsuka America Pharmaceutical, Inc. | 04/30/2024 | Jynarque 30mg tablets, 30 count bottle | 59148008313 | 04/07/2030 | Single Source Drug | |||
| Rx0000067 | Otsuka America Pharmaceutical, Inc. | 04/30/2024 | Jynarque 30mg/15mg tablets, 4x weekly blister cards | 59148008028 | 04/07/2030 | Single Source Drug | |||
| Rx0000067 | Otsuka America Pharmaceutical, Inc. | 04/30/2024 | Jynarque 45mg/15mg tablets, 4x weekly blister cards | 59148008728 | 04/07/2030 | Single Source Drug | |||
| Rx0000067 | Otsuka America Pharmaceutical, Inc. | 04/30/2024 | Jynarque 60mg/30mg tablets, 4x weekly blister cards | 59148008828 | 04/07/2030 | Single Source Drug | |||
| Rx0000067 | Otsuka America Pharmaceutical, Inc. | 04/30/2024 | Jynarque 90mg/30mg tablets, 4x weekly blister cards | 59148008928 | 04/07/2030 | Single Source Drug | |||
| Rx0000067 | Otsuka America Pharmaceutical, Inc. | 04/30/2024 | Nuedexta 20mg/10mg CP, 60 count bottle | 64597030160 | 08/13/2026 | Single Source Drug | |||
| Rx0000067 | Otsuka America Pharmaceutical, Inc. | 04/30/2024 | Rexulti 0.25mg tablets, 30 count bottle | 59148003513 | 10/12/2032 | Single Source Drug | |||
| Rx0000067 | Otsuka America Pharmaceutical, Inc. | 04/30/2024 | Rexulti 0.5mg tablets, 30 count bottle | 59148003613 | 10/12/2032 | Single Source Drug | |||
| Rx0000067 | Otsuka America Pharmaceutical, Inc. | 04/30/2024 | Rexulti 1mg tablets, 30 count bottle | 59148003713 | 10/12/2032 | Single Source Drug | |||
| Rx0000067 | Otsuka America Pharmaceutical, Inc. | 04/30/2024 | Rexulti 2mg tablets, 30 count bottle | 59148003813 | 10/12/2032 | Single Source Drug | |||
| Rx0000067 | Otsuka America Pharmaceutical, Inc. | 04/30/2024 | Rexulti 3mg tablets, 30 count bottle | 59148003913 | 10/12/2032 | Single Source Drug | |||
| Rx0000067 | Otsuka America Pharmaceutical, Inc. | 04/30/2024 | Rexulti 4mg tablets, 30 count bottle | 59148004013 | 10/12/2032 | Single Source Drug | |||
| Rx0000495 | Otter Pharmaceuticals LLC | 07/24/2024 | Otrexup Subcutaneous Solution Auto-injector 10 MG/0.4ML 1 Syringe | 54436001002 | 2014 | 05/27/2031 | Single Source Drug | ||
| Rx0000495 | Otter Pharmaceuticals LLC | 07/24/2024 | Otrexup Subcutaneous Solution Auto-injector 10 MG/0.4ML 4 Syringe | 54436001004 | 2014 | 05/27/2031 | Single Source Drug | ||
| Rx0000495 | Otter Pharmaceuticals LLC | 07/24/2024 | Otrexup Subcutaneous Solution Auto-injector 12.5 MG/0.4ML 1 Syringe | 54436001202 | 2014 | 05/27/2031 | Single Source Drug | ||
| Rx0000495 | Otter Pharmaceuticals LLC | 07/24/2024 | Otrexup Subcutaneous Solution Auto-injector 12.5 MG/0.4ML 4 Syringe | 54436001204 | 2014 | 05/27/2031 | Single Source Drug | ||
| Rx0000495 | Otter Pharmaceuticals LLC | 07/24/2024 | Otrexup Subcutaneous Solution Auto-injector 15 MG/0.4ML 1 Syringe | 54436001502 | 2014 | 05/27/2031 | Single Source Drug | ||
| Rx0000495 | Otter Pharmaceuticals LLC | 07/24/2024 | Otrexup Subcutaneous Solution Auto-injector 15 MG/0.4ML 4 Syringe | 54436001504 | 2014 | 05/27/2031 | Single Source Drug | ||
| Rx0000495 | Otter Pharmaceuticals LLC | 07/24/2024 | Otrexup Subcutaneous Solution Auto-injector 17.5 MG/0.4ML 1 Syringe | 54436001702 | 2014 | 05/27/2031 | Single Source Drug | ||
| Rx0000495 | Otter Pharmaceuticals LLC | 07/24/2024 | Otrexup Subcutaneous Solution Auto-injector 17.5 MG/0.4ML 4 Syringe | 54436001704 | 2014 | 05/27/2031 | Single Source Drug | ||
| Rx0000495 | Otter Pharmaceuticals LLC | 07/24/2024 | Otrexup Subcutaneous Solution Auto-injector 20 MG/0.4ML 1 Syringe | 54436002002 | 2014 | 05/27/2031 | Single Source Drug | ||
| Rx0000495 | Otter Pharmaceuticals LLC | 07/24/2024 | Otrexup Subcutaneous Solution Auto-injector 20 MG/0.4ML 4 Syringe | 54436002004 | 2014 | 05/27/2031 | Single Source Drug | ||
| Rx0000495 | Otter Pharmaceuticals LLC | 07/24/2024 | Otrexup Subcutaneous Solution Auto-injector 22.5 MG/0.4ML 1 Syringe | 54436002202 | 2014 | 05/27/2031 | Single Source Drug | ||
| Rx0000495 | Otter Pharmaceuticals LLC | 07/24/2024 | Otrexup Subcutaneous Solution Auto-injector 22.5 MG/0.4ML 4 Syringe | 54436002204 | 2014 | 05/27/2031 | Single Source Drug | ||
| Rx0000495 | Otter Pharmaceuticals LLC | 07/24/2024 | Otrexup Subcutaneous Solution Auto-injector 25 MG/0.4ML 1 Syringe | 54436002502 | 2014 | 05/27/2031 | Single Source Drug | ||
| Rx0000495 | Otter Pharmaceuticals LLC | 07/24/2024 | Otrexup Subcutaneous Solution Auto-injector 25 MG/0.4ML 4 Syringe | 54436002504 | 2014 | 05/27/2031 | Single Source Drug | ||
| Rx0000484 | Pacira Pharmaceuticals, Inc. | 04/18/2024 | EXPAREL 13.3mg/mL Injection Suspension Liposomal 10 vials in 1 carton | 65250013309 | 02/02/2043 | Single Source Drug | |||
| Rx0000484 | Pacira Pharmaceuticals, Inc. | 04/18/2024 | EXPAREL 13.3mg/mL Injection Suspension Liposomal 4 vials in 1 carton | 65250013304 | 02/02/2043 | Single Source Drug | |||
| Rx0000053 | Paratek Pharmaceuticals, Inc. | 10/17/2024 | Nuzyra 100mg/5mL Intravenous Injection; Powder; Lyophilized 10 Carton | 71715000102 | 10/31/2037 | Single Source Drug | |||
| Rx0000006 | Pfizer | 04/29/2024 | Acetylcysteine Solution Rx, 100 mg/mL (10 %), VIAL (ML), 30 | 00409330703 | Non-innovator Multiple Source Drug | https://reports.siera.hcai.ca.gov/api/report/drug-pricing/attachment?id=769 | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | ||
| Rx0000006 | Pfizer | 04/29/2024 | Acetylcysteine Solution Rx, 200 mg/mL (20 %), VIAL (ML), 30 | 00409330803 | Non-innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | ADD-Vantage, ADDapter Connector, 1 | 00409005101 | Single Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | Aminophylline Injection Rx, 250 mg/10 mL, VIAL (ML), 10 | 00409592101 | Non-innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | Antivenin (micrurus fulvius equine origin), 10mL, VIAL (ML), 1 | 00008042303 | Single Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | ATGAM (lymphocyte immune globulin,antithymocyte (equine)), 50 mg/mL, Ampul(ML), 5 | 00009722402 | Single Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | ATROPINE SULFATE (atropine sulfate), 0.05 mg/mL, SYRINGE (ML), 1 | 00409963005 | Single Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | ATROPINE SULFATE (atropine sulfate), 0.1 mg/mL, SYRINGE (ML), 1 | 00409491134 | Innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | ATROPINE SULFATE (atropine sulfate), 0.1 mg/mL, SYRINGE (ML), 1 | 00409491034 | Innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | BeneFIX® (coagulation factor IX (recombinant)) Lyophilized Powder for Reconstitution Rx, 1000 unit, VIAL (EA), 1 | 58394063503 | Single Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | BeneFIX® (coagulation factor IX (recombinant)) Lyophilized Powder for Reconstitution Rx, 2000 unit, VIAL (EA), 1 | 58394063603 | Single Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | BeneFIX® (coagulation factor IX (recombinant)) Lyophilized Powder for Reconstitution Rx, 250 unit, VIAL (EA), 1 | 58394063303 | Single Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | BeneFIX® (coagulation factor IX (recombinant)) Lyophilized Powder for Reconstitution Rx, 3000 unit, VIAL (EA), 1 | 58394063703 | Single Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | BeneFIX® (coagulation factor IX (recombinant)) Lyophilized Powder for Reconstitution Rx, 500 unit, VIAL (EA), 1 | 58394063403 | Single Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | BICILLIN C-R (penicillin G benzathine/penicillin G procaine), 1,200,000 unit/2 mL (600,000/600,000), SYRINGE (ML), 1 | 60793060110 | Single Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | BICILLIN C-R (penicillin G benzathine/penicillin G procaine), 1,200,000 unit/2 mL (600,000/600,000), SYRINGE (ML), 1 | 60793060010 | Single Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | BICILLIN C-R (penicillin G benzathine/penicillin G procaine), 1,200,000 unit/2 mL (900,000/300,000), SYRINGE (ML), 1 | 60793060210 | Single Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | BICILLIN L-A (penicillin G benzathine), 1.2 million unit/2 mL, SYRINGE (ML), 1 | 60793070110 | Single Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | BICILLIN L-A (penicillin G benzathine), 2.4 million unit/4 mL, SYRINGE (ML), 1 | 60793070210 | Single Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | BICILLIN L-A (penicillin G benzathine), 600,000 unit/mL, SYRINGE (ML), 1 | 60793070010 | Single Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | BOSULIF (bosutinib), 100 mg, TABLET, 1 | 00069013501 | 06/11/2026 | Single Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | ||
| Rx0000006 | Pfizer | 04/29/2024 | BOSULIF (bosutinib), 400 mg, TABLET, 1 | 00069019301 | 06/11/2026 | Single Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | ||
| Rx0000006 | Pfizer | 04/29/2024 | BOSULIF (bosutinib), 500 mg, TABLET, 1 | 00069013601 | 06/11/2026 | Single Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | ||
| Rx0000006 | Pfizer | 04/29/2024 | BRAFTOVI (encorafenib), 75 mg, CAPSULE, 120 | 70255002503 | 2018 | 08/27/2030 | Single Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |
| Rx0000006 | Pfizer | 04/29/2024 | BRAFTOVI (encorafenib), 75 mg, CAPSULE, 180 | 70255002501 | 2018 | 08/27/2030 | Single Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |
| Rx0000006 | Pfizer | 04/29/2024 | Butorphanol Tartrate Injection - Controlled Substance - SCHEDULE IV Rx, 1 mg/mL (1 mg/mL) Single Dose Glass Fliptop Vial, 10 | 00409162301 | Non-innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | Butorphanol Tartrate Injection - Controlled Substance - SCHEDULE IV Rx, 2 mg/mL (2 mg/mL) Single Dose Glass Fliptop Vial, 10 | 00409162601 | Non-innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | Butorphanol Tartrate Injection - Controlled Substance - SCHEDULE IV Rx, 2 mg/mL (4 mg/2 mL) Single Dose Glass Fliptop Vial, 10 | 00409162602 | Non-innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | Cerebyx® (fosphenytoin sodium) Injection Rx, 100 mg PE/2 mL Vial, 25 | 00069600125 | Innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | Cerebyx® (fosphenytoin sodium) Injection Rx, 500 mg PE/10 mL Vial, 10 | 00069600121 | Innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | COPPER CHLORIDE (cupric chloride), 0.4 mg/mL, VIAL (ML), 25 | 00409409201 | Innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | Demerol (meperidine hydrochloride) Injection - Controlled Substance - SCHEDULE II Rx, 50 mg/mL (1,500 mg/30 mL) Multiple Dose Glass Fliptop Vial, 1 | 00409118130 | Innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | DEPO-ESTRADIOL (estradiol cypionate), 5 mg/mL, VIAL (ML), 1 | 00009027101 | Non-innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | Dextran (dextran) Injection Rx, 500 mL (10% LMD in 0.9% Sodium Chloride), Intravenous solution, 12 | 00409741903 | Non-innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | Dextran (dextran) Injection Rx, 500 mL (10% LMD in 5% Dextrose), Intravenous solution, 12 | 00409741803 | Non-innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | Diazepam Injection - Controlled Substance - SCHEDULE IV Rx, 5 mg/mL, VIAL (ML), 10 | 00409321312 | Non-innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | DOPAMINE HCL (dopamine HCl), 200 mg/5 mL (40 mg/mL), VIAL (ML), 25 | 00409582001 | Innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | DOPAMINE HCL (dopamine HCl), 400 mg/10 mL (40 mg/mL), VIAL (ML), 1 | 00409910420 | Innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | Epinephrine Injection Rx, 1mg/10mL (0.1 mg/mL) ABBOJECT Single-dose syringe, 10 | 00409493301 | Innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | Gemcitabine Injection (Lyophilized) Rx, 200 mg, VIAL (EA), 1 | 00409018501 | Non-innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | Gentamicin Sulfate Injection Rx, 40 mg/mL (80 mg/2 mL) Single Dose Glass Fliptop Vial, 25 | 00409120703 | Non-innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | Heparin Sodium (0.45% Sodium Chloride) Injection Rx, 100 Units/mL (25,000 Units/250 mL) Flexible Container, 24 | 00409765062 | Innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | Heparin Sodium (0.45% Sodium Chloride) Injection Rx, 12500 unit/250 mL, INTRAVENOUS SOLUTION, 250 | 00409001230 | Innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | Heparin Sodium (0.45% Sodium Chloride) Injection Rx, 25000 unit/250 mL (100 unit/mL), INTRAVENOUS SOLUTION, 250 | 00409765030 | Innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | Heparin Sodium (0.45% Sodium Chloride) Injection Rx, 25000 unit/500 mL (50 unit/mL), INTRAVENOUS SOLUTION, 500 | 00409315020 | Innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | HEXTEND LACTATED ELECTROLYTE (hetastarch/electrolyte solution,lactated), 500mL, Vial, 12 | 00409155554 | Single Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | IBRANCE (palbociclib), 100 mg, CAPSULE, 1 | 00069018821 | 03/05/2027 | Single Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | ||
| Rx0000006 | Pfizer | 04/29/2024 | IBRANCE (palbociclib), 100 mg, TABLET, 21 | 00069048603 | 03/05/2027 | Single Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | ||
| Rx0000006 | Pfizer | 04/29/2024 | IBRANCE (palbociclib), 125 mg, CAPSULE, 1 | 00069018921 | 03/05/2027 | Single Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | ||
| Rx0000006 | Pfizer | 04/29/2024 | IBRANCE (palbociclib), 125 mg, TABLET, 21 | 00069068803 | 03/05/2027 | Single Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | ||
| Rx0000006 | Pfizer | 04/29/2024 | IBRANCE (palbociclib), 75 mg, CAPSULE, 1 | 00069018721 | 03/05/2027 | Single Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | ||
| Rx0000006 | Pfizer | 04/29/2024 | IBRANCE (palbociclib), 75 mg, TABLET, 21 | 00069028403 | 03/05/2027 | Single Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | ||
| Rx0000006 | Pfizer | 04/29/2024 | INLYTA (axitinib), 1 mg, TABLET, 1 | 00069014501 | 04/29/2025 | Single Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | ||
| Rx0000006 | Pfizer | 04/29/2024 | INLYTA (axitinib), 5 mg, TABLET, 1 | 00069015111 | 04/29/2025 | Single Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | ||
| Rx0000006 | Pfizer | 04/29/2024 | LIDOCAINE HCL (lidocaine HCl/PF), 50 mg/5 mL (1 %), SYRINGE (ML), 1 | 00409913705 | Non-innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | LIDOCAINE HCL (lidocaine HCl/PF), 50 mg/5 mL (1 %), SYRINGE (ML), 1 | 00409490434 | Non-innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | LORBRENA (lorlatinib), 100 mg, TABLET, 1 | 00069023101 | 03/05/2033 | Single Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | ||
| Rx0000006 | Pfizer | 04/29/2024 | LORBRENA (lorlatinib), 25 mg, TABLET, 1 | 00069022701 | 03/05/2033 | Single Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | ||
| Rx0000006 | Pfizer | 04/29/2024 | MAGNESIUM SULFATE (magnesium sulfate), 4 mEq/mL (50 %), SYRINGE (ML), 1 | 00409175410 | Non-innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | MANGANESE CHLORIDE (manganese chloride), 0.1 mg/mL, VIAL (ML), 25 | 00409409101 | Innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | Mannitol Injection Rx, 25% (12.5 g/50 mL), Vial, 25 | 00409403101 | Innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | Marcaine with Epinephrine 1:200,000 as the bitartrate (bupivacaine hydrochloride & epinephrine) Injection Rx, 2.5 mg/mL (25 mg/10 mL), Vial, 10 | 00409174610 | Innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | Marcaine with Epinephrine 1:200,000 as the bitartrate (bupivacaine hydrochloride & epinephrine) Injection Rx, 2.5 mg/mL (75 mg/30 mL), Vial, 10 | 00409174630 | Innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | Marcaine with Epinephrine 1:200,000 as the bitartrate (bupivacaine hydrochloride & epinephrine) Injection Rx, 5 mg/mL (50 mg/10 mL), Vial, 10 | 00409174910 | Innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | Marcaine (bupivacaine hydrochloride and epinephrine) Injection for NovaPlus, 2.5 mg/mL (0.25 %)-1:200000, VIAL (ML), 10 | 00409573810 | Innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | Marcaine (bupivacaine hydrochloride and epinephrine) Injection for NovaPlus, 2.5 mg/mL (0.25 %)-1:200000, VIAL (ML), 30 | 00409154110 | Innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | Marcaine (bupivacaine hydrochloride) Injection Rx, 2.5 mg/mL, VIAL (ML), 10 | 00409155910 | Innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | MEKTOVI (binimetinib), 15 mg, TABLET, 180 | 70255001002 | 2018 | 07/04/2031 | Single Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |
| Rx0000006 | Pfizer | 04/29/2024 | Nalbuphine Hydrochloride Injection for NovaPlus® Rx, 10 mg/mL, AMPUL (ML), 1 | 00409146349 | Non-innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | Nalbuphine Hydrochloride Injection for NovaPlus® Rx, 10 mg/mL, AMPUL (ML), 1 | 00409146349 | Non-innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | Nalbuphine Hydrochloride Injection Rx, 10 mg/mL, AMPUL (ML), 1 | 00409146301 | Non-innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | Nalbuphine Hydrochloride Injection Rx, 10 mg/mL, AMPUL (ML), 1 | 00409146301 | Non-innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | Nalbuphine Hydrochloride Injection Rx, 20 mg/mL, AMPUL (ML), 1 | 00409146501 | Non-innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | Nipent (pentostatin) Injection Rx, 10 mg, VIAL (EA), 1 | 00409080101 | Innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | Oxbryta® (voxelotor) Tablets Rx, 300 mg, TABLET FOR SUSPENSION, 60 | 72786011102 | 11/25/2033 | Single Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | ||
| Rx0000006 | Pfizer | 04/29/2024 | Oxbryta® (voxelotor) Tablets Rx, 300 mg, TABLET FOR SUSPENSION, 90 | 72786011103 | 11/25/2033 | Single Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | ||
| Rx0000006 | Pfizer | 04/29/2024 | Oxbryta® (voxelotor) Tablets Rx, 500 mg, TABLET, 90 | 72786010101 | 11/25/2033 | Single Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | ||
| Rx0000006 | Pfizer | 04/29/2024 | Panzyga® (immune globulin intravenous, human - ifas) Solution Rx, 10 g/100 mL Vial, 1 | 00069131202 | Single Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | Panzyga® (immune globulin intravenous, human - ifas) Solution Rx, 2.5 g/25 mL Vial, 1 | 00069110902 | Single Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | Panzyga® (immune globulin intravenous, human - ifas) Solution Rx, 20 g/200 mL Vial, 1 | 00069141502 | Single Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | Panzyga® (immune globulin intravenous, human - ifas) Solution Rx, 30 g/300 mL Vial, 1 | 00069155802 | Single Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | Panzyga® (immune globulin intravenous, human - ifas) Solution Rx, 5 g/50 mL Vial, 1 | 00069122402 | Single Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | PIPERACILLIN-TAZOBACTAM (piperacillin sodium/tazobactam sodium), 13.5 gram, VIAL (EA), 1 | 00409299914 | Non-innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | PLEGISOL (cardioplegic solution), 1000mL, PLASTIC BAG, PERFUSION (ML), 12 | 00409796905 | Innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | Potassium Chloride Concentrate Injection Rx, 2 mEq/mL, VIAL (ML), 10 | 00409665106 | Non-innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | Potassium Chloride Concentrate Injection Rx, 2 mEq/mL, VIAL (ML), 5 | 00409663501 | Non-innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | Prempro® (conjugated estrogens/medroxy progesterone acetate) Tablets Rx, 0.3 mg-1.5 mg, TABLET, 28 | 00046110511 | Single Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | PREPIDIL (dinoprostone), 0.5 mg/3 gram, GEL WITH PREFILLED APPLICATOR (GRAM), 1 | 00009335901 | Innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | Sodium Bicarbonate Injection Rx, 4.2% (5mEq/10mL) per glass Abboject® syringe, 10 | 00409553414 | Non-innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | Sodium Bicarbonate Injection Rx, 7.5% (44/6 mEq/50mL) per glass Abboject® syringe, 10 | 00409491614 | Non-innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | Sodium Bicarbonate Injection Rx, 8.4% (10mEq/10mL) per glass vial Abboject® syringe, 10 | 00409490014 | Non-innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | Sodium Bicarbonate Injection Rx, 8.4% (50mEq/50mL) per glass Abbotject® syringe, 10 | 00409663714 | Non-innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | SOLU-CORTEF (hydrocortisone sodium succinate) 500 mg/4 mL, VIAL (EA), 1 | 00009001612 | Innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | SOLU-CORTEF (hydrocortisone sodium succinate), 100 mg, VIAL (EA), 1 | 00009082501 | Innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | SOLU-CORTEF (hydrocortisone sodium succinate), 100 mg/2 mL, VIAL (EA), 1 | 00009001104 | Innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | SOLU-CORTEF (hydrocortisone sodium succinate), 100 mg/2 mL, VIAL EA, 1 | 00009001103 | Innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | SOLU-CORTEF (hydrocortisone sodium succinate), 250 mg/2 mL VIAL (EA), 1 | 00009001305 | Innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | SOLU-CORTEF (hydrocortisone sodium succinate), 250 mg/2 mL, VIAL EA 1 | 00009001306 | Innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | SOLU-CORTEF(hydrocortisone sodium succinate), 1000 mg/8 mL, VIAL EA 1 | 00009000501 | Innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | Solu-Medrol® (methylprednisolone sodium succinate) Sterile Powder for Injection Rx, 2 gram, VIAL (EA), 1 | 00009085001 | Innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | Somavert® (pegvisomant) Injection with Prefilled Diluent Syringe Rx, 10 mg, VIAL (EA), 1 | 00009716601 | Single Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | Somavert® (pegvisomant) Injection with Prefilled Diluent Syringe Rx, 15 mg, VIAL (EA), 1 | 00009716801 | Single Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | Somavert® (pegvisomant) Injection with Prefilled Diluent Syringe Rx, 20 mg, VIAL (EA), 1 | 00009718801 | Single Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | Somavert® (pegvisomant) Injection with Prefilled Diluent Syringe Rx, 25 mg, VIAL (EA), 1 | 00009719901 | Single Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | Somavert® (pegvisomant) Injection with Prefilled Diluent Syringe Rx, 30 mg, VIAL (EA), 1 | 00009720001 | Single Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | Talzenna® (talazoparib) Rx, 0.25 mg, CAPSULE, 30 | 00069029630 | 10/19/2029 | Single Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | ||
| Rx0000006 | Pfizer | 04/29/2024 | Talzenna® (talazoparib) Rx, 1 mg, CAPSULE, 30 | 00069119530 | 10/19/2029 | Single Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | ||
| Rx0000006 | Pfizer | 04/29/2024 | THAM (tromethamine), 36 mg/mL (0.3 M), INTRAVENOUS SOLUTION, 6 | 00409159304 | Innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | TPN ELECTROLYTES (multiple electrolyte additive) Solution Rx, 20 mL, VIAL (ML), 25 | 00409577901 | Innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | TRUMENBA (Neisseria meningitidis group B, lipidated fHBP recombinant), 120 mcg / 0.5 mL, SYRINGE (ML), 1 | 00005010010 | 10/29/2026 | Single Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | ||
| Rx0000006 | Pfizer | 04/29/2024 | TRUMENBA (Neisseria meningitidis group B, lipidated fHBP recombinant), 120 mcg/0.5 mL, SYRINGE (ML), 1 | 00005010005 | 10/29/2026 | Single Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | ||
| Rx0000006 | Pfizer | 04/29/2024 | Verapamil Hydrochloride Injection Rx, 2.5 mg/mL (10 mg/4 mL) Ansyr Plastic Syringe, 10 | 00409963305 | Non-innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | VINCRISTINE SULFATE (vincristine sulfate), 1 mg/mL, VIAL (ML) 1 | 61703030926 | Non-innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | VINCRISTINE SULFATE (vincristine sulfate), 1 mg/mL, VIAL (ML) 1 | 61703030926 | Non-innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | VINCRISTINE SULFATE (vincristine sulfate), 1 mg/mL, VIAL ML, 1 | 61703030906 | Non-innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | VINCRISTINE SULFATE (vincristine sulfate), 1 mg/mL, VIAL ML, 1 | 61703030906 | Non-innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | VINCRISTINE SULFATE (vincristine sulfate), 2 mg/2 mL VIAL (ML), 1 | 61703030916 | Non-innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | VINCRISTINE SULFATE (vincristine sulfate), 2 mg/2 mL VIAL (ML), 1 | 61703030916 | Non-innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | VINCRISTINE SULFATE (vincristine sulfate), 2 mg/2 mL, VIAL (ML), 1 | 61703030925 | Non-innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | VINCRISTINE SULFATE (vincristine sulfate), 2 mg/2 mL, VIAL (ML), 1 | 61703030925 | Non-innovator Multiple Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | |||
| Rx0000006 | Pfizer | 04/29/2024 | VIZIMPRO (dacomitinib), 15 mg, TABLET, 1 | 00069019730 | 08/26/2028 | Single Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | ||
| Rx0000006 | Pfizer | 04/29/2024 | VIZIMPRO (dacomitinib), 30 mg, TABLET, 1 | 00069119830 | 08/26/2028 | Single Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | ||
| Rx0000006 | Pfizer | 04/29/2024 | VIZIMPRO (dacomitinib), 45 mg, TABLET, 1 | 00069229930 | 08/26/2028 | Single Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | ||
| Rx0000006 | Pfizer | 04/29/2024 | Vyndamax (tafamidis) Capsule Rx, 61 mg, CAPSULE, 30 | 00069873030 | 12/19/2024 | Single Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | ||
| Rx0000006 | Pfizer | 04/29/2024 | Vyndaqel® (tafamidis meglumine) Capsules Rx, 20 mg, CAPSULE, 120 | 00069197540 | 12/19/2024 | Single Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | ||
| Rx0000006 | Pfizer | 04/29/2024 | XALKORI (crizotinib), 200 mg, CAPSULE, 1 | 00069814120 | 10/08/2029 | Single Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | ||
| Rx0000006 | Pfizer | 04/29/2024 | XALKORI (crizotinib), 250 mg, CAPSULE, 1 | 00069814020 | 10/08/2029 | Single Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | ||
| Rx0000006 | Pfizer | 04/29/2024 | XELJANZ (tofacitinib citrate), 10 mg, TABLET, 1 | 00069100201 | 12/08/2025 | Single Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | ||
| Rx0000006 | Pfizer | 04/29/2024 | XELJANZ (tofacitinib citrate), 5 mg, TABLET, 1 | 00069100101 | 12/08/2025 | Single Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | ||
| Rx0000006 | Pfizer | 04/29/2024 | XELJANZ XR (tofacitinib citrate), 11 mg, TABLET, EXTENDED RELEASE 24 HR, 1 | 00069050130 | 12/08/2025 | Single Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | ||
| Rx0000006 | Pfizer | 04/29/2024 | XELJANZ XR (tofacitinib citrate), 22 mg, TABLET, EXTENDED RELEASE 24 HR, 30 | 00069050230 | 12/08/2025 | Single Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | ||
| Rx0000006 | Pfizer | 04/29/2024 | Xeljanz® (tofacitinib ) Oral Solution Rx, 1 mg/mL, SOLUTION ORAL, 240 | 00069102902 | 12/08/2025 | Single Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website. | ||
| Rx0000135 | Pharmaceutical Associates, Inc | 10/17/2024 | (DIPHENHYDRAMINE HYDROCHLORIDE) DIPHENHYDRAMINE HYDROCHLORIDE 12.5mg/5mL Oral Elixir, 5mL Cup [Qty: 1] | 00121048905 | Non-innovator Multiple Source Drug | ||||
| Rx0000135 | Pharmaceutical Associates, Inc | 10/17/2024 | DIPHENHYDRAMINE HYDROCHLORIDE (DIPHENHYDRAMINE HYDROCHLORIDE) 12.5mg/5mL Oral Elixir, 10mL Cup [Qty: 1] | 00121097810 | Non-innovator Multiple Source Drug | ||||
| Rx0000135 | Pharmaceutical Associates, Inc | 10/17/2024 | DIPHENHYDRAMINE HYDROCHLORIDE (DIPHENHYDRAMINE HYDROCHLORIDE) 12.5mg/5mL Oral Elixir, 10mL Cup [Qty: 100] | 00121097800 | Non-innovator Multiple Source Drug | ||||
| Rx0000135 | Pharmaceutical Associates, Inc | 10/17/2024 | DIPHENHYDRAMINE HYDROCHLORIDE (DIPHENHYDRAMINE HYDROCHLORIDE) 12.5mg/5mL Oral Elixir, 5mL Cup [Qty: 100] | 00121048900 | Non-innovator Multiple Source Drug | ||||
| Rx0000135 | Pharmaceutical Associates, Inc | 10/17/2024 | HYDROCODONE BITARTRATE AND ACETAMINOPHEN (ACETAMINOPHEN; HYDROCODONE BITARTRATE) 325mg/15mL;7.5mg/15mL Oral Solution, 5mL Cup [Qty: 1] | 00121477205 | Non-innovator Multiple Source Drug | ||||
| Rx0000135 | Pharmaceutical Associates, Inc | 10/17/2024 | HYDROCODONE BITARTRATE AND ACETAMINOPHEN (ACETAMINOPHEN; HYDROCODONE BITARTRATE) 325mg/15mL;7.5mg/15mL Oral Solution, 5mL Cup [Qty: 40] | 00121477240 | Non-innovator Multiple Source Drug | ||||
| Rx0000135 | Pharmaceutical Associates, Inc | 04/02/2024 | Lactulose Oral Solution 10 GM/15ML - 473mL Bottle [Qty: 1] | 00121087316 | Non-innovator Multiple Source Drug | ||||
| Rx0000135 | Pharmaceutical Associates, Inc | 04/02/2024 | Lactulose Oral Solution 10 GM/15ML. - 946mL Bottle [Qty: 1] | 00121087332 | Non-innovator Multiple Source Drug | ||||
| Rx0000135 | Pharmaceutical Associates, Inc | 10/17/2024 | SODIUM CITRATE AND CITRIC ACID (SODIUM CITRATE; CITRIC ACID) 500-334mg/5mL Oral Solution, 15mL Cup [Qty: 1] | 00121059515 | Non-innovator Multiple Source Drug | ||||
| Rx0000135 | Pharmaceutical Associates, Inc | 10/17/2024 | SODIUM CITRATE AND CITRIC ACID (SODIUM CITRATE; CITRIC ACID) 500-334mg/5mL Oral Solution, 15mL Cup [Qty: 100] | 00121059500 | Non-innovator Multiple Source Drug | ||||
| Rx0000135 | Pharmaceutical Associates, Inc | 10/17/2024 | SODIUM CITRATE AND CITRIC ACID (SODIUM CITRATE; CITRIC ACID) 500-334mg/5mL Oral Solution, 30mL Cup [Qty: 1] | 00121119030 | Non-innovator Multiple Source Drug | ||||
| Rx0000135 | Pharmaceutical Associates, Inc | 10/17/2024 | SODIUM CITRATE AND CITRIC ACID (SODIUM CITRATE; CITRIC ACID) 500-334mg/5mL Oral Solution, 30mL Cup [Qty: 100] | 00121119000 | Non-innovator Multiple Source Drug | ||||
| Rx0000135 | Pharmaceutical Associates, Inc | 10/17/2024 | SULFAMETHOXAZOLE-TRIMETHOPRIM (SULFAMETHOXAZOLE; TRIMETHOPRIM) | 00121085320 | Non-innovator Multiple Source Drug | ||||
| Rx0000135 | Pharmaceutical Associates, Inc | 10/17/2024 | SULFAMETHOXAZOLE-TRIMETHOPRIM (SULFAMETHOXAZOLE; TRIMETHOPRIM) 200-40mg/5mL Oral Suspension, 20mL Cup [Qty: 40] | 00121085340 | Non-innovator Multiple Source Drug | ||||
| Rx0000319 | Pharmacosmos Therapeutics | 03/31/2024 | Monoferric (ferric derisomaltose) Injection 1000mg/10mL 1 unit vial | 73594931001 | 06/22/2036 | Single Source Drug | |||
| Rx0000410 | PharmaEssentia USA Corporation | 05/13/2024 | Besremi Subcutaneous Solution Prefilled Syringe 500 MCG/ML | 73536050001 | 02/26/2034 | Single Source Drug | |||
| Rx0000410 | PharmaEssentia USA Corporation | 03/31/2024 | Besremi Subcutaneous Solution Prefilled Syringe 500 MCG/ML, 1 1ML syringe per package | 73536050001 | 02/26/2034 | Single Source Drug | |||
| Rx0000469 | Pharming Healthcare Inc | 04/12/2024 | Ruconest 2100 U; Injection; Powder for Solution; 1 Carton | 71274035002 | 10/07/2026 | Single Source Drug | |||
| Rx0000469 | Pharming Healthcare Inc | 04/12/2024 | Ruconest C1 Esterase Inhibitor (Recombinant) 2100 UNIT Solution Reconstituted 1 EA UD | 71274035001 | 10/07/2026 | Single Source Drug | |||
| Rx0000589 | Prasco, LLC d/b/a Prasco Laboratories | 07/30/2024 | Spritam (levetiracetam) tablet, 1000mg, 6 x 10 | 43485010460 | Single Source Drug | ||||
| Rx0000589 | Prasco, LLC d/b/a Prasco Laboratories | 07/30/2024 | Spritam (levetiracetam) tablet, 250mg, 6 x 10 | 43485010160 | Single Source Drug | ||||
| Rx0000589 | Prasco, LLC d/b/a Prasco Laboratories | 07/30/2024 | Spritam (levetiracetam) tablet, 500mg, 6 x 10 | 43485010260 | Single Source Drug | ||||
| Rx0000589 | Prasco, LLC d/b/a Prasco Laboratories | 07/30/2024 | Spritam (levetiracetam) tablet, 750mg, 6 x 10 | 43485010360 | Single Source Drug | ||||
| Rx0000536 | Protega Pharmaceuticals, Inc. | 03/31/2024 | RoxyBond 15mg is formulated with inactive ingredients that make the tablet more difficult to manipulate for misuse and abuse even if the tablet is subjected to physical manipulation and/or chemical extraction. | 81140010210 | 08/12/2028 | Single Source Drug | |||
| Rx0000536 | Protega Pharmaceuticals, Inc. | 03/31/2024 | RoxyBond 30mg is formulated with inactive ingredients that make the tablet more difficult to manipulate for misuse and abuse even if the tablet is subjected to physical manipulation and/or chemical extraction. | 81140010310 | 08/12/2028 | Single Source Drug | |||
| Rx0000536 | Protega Pharmaceuticals, Inc. | 03/31/2024 | RoxyBond 5mg is formulated with inactive ingredients that make the tablet more difficult to manipulate for misuse and abuse even if the tablet is subjected to physical manipulation and/or chemical extraction. | 81140010110 | 08/12/2028 | Single Source Drug | |||
| Rx0000220 | Puma Biotechnology, Inc. | 03/31/2024 | Nerlynx Oral Tablet 40 mg, 133 tablet package | 70437024033 | 07/18/2031 | Single Source Drug | |||
| Rx0000220 | Puma Biotechnology, Inc. | 03/31/2024 | Nerlynx Oral Tablet 40 mg, 180 tablet package | 70437024018 | 07/18/2031 | Single Source Drug | |||
| Rx0000056 | Purdue Pharma LP | 04/23/2024 | OXYCONTIN 10MG TABLETS 100S | 59011041010 | 03/29/2030 | Innovator Multiple Source Drug | As all companies do, from time to time we review and update our pricing based on various business and marketplace factors. We remain committed to serving patients who rely on our FDA-approved medicines. | ||
| Rx0000056 | Purdue Pharma LP | 04/23/2024 | OXYCONTIN 10MG TABLETS HUD 20S | 59011041020 | 03/29/2030 | Innovator Multiple Source Drug | As all companies do, from time to time we review and update our pricing based on various business and marketplace factors. We remain committed to serving patients who rely on our FDA-approved medicines. | ||
| Rx0000056 | Purdue Pharma LP | 04/23/2024 | OXYCONTIN 15MG TABLETS 100S | 59011041510 | 03/29/2030 | Innovator Multiple Source Drug | As all companies do, from time to time we review and update our pricing based on various business and marketplace factors. We remain committed to serving patients who rely on our FDA-approved medicines. | ||
| Rx0000056 | Purdue Pharma LP | 04/23/2024 | OXYCONTIN 15MG TABLETS HUD 20S | 59011041520 | 03/29/2030 | Innovator Multiple Source Drug | As all companies do, from time to time we review and update our pricing based on various business and marketplace factors. We remain committed to serving patients who rely on our FDA-approved medicines. | ||
| Rx0000056 | Purdue Pharma LP | 04/23/2024 | OXYCONTIN 20MG TABLETS 100S | 59011042010 | 03/29/2030 | Innovator Multiple Source Drug | As all companies do, from time to time we review and update our pricing based on various business and marketplace factors. We remain committed to serving patients who rely on our FDA-approved medicines. | ||
| Rx0000056 | Purdue Pharma LP | 04/23/2024 | OXYCONTIN 20MG TABLETS HUD 20S | 59011042020 | 03/29/2030 | Innovator Multiple Source Drug | As all companies do, from time to time we review and update our pricing based on various business and marketplace factors. We remain committed to serving patients who rely on our FDA-approved medicines. | ||
| Rx0000056 | Purdue Pharma LP | 04/23/2024 | OXYCONTIN 30MG TABLETS 100S | 59011043010 | 03/29/2030 | Innovator Multiple Source Drug | As all companies do, from time to time we review and update our pricing based on various business and marketplace factors. We remain committed to serving patients who rely on our FDA-approved medicines. | ||
| Rx0000056 | Purdue Pharma LP | 04/23/2024 | OXYCONTIN 30MG TABLETS HUD 20S | 59011043020 | 03/29/2030 | Innovator Multiple Source Drug | As all companies do, from time to time we review and update our pricing based on various business and marketplace factors. We remain committed to serving patients who rely on our FDA-approved medicines. | ||
| Rx0000056 | Purdue Pharma LP | 04/23/2024 | OXYCONTIN 40MG TABLETS 100S | 59011044010 | 08/24/2027 | Innovator Multiple Source Drug | As all companies do, from time to time we review and update our pricing based on various business and marketplace factors. We remain committed to serving patients who rely on our FDA-approved medicines. | ||
| Rx0000056 | Purdue Pharma LP | 04/23/2024 | OXYCONTIN 40MG TABLETS HUD 20S | 59011044020 | 08/24/2027 | Innovator Multiple Source Drug | As all companies do, from time to time we review and update our pricing based on various business and marketplace factors. We remain committed to serving patients who rely on our FDA-approved medicines. | ||
| Rx0000056 | Purdue Pharma LP | 04/23/2024 | OXYCONTIN 60MG TABLETS 100S | 59011046010 | 08/24/2027 | Innovator Multiple Source Drug | As all companies do, from time to time we review and update our pricing based on various business and marketplace factors. We remain committed to serving patients who rely on our FDA-approved medicines. | ||
| Rx0000056 | Purdue Pharma LP | 04/23/2024 | OXYCONTIN 60MG TABLETS HUD 20S | 59011046020 | 08/24/2027 | Innovator Multiple Source Drug | As all companies do, from time to time we review and update our pricing based on various business and marketplace factors. We remain committed to serving patients who rely on our FDA-approved medicines. | ||
| Rx0000056 | Purdue Pharma LP | 04/23/2024 | OXYCONTIN 80MG TABLETS 100S | 59011048010 | 08/24/2027 | Innovator Multiple Source Drug | As all companies do, from time to time we review and update our pricing based on various business and marketplace factors. We remain committed to serving patients who rely on our FDA-approved medicines. | ||
| Rx0000056 | Purdue Pharma LP | 04/23/2024 | OXYCONTIN 80MG TABLETS HUD 20S | 59011048020 | 08/24/2027 | Innovator Multiple Source Drug | As all companies do, from time to time we review and update our pricing based on various business and marketplace factors. We remain committed to serving patients who rely on our FDA-approved medicines. | ||
| Rx0000342 | PureTek Corporation | 07/16/2024 | Davimet with Fluoride 0.75mg, chewable multivitamin, Grape flavor, 30 tablets, Vit A, Vit C, Vit D3, Vit. E, Thiamin, Riboflavin, Niacin, Vit. B6, Folate, Vit. B12, Fluoride | 59088017054 | Non-innovator Multiple Source Drug | ||||
| Rx0000342 | PureTek Corporation | 07/16/2024 | Hydroxate Gel, gel, hydrocortisone 2%, 1oz | 59088032803 | Non-innovator Multiple Source Drug | ||||
| Rx0000342 | PureTek Corporation | 07/16/2024 | Hydroxym Cream, Anti-itch cream, hydrocortisone 2%, 1oz | 59088020803 | Non-innovator Multiple Source Drug | ||||
| Rx0000356 | Radius Health, Inc. | 03/31/2024 | TYMLOS 80 MCG Pen | 70539000101 | 01/10/2040 | Single Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Radius believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administrations Orange Book, as of 10/26/2023. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Radius Health, Inc. did not acquire this product from another manufacturer within the previous five years. As a result, Radius Health has left columns N-U blank because they are not applicable to this product. | ||
| Rx0000356 | Radius Health, Inc. | 03/31/2024 | TYMLOS 80 MCG Pen / Carton | 70539000102 | 01/10/2040 | Single Source Drug | The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Radius believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administrations Orange Book, as of 10/26/2023. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Radius Health, Inc. did not acquire this product from another manufacturer within the previous five years. As a result, Radius Health has left columns N-U blank because they are not applicable to this product. | ||
| Rx0000363 | Recordati Rare Diseases, inc. | 12/13/2024 | Sylvant Intravenous Solution Reconstituted 100 MG 1 Vial | 73090042001 | 02/08/2033 | Single Source Drug | |||
| Rx0000363 | Recordati Rare Diseases, inc. | 12/13/2024 | Sylvant Intravenous Solution Reconstituted 400 MG 1 Vial | 73090042101 | 02/08/2033 | Single Source Drug | |||
| Rx0000166 | Redhill Biopharma, Inc. | 04/22/2024 | Talicia, Amoxicillin-Rifabutin-Omeprazole Cap DR 250-12.5-10 MG, 84 Each, Unit-of-Use, Bottle | 57841115001 | 05/27/2042 | Single Source Drug | |||
| Rx0000166 | Redhill Biopharma, Inc. | 04/22/2024 | Talicia, Amoxicillin-Rifabutin-Omeprazole Cap DR 250-12.5-10 MG, 84 Each, Unit-of-Use, Bottle Qty 2 | 57841115002 | 05/27/2042 | Single Source Drug | |||
| Rx0000563 | Rhodes Pharmaceuticals LP | 07/16/2024 | Dronabinol Capsules 2.5mg 60s | 42858086706 | Non-innovator Multiple Source Drug | As all companies do, from time to time we review and update our pricing based on various business and marketplace factors. We remain committed to serving patients who rely on our FDA-approved medicines. | |||
| Rx0000563 | Rhodes Pharmaceuticals LP | 07/16/2024 | Hydromorphone HCL 4mg Tablets 100s | 42858030201 | Innovator Multiple Source Drug | As all companies do, from time to time we review and update our pricing based on various business and marketplace factors. We remain committed to serving patients who rely on our FDA-approved medicines. | |||
| Rx0000563 | Rhodes Pharmaceuticals LP | 07/16/2024 | Hydromorphone HCL 8mg Tablets 100s | 42858030301 | Innovator Multiple Source Drug | As all companies do, from time to time we review and update our pricing based on various business and marketplace factors. We remain committed to serving patients who rely on our FDA-approved medicines. | |||
| Rx0000563 | Rhodes Pharmaceuticals LP | 04/23/2024 | Morphine Sulfate ER 15mg Tablets 100s | 42858080101 | Non-innovator Multiple Source Drug | As all companies do, from time to time we review and update our pricing based on various business and marketplace factors. We remain committed to serving patients who rely on our FDA-approved medicines. | |||
| Rx0000563 | Rhodes Pharmaceuticals LP | 07/16/2024 | Oxycodone Hydrochloride 20mg Tablets 100s | 42858000401 | Non-innovator Multiple Source Drug | As all companies do, from time to time we review and update our pricing based on various business and marketplace factors. We remain committed to serving patients who rely on our FDA-approved medicines. | |||
| Rx0000563 | Rhodes Pharmaceuticals LP | 07/16/2024 | Oxycodone Hydrochloride 30mg Tablets 100s | 42858000501 | Non-innovator Multiple Source Drug | As all companies do, from time to time we review and update our pricing based on various business and marketplace factors. We remain committed to serving patients who rely on our FDA-approved medicines. | |||
| Rx0000239 | Rigel Pharmaceuticals, Inc. | 04/04/2024 | TAVALISSE TAB 100MG 60 TABS | 71332000101 | 07/27/2032 | Single Source Drug | |||
| Rx0000239 | Rigel Pharmaceuticals, Inc. | 04/04/2024 | TAVALISSE Tab 150MG 60 TABS | 71332000201 | 07/27/2032 | Single Source Drug | |||
| Rx0000158 | RISING PHARMA HOLDINGS, INC. | 04/05/2024 | METHIMAZOLE TAB 10 MG 100CT | 64980026501 | Non-innovator Multiple Source Drug | ||||
| Rx0000158 | RISING PHARMA HOLDINGS, INC. | 04/05/2024 | METHIMAZOLE TAB 5 MG 100CT | 64980026401 | Non-innovator Multiple Source Drug | ||||
| Rx0000095 | Salix Pharmaceuticals, Inc. | 04/28/2024 | COLAZAL® (balsalazide disodium) 750mg Capsules, 280ct BTL | 65649010102 | 02/24/2027 | Single Source Drug | The product was not acquired within the last 5 years. | ||
| Rx0000095 | Salix Pharmaceuticals, Inc. | 04/28/2024 | RELISTOR® (methylnaltrexone bromide) 12mg/0.6mL, vial | 65649055102 | 12/31/2030 | Single Source Drug | The product was not acquired within the last 5 years. | ||
| Rx0000095 | Salix Pharmaceuticals, Inc. | 04/28/2024 | RELISTOR® (methylnaltrexone bromide) PFS 12 mg/0.6mL, 7ct | 65649055103 | 12/31/2030 | Single Source Drug | The product was not acquired within the last 5 years. | ||
| Rx0000095 | Salix Pharmaceuticals, Inc. | 04/28/2024 | RELISTOR® (methylnaltrexone bromide) PFS 12 mg/0.6mL, vial | 65649055107 | 12/31/2030 | Single Source Drug | The product was not acquired within the last 5 years. | ||
| Rx0000095 | Salix Pharmaceuticals, Inc. | 04/28/2024 | RELISTOR® (methylnaltrexone bromide) PFS 8 mg/0.4mL, 7ct | 65649055204 | 12/31/2030 | Single Source Drug | The product was not acquired within the last 5 years. | ||
| Rx0000095 | Salix Pharmaceuticals, Inc. | 04/28/2024 | RELISTOR® (methylnaltrexone bromide) Tablets 150mg, 90ct | 65649015090 | 03/10/2031 | Single Source Drug | The product was not acquired within the last 5 years. | ||
| Rx0000095 | Salix Pharmaceuticals, Inc. | 04/28/2024 | Trulance® (plecanatide) 3mg Tablets, 30 | 65649000330 | 2017 | 06/05/2034 | Single Source Drug | ||
| Rx0000095 | Salix Pharmaceuticals, Inc. | 04/28/2024 | XIFAXAN® (rifaximin) 550mg Tablets HUD 6 cards of 10, 60ct Card | 65649030303 | 10/02/2029 | Single Source Drug | The product was not acquired within the last 5 years. | ||
| Rx0000095 | Salix Pharmaceuticals, Inc. | 04/28/2024 | XIFAXAN® (rifaximin) 550mg Tablets, 60ct | 65649030302 | 10/02/2029 | Single Source Drug | The product was not acquired within the last 5 years. | ||
| Rx0000027 | Sandoz Inc. | 04/02/2024 | CILOXAN OINTMENT 0.3% 3.5G 1EOIN US | 00078084101 | Single Source Drug | Sandoz Inc. provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127679 and its provisions. In providing this report, Sandoz Inc. does not waive any rights that may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127679 as it may relate to Sandoz Inc. or any of its affiliates now or in the future. Sandoz Inc., on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Sandoz Inc.s related information herein is confidential and proprietary commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that your company or organization maintain the confidentiality of this submission and of all Sandoz Inc.s related information herein to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that your company or organization notify us of the request and afford us the opportunity to submit objections to disclosure. | |||
| Rx0000027 | Sandoz Inc. | 04/02/2024 | HYCAMTIN 0.25MG 10HGC US | 00078067201 | Single Source Drug | Sandoz Inc. provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127679 and its provisions. In providing this report, Sandoz Inc. does not waive any rights that may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127679 as it may relate to Sandoz Inc. or any of its affiliates now or in the future. Sandoz Inc., on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Sandoz Inc.s related information herein is confidential and proprietary commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that your company or organization maintain the confidentiality of this submission and of all Sandoz Inc.s related information herein to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that your company or organization notify us of the request and afford us the opportunity to submit objections to disclosure. | |||
| Rx0000027 | Sandoz Inc. | 04/02/2024 | HYCAMTIN 1MG 10HGC US | 00078067301 | Single Source Drug | Sandoz Inc. provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127679 and its provisions. In providing this report, Sandoz Inc. does not waive any rights that may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127679 as it may relate to Sandoz Inc. or any of its affiliates now or in the future. Sandoz Inc., on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Sandoz Inc.s related information herein is confidential and proprietary commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that your company or organization maintain the confidentiality of this submission and of all Sandoz Inc.s related information herein to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that your company or organization notify us of the request and afford us the opportunity to submit objections to disclosure. | |||
| Rx0000027 | Sandoz Inc. | 04/02/2024 | HYCAMTIN 4MG 1LYVI US | 00078067461 | Innovator Multiple Source Drug | Sandoz Inc. provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127679 and its provisions. In providing this report, Sandoz Inc. does not waive any rights that may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127679 as it may relate to Sandoz Inc. or any of its affiliates now or in the future. Sandoz Inc., on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Sandoz Inc.s related information herein is confidential and proprietary commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that your company or organization maintain the confidentiality of this submission and of all Sandoz Inc.s related information herein to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that your company or organization notify us of the request and afford us the opportunity to submit objections to disclosure. | |||
| Rx0000027 | Sandoz Inc. | 04/02/2024 | LESCOL XL 80MG 30TAB US | 00078035415 | Innovator Multiple Source Drug | Sandoz Inc. provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127679 and its provisions. In providing this report, Sandoz Inc. does not waive any rights that may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127679 as it may relate to Sandoz Inc. or any of its affiliates now or in the future. Sandoz Inc., on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Sandoz Inc.s related information herein is confidential and proprietary commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that your company or organization maintain the confidentiality of this submission and of all Sandoz Inc.s related information herein to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that your company or organization notify us of the request and afford us the opportunity to submit objections to disclosure. | |||
| Rx0000027 | Sandoz Inc. | 04/02/2024 | LOTREL 10+20MG 100HGC BO US | 00078036405 | Innovator Multiple Source Drug | Sandoz Inc. provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127679 and its provisions. In providing this report, Sandoz Inc. does not waive any rights that may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127679 as it may relate to Sandoz Inc. or any of its affiliates now or in the future. Sandoz Inc., on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Sandoz Inc.s related information herein is confidential and proprietary commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that your company or organization maintain the confidentiality of this submission and of all Sandoz Inc.s related information herein to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that your company or organization notify us of the request and afford us the opportunity to submit objections to disclosure. | |||
| Rx0000027 | Sandoz Inc. | 04/02/2024 | LOTREL 10+40MG 100HGC BO US | 00078037905 | Innovator Multiple Source Drug | Sandoz Inc. provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127679 and its provisions. In providing this report, Sandoz Inc. does not waive any rights that may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127679 as it may relate to Sandoz Inc. or any of its affiliates now or in the future. Sandoz Inc., on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Sandoz Inc.s related information herein is confidential and proprietary commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that your company or organization maintain the confidentiality of this submission and of all Sandoz Inc.s related information herein to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that your company or organization notify us of the request and afford us the opportunity to submit objections to disclosure. | |||
| Rx0000027 | Sandoz Inc. | 04/02/2024 | LOTREL 5+10MG 100HGC BO US | 00078040505 | Innovator Multiple Source Drug | Sandoz Inc. provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127679 and its provisions. In providing this report, Sandoz Inc. does not waive any rights that may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127679 as it may relate to Sandoz Inc. or any of its affiliates now or in the future. Sandoz Inc., on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Sandoz Inc.s related information herein is confidential and proprietary commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that your company or organization maintain the confidentiality of this submission and of all Sandoz Inc.s related information herein to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that your company or organization notify us of the request and afford us the opportunity to submit objections to disclosure. | |||
| Rx0000027 | Sandoz Inc. | 04/02/2024 | LOTREL 5+20MG 100HGC BO US | 00078040605 | Innovator Multiple Source Drug | Sandoz Inc. provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127679 and its provisions. In providing this report, Sandoz Inc. does not waive any rights that may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127679 as it may relate to Sandoz Inc. or any of its affiliates now or in the future. Sandoz Inc., on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Sandoz Inc.s related information herein is confidential and proprietary commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that your company or organization maintain the confidentiality of this submission and of all Sandoz Inc.s related information herein to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that your company or organization notify us of the request and afford us the opportunity to submit objections to disclosure. | |||
| Rx0000027 | Sandoz Inc. | 04/02/2024 | RECLAST 5MG/100ML 1LIVI US | 00078043561 | Innovator Multiple Source Drug | Sandoz Inc. provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127679 and its provisions. In providing this report, Sandoz Inc. does not waive any rights that may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127679 as it may relate to Sandoz Inc. or any of its affiliates now or in the future. Sandoz Inc., on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Sandoz Inc.s related information herein is confidential and proprietary commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that your company or organization maintain the confidentiality of this submission and of all Sandoz Inc.s related information herein to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that your company or organization notify us of the request and afford us the opportunity to submit objections to disclosure. | |||
| Rx0000027 | Sandoz Inc. | 04/02/2024 | RITALIN IR 10MG 100TAB BO US | 00078044005 | Innovator Multiple Source Drug | Sandoz Inc. provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127679 and its provisions. In providing this report, Sandoz Inc. does not waive any rights that may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127679 as it may relate to Sandoz Inc. or any of its affiliates now or in the future. Sandoz Inc., on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Sandoz Inc.s related information herein is confidential and proprietary commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that your company or organization maintain the confidentiality of this submission and of all Sandoz Inc.s related information herein to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that your company or organization notify us of the request and afford us the opportunity to submit objections to disclosure. | |||
| Rx0000027 | Sandoz Inc. | 04/02/2024 | RITALIN IR 20MG 100TAB BO US | 00078044105 | Innovator Multiple Source Drug | Sandoz Inc. provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127679 and its provisions. In providing this report, Sandoz Inc. does not waive any rights that may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127679 as it may relate to Sandoz Inc. or any of its affiliates now or in the future. Sandoz Inc., on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Sandoz Inc.s related information herein is confidential and proprietary commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that your company or organization maintain the confidentiality of this submission and of all Sandoz Inc.s related information herein to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that your company or organization notify us of the request and afford us the opportunity to submit objections to disclosure. | |||
| Rx0000027 | Sandoz Inc. | 04/02/2024 | RITALIN IR 5MG 100TAB BO US | 00078043905 | Innovator Multiple Source Drug | Sandoz Inc. provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127679 and its provisions. In providing this report, Sandoz Inc. does not waive any rights that may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127679 as it may relate to Sandoz Inc. or any of its affiliates now or in the future. Sandoz Inc., on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Sandoz Inc.s related information herein is confidential and proprietary commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that your company or organization maintain the confidentiality of this submission and of all Sandoz Inc.s related information herein to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that your company or organization notify us of the request and afford us the opportunity to submit objections to disclosure. | |||
| Rx0000027 | Sandoz Inc. | 04/02/2024 | RITALIN LA 10MG 100PRCH US | 00078042405 | Innovator Multiple Source Drug | Sandoz Inc. provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127679 and its provisions. In providing this report, Sandoz Inc. does not waive any rights that may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127679 as it may relate to Sandoz Inc. or any of its affiliates now or in the future. Sandoz Inc., on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Sandoz Inc.s related information herein is confidential and proprietary commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that your company or organization maintain the confidentiality of this submission and of all Sandoz Inc.s related information herein to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that your company or organization notify us of the request and afford us the opportunity to submit objections to disclosure. | |||
| Rx0000027 | Sandoz Inc. | 04/02/2024 | RITALIN LA 20MG 100PRCH US | 00078037005 | Innovator Multiple Source Drug | Sandoz Inc. provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127679 and its provisions. In providing this report, Sandoz Inc. does not waive any rights that may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127679 as it may relate to Sandoz Inc. or any of its affiliates now or in the future. Sandoz Inc., on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Sandoz Inc.s related information herein is confidential and proprietary commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that your company or organization maintain the confidentiality of this submission and of all Sandoz Inc.s related information herein to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that your company or organization notify us of the request and afford us the opportunity to submit objections to disclosure. | |||
| Rx0000027 | Sandoz Inc. | 04/02/2024 | RITALIN LA 30MG 100PRCH US | 00078037105 | Innovator Multiple Source Drug | Sandoz Inc. provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127679 and its provisions. In providing this report, Sandoz Inc. does not waive any rights that may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127679 as it may relate to Sandoz Inc. or any of its affiliates now or in the future. Sandoz Inc., on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Sandoz Inc.s related information herein is confidential and proprietary commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that your company or organization maintain the confidentiality of this submission and of all Sandoz Inc.s related information herein to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that your company or organization notify us of the request and afford us the opportunity to submit objections to disclosure. | |||
| Rx0000027 | Sandoz Inc. | 04/02/2024 | RITALIN LA 40MG 100PRCH US | 00078037205 | Innovator Multiple Source Drug | Sandoz Inc. provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127679 and its provisions. In providing this report, Sandoz Inc. does not waive any rights that may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127679 as it may relate to Sandoz Inc. or any of its affiliates now or in the future. Sandoz Inc., on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Sandoz Inc.s related information herein is confidential and proprietary commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that your company or organization maintain the confidentiality of this submission and of all Sandoz Inc.s related information herein to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that your company or organization notify us of the request and afford us the opportunity to submit objections to disclosure. | |||
| Rx0000027 | Sandoz Inc. | 04/02/2024 | TRAVATAN Z SOL .004% 2.5ML LDP US | 00078094640 | Innovator Multiple Source Drug | Sandoz Inc. provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127679 and its provisions. In providing this report, Sandoz Inc. does not waive any rights that may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127679 as it may relate to Sandoz Inc. or any of its affiliates now or in the future. Sandoz Inc., on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Sandoz Inc.s related information herein is confidential and proprietary commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that your company or organization maintain the confidentiality of this submission and of all Sandoz Inc.s related information herein to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that your company or organization notify us of the request and afford us the opportunity to submit objections to disclosure. | |||
| Rx0000027 | Sandoz Inc. | 04/02/2024 | TRAVATAN Z SOL .004% 5ML LDP US | 00078094625 | Innovator Multiple Source Drug | Sandoz Inc. provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127679 and its provisions. In providing this report, Sandoz Inc. does not waive any rights that may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127679 as it may relate to Sandoz Inc. or any of its affiliates now or in the future. Sandoz Inc., on behalf of itself and affiliates, expressly reserves all such rights. We believe that this submission and of all Sandoz Inc.s related information herein is confidential and proprietary commercial or financial information not subject to disclosure, including under the California Public Records Act (Government Code Section 6250 et seq.) and applicable laws pertaining to trade secrets. We request that your company or organization maintain the confidentiality of this submission and of all Sandoz Inc.s related information herein to the maximum extent permitted by law. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that your company or organization notify us of the request and afford us the opportunity to submit objections to disclosure. | |||
| Rx0000011 | Sanofi | 04/30/2024 | DUPIXENT (dupilumab) 100 mg/0.67 mL (0.67 mL/syringe) - 2 syringes | 00024591102 | 03/28/2031 | Single Source Drug | |||
| Rx0000011 | Sanofi | 04/30/2024 | DUPIXENT (dupilumab) 200 mg/1.14 mL (1.14 mL/pen) - 2 pens | 00024591902 | 03/28/2031 | Single Source Drug | |||
| Rx0000011 | Sanofi | 04/30/2024 | DUPIXENT (dupilumab) 200 mg/1.14 mL (1.14 mL/syringe) - 2 syringes | 00024591801 | 03/28/2031 | Single Source Drug | |||
| Rx0000011 | Sanofi | 04/30/2024 | DUPIXENT (dupilumab) 300 mg/2 mL (2 mL/pen) - 2 pens | 00024591502 | 03/28/2031 | Single Source Drug | |||
| Rx0000011 | Sanofi | 04/30/2024 | DUPIXENT (dupilumab) 300 mg/2 mL (2 mL/syringe) - 2 syringes | 00024591401 | 03/28/2031 | Single Source Drug | |||
| Rx0000011 | Sanofi | 10/30/2024 | Jevtana® (cabazitaxel) Injection Concentrate) 60mg vial, 1.5ml carton | 00024582411 | 04/27/2031 | Single Source Drug | As per patent litigation settlements with generic manufacturers, Sanofi expects generic competition in Q2/Q3 2029. In addition to the method of treating patent referenced in the Patent Expiration Date field (US Patent No. 8,927,592), there are three other extant U.S. patents for this product (US Patent Nos. 7,241,907 expiring 10 June 2026, and 10,583,110 and 10,716,777 both having expiration dates of 27 October 2030.) | ||
| Rx0000011 | Sanofi | 04/30/2024 | KEVZARA® (sarilumab) 150 mg/1.14 mL pen - carton of 2 pens | 00024592001 | 09/19/2031 | Single Source Drug | |||
| Rx0000011 | Sanofi | 04/30/2024 | KEVZARA® (sarilumab) 150 mg/1.14 mL syringe - carton of 2 syringes | 00024590801 | 09/19/2031 | Single Source Drug | |||
| Rx0000011 | Sanofi | 04/30/2024 | KEVZARA® (sarilumab) 200 mg/1.14 mL pen - carton of 2 pens | 00024592201 | 09/19/2031 | Single Source Drug | |||
| Rx0000011 | Sanofi | 04/30/2024 | KEVZARA® (sarilumab) 200 mg/1.14 mL syringe - carton of 2 syringes | 00024591001 | 09/19/2031 | Single Source Drug | |||
| Rx0000011 | Sanofi | 04/30/2024 | MenQuadfi® (Meningococcal tetanus conjugate vaccine)10 mcg/0.5 mL (0.5 mL dose/vial) - 5 vials | 49281059005 | 12/30/2037 | Single Source Drug | |||
| Rx0000011 | Sanofi | 10/30/2024 | Typhim Vi® (Typhoid vaccine) 0.5 mL (1-dose) syringe | 49281079051 | Single Source Drug | ||||
| Rx0000011 | Sanofi | 10/30/2024 | Typhim Vi® (Typhoid vaccine) 10 mL (0.5 mL dose) vial | 49281079020 | Single Source Drug | ||||
| Rx0000011 | Sanofi | 04/30/2024 | Typhim Vi® (Typhoid vaccine)25 mcg/0.5 mL (0.5 ml dose/10 mL vial) - 1 vial | 49281079020 | Single Source Drug | ||||
| Rx0000011 | Sanofi | 04/30/2024 | Typhim Vi® (Typhoid vaccine)25 mcg/0.5 mL (0.5 ml dose/syringe) - 1 syringe | 49281079051 | Single Source Drug | ||||
| Rx0000011 | Sanofi | 10/30/2024 | YF-VAX® (Yellow fever vaccine) 0.5 mL (1-dose) vial | 49281091501 | Single Source Drug | ||||
| Rx0000011 | Sanofi | 04/30/2024 | YF-VAX® (Yellow fever vaccine)10 exp4.74 unit/0.5 mL (0.5 mL dose/vial) - 5 vials | 49281091501 | Single Source Drug | ||||
| Rx0000092 | Santarus, Inc. | 04/28/2024 | CYCLOSET® (bromocriptine mesytate tablets) 0.8 mg tablets, 200 ct | 68012025820 | 04/30/2032 | Single Source Drug | The product was not acquired within the last 5 years. | ||
| Rx0000086 | Seagen, Inc. | 07/18/2024 | ADCETRIS, 50mg, single-dose vial, packaged singly | 51144005001 | 12/31/2031 | Single Source Drug | 1) Seagen (formerly Seattle Genetics) does not believe information related to the unit sales volume in the U.S., cost increase factors, or change/improvement descriptions are in the public domain or otherwise publicly available. As a result, for these data elements, Seagen limits its response pursuant to Cal. Health & Safety Code § 127679(b). (2) As described in our publicly available financial disclosures, for ADCETRIS and our related ADC technology, we own ten patents in the United States and Europe that will expire between 2020 and 2031. However, the specific day and month of the patent expiration is not publicly available, though the Department of Healthcare Access and Information ("HCAI") portal does not permit Seagen to insert only a year for this data field. As a result, Seagen has entered "12/31/2031" for the "patent expiration date" field in order to submit a report to HCAI, though this does not reflect the actual date and month which Seagen's patents expire. In addition, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Seagen did not acquire this product from another manufacturer within the previous five years. As a result, we have left columns N-V blank because they are not applicable to this product. | ||
| Rx0000086 | Seagen, Inc. | 04/26/2024 | PADCEV (enfortumab vedotin-ejfv) 20 mg lyophilized powder in a single-dose vial for reconstitution | 51144002001 | 12/31/2031 | Single Source Drug | 1) Seagen (formerly Seattle Genetics) does not believe information related to the unit sales volume in the U.S., cost increase factors, or change/improvement descriptions are in the public domain or otherwise publicly available. As a result, for these data elements, Seagen limits its response pursuant to Cal. Health & Safety Code § 127679(b). 2) As described in our publicly available financial disclosures, for PADCEV and our related ADC technology, we own, co-owned or have licensed the rights to fourteen patents in the United States and Europe that will expire between 2022 and 2031. However, the specific day and month of the patent expiration is not publicly available, though the Department of Health Care Access and Information ("HCAI") Portal does not permit Seagen to insert only a year for this data field. As a result, Seagen has entered "12/31/2031" for the "patent expiration date" field in order to submit a report to HCAI, though this does not reflect the actual date and month which Seagen's patents expire. In addition, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. | ||
| Rx0000086 | Seagen, Inc. | 04/26/2024 | PADCEV (enfortumab vedotin-ejfv) 30 mg lyophilized powder in a single-dose vial for reconstitution | 51144003001 | 12/31/2031 | Single Source Drug | 1) Seagen (formerly Seattle Genetics) does not believe information related to the unit sales volume in the U.S., cost increase factors, or change/improvement descriptions are in the public domain or otherwise publicly available. As a result, for these data elements, Seagen limits its response pursuant to Cal. Health & Safety Code § 127679(b). 2) As described in our publicly available financial disclosures, for PADCEV and our related ADC technology, we own, co-owned or have licensed the rights to fourteen patents in the United States and Europe that will expire between 2022 and 2031. However, the specific day and month of the patent expiration is not publicly available, though the Department of Health Care Access and Information ("HCAI") Portal does not permit Seagen to insert only a year for this data field. As a result, Seagen has entered "12/31/2031" for the "patent expiration date" field in order to submit a report to HCAI, though this does not reflect the actual date and month which Seagen's patents expire. In addition, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. | ||
| Rx0000086 | Seagen, Inc. | 04/26/2024 | TIVDAK (tisotumab vedotin-tftv) 40mg/vial, Lyophilized Powder in a single-dose vial for reconstitution | 51144000301 | 12/31/2036 | Single Source Drug | 1) Seagen (formerly Seattle Genetics) does not believe information related to the unit sales volume in the U.S., cost increase factors, or change/improvement descriptions are in the public domain or otherwise publicly available. As a result, for these data elements, Seagen limits its response pursuant to Cal. Health & Safety Code § 127679(b). 2) As described in our publicly available financial disclosures, for TIVDAK and our related ADC technology, we own or have licensed rights to ten patents in the United States and Europe that will expire between 2023 and 2036. However, the specific day and month of the patent expiration is not publicly available, though the Department of Health Care Access and Information ("HCAI") Portal does not permit Seagen to insert only a year for this data field. As a result, Seagen has entered "12/31/2036" for the "patent expiration date" field in order to submit a report to HCAI, though this does not reflect the actual date and month which Seagen's patents expire. In addition, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. | ||
| Rx0000086 | Seagen, Inc. | 10/31/2024 | TIVDAK (tisotumab vedotin-tftv) 40mg/vial, Lyophilized Powder in a single-dose vial for reconstitution | 51144000301 | 12/31/2036 | Single Source Drug | 1) Seagen (formerly Seattle Genetics) does not believe information related to the unit sales volume in the U.S., cost increase factors, or change/improvement descriptions are in the public domain or otherwise publicly available. As a result, for these data elements, Seagen limits its response pursuant to Cal. Health & Safety Code § 127679(b). 2) As described in our publicly available financial disclosures, for TIVDAK and our related ADC technology, we own or have licensed rights to ten patents in the United States and Europe that will expire between 2023 and 2036. However, the specific day and month of the patent expiration is not publicly available, though the Department of Health Care Access and Information ("HCAI") Portal does not permit Seagen to insert only a year for this data field. As a result, Seagen has entered "12/31/2036" for the "patent expiration date" field in order to submit a report to HCAI, though this does not reflect the actual date and month which Seagen's patents expire. In addition, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. | ||
| Rx0000028 | Servier Pharmaceuticals LLC | 04/24/2024 | Oncaspar Injection Solution 750 UNIT/ML, 5 ML, Unit-Dose, Vial | 72694095401 | 06/01/2027 | Single Source Drug | |||
| Rx0000028 | Servier Pharmaceuticals LLC | 04/24/2024 | Tibsovo Oral Tablet 250 MG, 60 Each, Bottle | 72694061760 | 2018 | 06/07/2039 | Single Source Drug | ||
| Rx0000175 | Sobi Inc | 04/12/2024 | KINERET (anakinra) 100 MG/0.67 ML SYRINGE. 7 syringes in 1 carton (.67 ML in 1 syringe). | 66658023407 | Single Source Drug | ||||
| Rx0000244 | Sprout Pharmaceuticals, Inc. | 09/09/2024 | ADDYI (FLIBANSERIN) 100mg Oral Tablet, 30ct Bottle - [Qty:1] | 58604021430 | 05/09/2028 | Single Source Drug | |||
| Rx0000005 | Sumitomo Pharma America, Inc. | 04/02/2024 | Aptiom 30 Oral Tablets 200 MG | 63402020230 | 08/24/2032 | Single Source Drug | |||
| Rx0000005 | Sumitomo Pharma America, Inc. | 04/02/2024 | Aptiom 30 Oral Tablets 400 MG | 63402020430 | 08/24/2032 | Single Source Drug | |||
| Rx0000005 | Sumitomo Pharma America, Inc. | 04/02/2024 | Aptiom 30 Oral Tablets 800 MG | 63402020830 | 08/24/2032 | Single Source Drug | |||
| Rx0000005 | Sumitomo Pharma America, Inc. | 04/02/2024 | Aptiom 60 Oral Tablets 600 MG | 63402020660 | 08/24/2032 | Single Source Drug | |||
| Rx0000165 | Supernus Pharmaceuticals, Inc. | 04/05/2024 | Oxtellar XR Oral Tablet Extended Release 24 Hour 150 MG Package Size 100 Package Qty 1 | 17772012101 | 04/13/2027 | Single Source Drug | |||
| Rx0000165 | Supernus Pharmaceuticals, Inc. | 04/05/2024 | Oxtellar XR Oral Tablet Extended Release 24 Hour 300 MG Package Size 100 Package Qty 1 | 17772012201 | 04/13/2027 | Single Source Drug | |||
| Rx0000165 | Supernus Pharmaceuticals, Inc. | 04/05/2024 | Oxtellar XR Oral Tablet Extended Release 24 Hour 600 MG Package Size 100 Package Qty 1 | 17772012301 | 04/13/2027 | Single Source Drug | |||
| Rx0000165 | Supernus Pharmaceuticals, Inc. | 04/05/2024 | Qelbree Oral Capsule Extended Release 24 Hour 100 MG Package Size 30 Package Qty 1 | 17772013130 | 02/07/2033 | Single Source Drug | |||
| Rx0000165 | Supernus Pharmaceuticals, Inc. | 04/05/2024 | Qelbree Oral Capsule Extended Release 24 Hour 150 MG Package Size 30 Package Qty 1 | 17772013230 | 02/07/2033 | Single Source Drug | |||
| Rx0000165 | Supernus Pharmaceuticals, Inc. | 04/05/2024 | Qelbree Oral Capsule Extended Release 24 Hour 200 MG Package Size 30 Package Qty 1 | 17772013330 | 02/07/2033 | Single Source Drug | |||
| Rx0000105 | Takeda Pharmaceuticals America, Inc. | 04/26/2024 | ALUNBRIG 180 MG TABLET * 30 PACK | 63020018030 | 11/10/2035 | Single Source Drug | Acquisition information was left blank as the NDC/Product was not acquired within the last 5 years. For more information about Takedas approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/ | ||
| Rx0000105 | Takeda Pharmaceuticals America, Inc. | 10/09/2024 | ALUNBRIG 180 MG TABLET * 30 PACK | 63020018030 | 11/10/2035 | Single Source Drug | Acquisition information was left blank as the NDC/Product was not acquired within the last 5 years. For more information about Takedas approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/ | ||
| Rx0000105 | Takeda Pharmaceuticals America, Inc. | 04/26/2024 | ALUNBRIG 30 MG TABLET * 30 PACK | 63020011330 | 11/10/2035 | Single Source Drug | Acquisition information was left blank as the NDC/Product was not acquired within the last 5 years. For more information about Takedas approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/ | ||
| Rx0000105 | Takeda Pharmaceuticals America, Inc. | 10/09/2024 | ALUNBRIG 30 MG TABLET * 30 PACK | 63020011330 | 11/10/2035 | Single Source Drug | Acquisition information was left blank as the NDC/Product was not acquired within the last 5 years. For more information about Takedas approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/ | ||
| Rx0000105 | Takeda Pharmaceuticals America, Inc. | 04/26/2024 | ALUNBRIG 90 MG TABLET * 30 PACK | 63020009030 | 11/10/2035 | Single Source Drug | Acquisition information was left blank as the NDC/Product was not acquired within the last 5 years. For more information about Takedas approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/ | ||
| Rx0000105 | Takeda Pharmaceuticals America, Inc. | 10/09/2024 | ALUNBRIG 90 MG TABLET * 30 PACK | 63020009030 | 11/10/2035 | Single Source Drug | Acquisition information was left blank as the NDC/Product was not acquired within the last 5 years. For more information about Takedas approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/ | ||
| Rx0000105 | Takeda Pharmaceuticals America, Inc. | 04/26/2024 | ALUNBRIG 90 MG TABLET * 7 PACK | 63020009007 | 11/10/2035 | Single Source Drug | Acquisition information was left blank as the NDC/Product was not acquired within the last 5 years. For more information about Takedas approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/ | ||
| Rx0000105 | Takeda Pharmaceuticals America, Inc. | 10/09/2024 | ALUNBRIG 90 MG TABLET * 7 PACK | 63020009007 | 11/10/2035 | Single Source Drug | Acquisition information was left blank as the NDC/Product was not acquired within the last 5 years. For more information about Takedas approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/ | ||
| Rx0000105 | Takeda Pharmaceuticals America, Inc. | 04/26/2024 | ALUNBRIG INITIATION PACK - 7 CT 90 MG TABLET and 23 CT 180 MG TABLET - PER PACK | 63020019830 | 11/10/2035 | Single Source Drug | Acquisition information was left blank as the NDC/Product was not acquired within the last 5 years. For more information about Takedas approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/ | ||
| Rx0000105 | Takeda Pharmaceuticals America, Inc. | 10/09/2024 | ALUNBRIG INITIATION PACK - 7 CT 90 MG TABLET and 23 CT 180 MG TABLET - PER PACK | 63020019830 | 11/10/2035 | Single Source Drug | Acquisition information was left blank as the NDC/Product was not acquired within the last 5 years. For more information about Takedas approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/ | ||
| Rx0000105 | Takeda Pharmaceuticals America, Inc. | 04/15/2024 | Entyvio Intravenous Solution Reconstituted 300 MG | 64764030020 | Single Source Drug | Not acquired in the last 5 years. Please note that Patent Expiration Date is not publicly available for Entyvio. For more information about Takedas approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/ | |||
| Rx0000105 | Takeda Pharmaceuticals America, Inc. | 04/26/2024 | ICLUSIG 10 MG TABLET * 30 PACK | 63020053630 | 12/12/2033 | Single Source Drug | Acquisition information was left blank as the NDC/Product was not acquired within the last 5 years. For more information about Takedas approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/ | ||
| Rx0000105 | Takeda Pharmaceuticals America, Inc. | 10/09/2024 | ICLUSIG 10 MG TABLET * 30 PACK | 63020053630 | 12/12/2033 | Single Source Drug | Acquisition information was left blank as the NDC/Product was not acquired within the last 5 years. For more information about Takedas approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/ | ||
| Rx0000105 | Takeda Pharmaceuticals America, Inc. | 04/26/2024 | ICLUSIG 15 MG TABLET * 30 PACK | 63020053530 | 12/12/2033 | Single Source Drug | Acquisition information was left blank as the NDC/Product was not acquired within the last 5 years. For more information about Takedas approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/ | ||
| Rx0000105 | Takeda Pharmaceuticals America, Inc. | 10/09/2024 | ICLUSIG 15 MG TABLET * 30 PACK | 63020053530 | 12/12/2033 | Single Source Drug | Acquisition information was left blank as the NDC/Product was not acquired within the last 5 years. For more information about Takedas approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/ | ||
| Rx0000105 | Takeda Pharmaceuticals America, Inc. | 04/26/2024 | ICLUSIG 30 MG TABLET * 30 PACK | 63020053330 | 12/12/2033 | Single Source Drug | Acquisition information was left blank as the NDC/Product was not acquired within the last 5 years. For more information about Takedas approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/ | ||
| Rx0000105 | Takeda Pharmaceuticals America, Inc. | 10/09/2024 | ICLUSIG 30 MG TABLET * 30 PACK | 63020053330 | 12/12/2033 | Single Source Drug | Acquisition information was left blank as the NDC/Product was not acquired within the last 5 years. For more information about Takedas approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/ | ||
| Rx0000105 | Takeda Pharmaceuticals America, Inc. | 04/26/2024 | ICLUSIG 45 MG TABLET * 30 PACK | 63020053430 | 12/12/2033 | Single Source Drug | Acquisition information was left blank as the NDC/Product was not acquired within the last 5 years. For more information about Takedas approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/ | ||
| Rx0000105 | Takeda Pharmaceuticals America, Inc. | 10/09/2024 | ICLUSIG 45 MG TABLET * 30 PACK | 63020053430 | 12/12/2033 | Single Source Drug | Acquisition information was left blank as the NDC/Product was not acquired within the last 5 years. For more information about Takedas approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/ | ||
| Rx0000105 | Takeda Pharmaceuticals America, Inc. | 04/26/2024 | NINLARO 2.3 MG CAPSULE * 3 PACK | 63020023002 | 11/20/2029 | Single Source Drug | Acquisition information was left blank as the NDC/Product was not acquired within the last 5 years. For more information about Takedas approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/ | ||
| Rx0000105 | Takeda Pharmaceuticals America, Inc. | 04/26/2024 | NINLARO 2.3 MG CAPSULE * SINGLE PACK | 63020023001 | 11/20/2029 | Single Source Drug | Acquisition information was left blank as the NDC/Product was not acquired within the last 5 years. For more information about Takedas approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/ | ||
| Rx0000105 | Takeda Pharmaceuticals America, Inc. | 04/26/2024 | NINLARO 3.0 MG CAPSULE * 3 PACK | 63020039002 | 11/20/2029 | Single Source Drug | Acquisition information was left blank as the NDC/Product was not acquired within the last 5 years. For more information about Takedas approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/ | ||
| Rx0000105 | Takeda Pharmaceuticals America, Inc. | 04/26/2024 | NINLARO 4.0 MG CAPSULE * 3 PACK | 63020040002 | 11/20/2029 | Single Source Drug | Acquisition information was left blank as the NDC/Product was not acquired within the last 5 years. For more information about Takedas approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/ | ||
| Rx0000105 | Takeda Pharmaceuticals America, Inc. | 04/26/2024 | NINLARO 4.0 MG CAPSULE * SINGLE PACK | 63020040001 | 11/20/2029 | Single Source Drug | Acquisition information was left blank as the NDC/Product was not acquired within the last 5 years. For more information about Takedas approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/ | ||
| Rx0000105 | Takeda Pharmaceuticals America, Inc. | 04/26/2024 | NINLARO 3.0 MG CAPSULE * SINGLE PACK | 63020039001 | 11/20/2029 | Single Source Drug | Acquisition information was left blank as the NDC/Product was not acquired within the last 5 years. For more information about Takedas approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/ | ||
| Rx0000232 | TerSera Therapeutics LLC | 04/30/2024 | Xermelo Oral Tablet 250 MG, 84 Each, Unit-of-Use, Box | 70720012585 | 2017 | 02/28/2031 | Single Source Drug | Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which TerSera believes is in the public domain or otherwise publicly available. | |
| Rx0000232 | TerSera Therapeutics LLC | 04/30/2024 | Zoladex Subcutaneous Implant 10.8 MG, 1 Each, Unit-of-Use, Box | 70720095130 | Single Source Drug | Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which TerSera believes is in the public domain or otherwise publicly available. | |||
| Rx0000232 | TerSera Therapeutics LLC | 10/30/2024 | Zoladex Subcutaneous Implant 10.8 MG, 1 Each, Unit-of-Use, Box | 70720095130 | Single Source Drug | ||||
| Rx0000232 | TerSera Therapeutics LLC | 04/30/2024 | Zoladex Subcutaneous Implant 3.6 MG, 1 Each, Unit-Dose, Syringe | 70720095036 | Single Source Drug | Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which TerSera believes is in the public domain or otherwise publicly available. | |||
| Rx0000232 | TerSera Therapeutics LLC | 10/30/2024 | Zoladex Subcutaneous Implant 3.6 MG, 1 Each, Unit-Dose, Syringe | 70720095036 | Single Source Drug | ||||
| Rx0000302 | Tetraphase Pharmaceuticals | 04/24/2024 | Xerava Intravenous Solution Reconstituted 50 MG, 1 Each, Unit-Dose, Vial Qty 12 | 71773005012 | 10/19/2037 | Single Source Drug | |||
| Rx0000217 | Teva Neuroscience, Inc. | 04/24/2024 | AUSTEDO 12 MG TABLET 60 | 68546017260 | 03/15/2038 | Single Source Drug | Acquisition fields left blank; product was not acquired within the previous five years. | ||
| Rx0000217 | Teva Neuroscience, Inc. | 04/24/2024 | AUSTEDO 6 MG TABLET 60 | 68546017060 | 03/15/2038 | Single Source Drug | Acquisition fields left blank; product was not acquired within the previous five years. | ||
| Rx0000217 | Teva Neuroscience, Inc. | 04/24/2024 | AUSTEDO 9 MG TABLET 60 | 68546017160 | 03/15/2038 | Single Source Drug | Acquisition fields left blank; product was not acquired within the previous five years. | ||
| Rx0000217 | Teva Neuroscience, Inc. | 04/24/2024 | AZILECT 0.5MG TABLET 30 | 68546014256 | 08/27/2027 | Innovator Multiple Source Drug | Acquisition fields left blank; product was not acquired within the previous five years. | ||
| Rx0000217 | Teva Neuroscience, Inc. | 04/24/2024 | AZILECT 1MG TABLET 30 | 68546022956 | 08/27/2027 | Innovator Multiple Source Drug | Acquisition fields left blank; product was not acquired within the previous five years. | ||
| Rx0000019 | Teva Pharmaceuticals USA | 04/24/2024 | ADDERALL 10MG TABLET 100 | 57844011001 | 01/06/2021 | Non-innovator Multiple Source Drug | Acquisition fields left blank; product was not acquired within the previous five years. | ||
| Rx0000019 | Teva Pharmaceuticals USA | 04/24/2024 | ADDERALL 12.5MG TABLET 100 | 57844011201 | 01/06/2021 | Non-innovator Multiple Source Drug | Acquisition fields left blank; product was not acquired within the previous five years. | ||
| Rx0000019 | Teva Pharmaceuticals USA | 04/24/2024 | ADDERALL 15MG TABLET 100 | 57844011501 | 01/06/2021 | Non-innovator Multiple Source Drug | Acquisition fields left blank; product was not acquired within the previous five years. | ||
| Rx0000019 | Teva Pharmaceuticals USA | 04/24/2024 | ADDERALL 20MG TABLET 100 | 57844012001 | 01/06/2021 | Non-innovator Multiple Source Drug | Acquisition fields left blank; product was not acquired within the previous five years. | ||
| Rx0000019 | Teva Pharmaceuticals USA | 04/24/2024 | ADDERALL 30MG TABLET 100 | 57844013001 | 01/06/2021 | Non-innovator Multiple Source Drug | Acquisition fields left blank; product was not acquired within the previous five years. | ||
| Rx0000019 | Teva Pharmaceuticals USA | 04/24/2024 | ADDERALL 5MG TABLET 100 | 57844010501 | 01/06/2021 | Non-innovator Multiple Source Drug | Acquisition fields left blank; product was not acquired within the previous five years. | ||
| Rx0000019 | Teva Pharmaceuticals USA | 04/24/2024 | ADDERALL 7.5MG TABLET 100 | 57844011701 | 01/06/2021 | Non-innovator Multiple Source Drug | Acquisition fields left blank; product was not acquired within the previous five years. | ||
| Rx0000019 | Teva Pharmaceuticals USA | 04/24/2024 | ADIPEX-P TABLETS 37.5 MG 100 | 57844014001 | 12/30/1899 | Innovator Multiple Source Drug | No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years. | ||
| Rx0000019 | Teva Pharmaceuticals USA | 04/24/2024 | ADIPEX-P TABLETS 37.5 MG 30 | 57844014056 | 12/30/1899 | Innovator Multiple Source Drug | No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years. | ||
| Rx0000019 | Teva Pharmaceuticals USA | 04/24/2024 | AMRIX 15 MG CAPSULE ER 60 | 63459070060 | Innovator Multiple Source Drug | Acquisition fields left blank; product was not acquired within the previous five years. | |||
| Rx0000019 | Teva Pharmaceuticals USA | 04/24/2024 | AMRIX 30 MG CAPSULE ER 60 | 63459070160 | Innovator Multiple Source Drug | Acquisition fields left blank; product was not acquired within the previous five years. | |||
| Rx0000019 | Teva Pharmaceuticals USA | 04/24/2024 | FENTORA 100 MCG TABLET 28 | 63459054128 | 06/15/2028 | Single Source Drug | Acquisition fields left blank; product was not acquired within the previous five years. | ||
| Rx0000019 | Teva Pharmaceuticals USA | 04/24/2024 | FENTORA 200 MCG TABLET 28 | 63459054228 | 06/15/2028 | Single Source Drug | Acquisition fields left blank; product was not acquired within the previous five years. | ||
| Rx0000019 | Teva Pharmaceuticals USA | 04/24/2024 | FENTORA 400 MCG TABLET 28 | 63459054428 | 06/15/2028 | Single Source Drug | Acquisition fields left blank; product was not acquired within the previous five years. | ||
| Rx0000019 | Teva Pharmaceuticals USA | 04/24/2024 | FENTORA 600 MCG TABLET 28 | 63459054628 | 06/15/2028 | Single Source Drug | Acquisition fields left blank; product was not acquired within the previous five years. | ||
| Rx0000019 | Teva Pharmaceuticals USA | 04/24/2024 | FENTORA 800 MCG TABLET 28 | 63459054828 | 06/15/2028 | Single Source Drug | Acquisition fields left blank; product was not acquired within the previous five years. | ||
| Rx0000019 | Teva Pharmaceuticals USA | 04/24/2024 | FIORICET 50/300/40 MG CAPSULE 100 | 52544008001 | 12/30/1899 | Non-innovator Multiple Source Drug | No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years. | ||
| Rx0000019 | Teva Pharmaceuticals USA | 04/24/2024 | FIORICET 50/300/40/30 MG CAPSULE 100 | 52544008201 | 12/30/1899 | Innovator Multiple Source Drug | No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years. | ||
| Rx0000019 | Teva Pharmaceuticals USA | 04/24/2024 | GALZIN 25 MG CAPSULE 250 | 57844021552 | 12/30/1899 | Single Source Drug | No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years. | ||
| Rx0000019 | Teva Pharmaceuticals USA | 04/24/2024 | GALZIN 50 MG CAPSULE 250 | 57844020852 | 12/30/1899 | Single Source Drug | No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years. | ||
| Rx0000019 | Teva Pharmaceuticals USA | 04/24/2024 | NUVIGIL 150MG TABLET 30 | 63459021530 | 06/18/2024 | Innovator Multiple Source Drug | |||
| Rx0000019 | Teva Pharmaceuticals USA | 04/24/2024 | NUVIGIL 200MG TABLET 30 | 63459022030 | 06/18/2024 | Innovator Multiple Source Drug | |||
| Rx0000019 | Teva Pharmaceuticals USA | 04/24/2024 | NUVIGIL 250MG TABLET 30 | 63459022530 | 06/18/2024 | Innovator Multiple Source Drug | |||
| Rx0000019 | Teva Pharmaceuticals USA | 04/24/2024 | NUVIGIL 50MG TABLET 30 | 63459020530 | 06/18/2024 | Innovator Multiple Source Drug | |||
| Rx0000019 | Teva Pharmaceuticals USA | 04/24/2024 | PROGLYCEM 50MG/ML ORAL SUS 30ML | 00575620030 | Single Source Drug | No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years. | |||
| Rx0000019 | Teva Pharmaceuticals USA | 04/24/2024 | PROVIGIL 100MG TABLET 30 | 63459010130 | 05/29/2024 | Innovator Multiple Source Drug | |||
| Rx0000019 | Teva Pharmaceuticals USA | 04/24/2024 | PROVIGIL 200MG TABLET 30 | 63459020130 | 05/29/2024 | Innovator Multiple Source Drug | |||
| Rx0000019 | Teva Pharmaceuticals USA | 10/17/2024 | SMX-TMP INJ 80MG-16MG/ML 10 X 10ML PRM | 00703951483 | Non-innovator Multiple Source Drug | No patent expiration date listed - no patents ever listed. Acquisition fields left blank; product was not acquired within the previous five years. Teva stopped selling this product in November 2017. Teva re-launched the product in July 2024. Given that the product was off the market for nearly 7 years, we believe that its reintroduction is more properly viewed as a new launch / re-launch at a higher WAC than before, rather than a price increase. We are nonetheless including the product in this report out of an abundance of caution. | |||
| Rx0000019 | Teva Pharmaceuticals USA | 10/17/2024 | SMX-TMP INJ 80MG-16MG/ML 10 X 10ML PRM | 00703951483 | Non-innovator Multiple Source Drug | No patent expiration date listed - no patents ever listed. Acquisition fields left blank; product was not acquired within the previous five years. Teva stopped selling this product in November 2017. Teva re-launched the product in July 2024. Given that the product was off the market for nearly 7 years, we believe that its reintroduction is more properly viewed as a new launch / re-launch at a higher WAC than before, rather than a price increase. We are nonetheless including the product in this report out of an abundance of caution. | |||
| Rx0000019 | Teva Pharmaceuticals USA | 04/24/2024 | TRISENOX VIAL 2 MG/ML 6 ML | 63459060106 | Innovator Multiple Source Drug | No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years. | |||
| Rx0000218 | Teva Respiratory, LLC | 04/24/2024 | QNASL PEDS Nasal Aerosol Solution 40 MCG/ACT 6.8GM | 59310040606 | 10/21/2031 | Single Source Drug | Acquisition fields left blank; product was not acquired within the previous five years. | ||
| Rx0000218 | Teva Respiratory, LLC | 04/24/2024 | QNASL PLV Nasal Aerosol Solution 80 MCG/ACT | 59310041012 | 10/21/2031 | Single Source Drug | Acquisition fields left blank; product was not acquired within the previous five years. | ||
| Rx0000219 | Teva Women's Health, Inc. | 04/24/2024 | TREXALL 10 MG TABLET 30 | 51285036801 | Single Source Drug | No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years. | |||
| Rx0000219 | Teva Women's Health, Inc. | 04/24/2024 | TREXALL 15 MG TABLET 30 | 51285036901 | Single Source Drug | No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years. | |||
| Rx0000219 | Teva Women's Health, Inc. | 04/24/2024 | TREXALL 5 MG TABLET 30 | 51285036601 | Single Source Drug | No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years. | |||
| Rx0000219 | Teva Women's Health, Inc. | 04/24/2024 | TREXALL 7.5 MG TABLET 30 | 51285036701 | Single Source Drug | No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years. | |||
| Rx0000134 | Therakos, Inc. | 04/30/2024 | UVADEX (Methoxsalen) STERILE SOLUTION, 20 mcg/ML, 12 - 10ml vials per carton | 64067021601 | Single Source Drug | This price information is reflective of the case unit of sale of the product. Uvadex is a unique prescription drug product that is used only as a component of extracorporeal photopheresis (ECP) therapy, a drug/device combination therapy, and is administered by a healthcare professional in a clinical setting. | |||
| Rx0000395 | Travere Therapeutics, Inc. | 10/25/2024 | Filspari Oral Tablet 200 MG 30 tablets 1 bottle | 68974020030 | 03/29/2030 | Single Source Drug | |||
| Rx0000395 | Travere Therapeutics, Inc. | 10/25/2024 | Filspari Oral Tablet 400 MG 30 tablets 1 bottle | 68974040030 | 03/29/2030 | Single Source Drug | |||
| Rx0000090 | UCB, Inc | 04/30/2024 | BRIVIACT 100MG 60 TABLETS | 50474077066 | 04/09/2030 | Single Source Drug | Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. Our Public Gross Sales Volumes are rolled up to the Product level and not NDC specific. Amount supplied represents the whole Product family. | ||
| Rx0000090 | UCB, Inc | 04/30/2024 | BRIVIACT 100MG UNIT DOSE CARTON OF 100 TABLETS | 50474077009 | 04/09/2030 | Single Source Drug | Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. Our Public Gross Sales Volumes are rolled up to the Product level and not NDC specific. Amount supplied represents the whole Product family. | ||
| Rx0000090 | UCB, Inc | 04/30/2024 | BRIVIACT 10MG 60 TABLETS | 50474037066 | 04/09/2030 | Single Source Drug | Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. Our Public Gross Sales Volumes are rolled up to the Product level and not NDC specific. Amount supplied represents the whole Product family. | ||
| Rx0000090 | UCB, Inc | 04/30/2024 | BRIVIACT 10MG ORAL SOLUTION-300ML | 50474087015 | 02/21/2026 | Single Source Drug | Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. Our Public Gross Sales Volumes are rolled up to the Product level and not NDC specific. Amount supplied represents the whole Product family. | ||
| Rx0000090 | UCB, Inc | 04/30/2024 | BRIVIACT 25MG 60 TABLETS | 50474047066 | 04/09/2030 | Single Source Drug | Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. Our Public Gross Sales Volumes are rolled up to the Product level and not NDC specific. Amount supplied represents the whole Product family. | ||
| Rx0000090 | UCB, Inc | 04/30/2024 | BRIVIACT 25MG UNIT DOSE CARTON OF 100 TABLETS | 50474047009 | 04/09/2030 | Single Source Drug | Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. Our Public Gross Sales Volumes are rolled up to the Product level and not NDC specific. Amount supplied represents the whole Product family. | ||
| Rx0000090 | UCB, Inc | 04/30/2024 | BRIVIACT 50MG 60 TABLETS | 50474057066 | 04/09/2030 | Single Source Drug | Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. Our Public Gross Sales Volumes are rolled up to the Product level and not NDC specific. Amount supplied represents the whole Product family. | ||
| Rx0000090 | UCB, Inc | 04/30/2024 | BRIVIACT 50MG UNIT DOSE CARTON OF 100 TABLETS | 50474057009 | 04/09/2030 | Single Source Drug | Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. Our Public Gross Sales Volumes are rolled up to the Product level and not NDC specific. Amount supplied represents the whole Product family. | ||
| Rx0000090 | UCB, Inc | 04/30/2024 | BRIVIACT 75MG 60 TABLETS | 50474067066 | 04/09/2030 | Single Source Drug | Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. Our Public Gross Sales Volumes are rolled up to the Product level and not NDC specific. Amount supplied represents the whole Product family. | ||
| Rx0000090 | UCB, Inc | 04/30/2024 | BRIVIACT IV INJECTION FOR INTRAVENOUS USE 50mg/5mL | 50474097075 | 02/21/2026 | Single Source Drug | Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. Our Public Gross Sales Volumes are rolled up to the Product level and not NDC specific. Amount supplied represents the whole Product family. | ||
| Rx0000090 | UCB, Inc | 04/30/2024 | CIMZIA LYOPHOLIZED POWDER FOR INJECTION, 2 X 200 MG VIALS | 50474070062 | Single Source Drug | Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. Our Public Gross Sales Volumes are rolled up to the Product level and not NDC specific. Amount supplied represents the whole Product family. | |||
| Rx0000090 | UCB, Inc | 04/30/2024 | CIMZIA PRE-FILLED SYRINGE KIT, 2 X 200 MG/ML PRE-FILLED SYRINGES | 50474071079 | Single Source Drug | Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. Our Public Gross Sales Volumes are rolled up to the Product level and not NDC specific. Amount supplied represents the whole Product family. | |||
| Rx0000090 | UCB, Inc | 04/30/2024 | CIMZIA PRE-FILLED SYRINGE STARTER KIT, 6 X 200 MG/ML PRE-FILLED SYRINGES | 50474071081 | Single Source Drug | Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. Our Public Gross Sales Volumes are rolled up to the Product level and not NDC specific. Amount supplied represents the whole Product family. | |||
| Rx0000090 | UCB, Inc | 04/30/2024 | FINTEPLA 2.2MG/ML, 30ML | 43376032230 | 2020 | 12/29/2038 | Single Source Drug | Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. Our Public Gross Sales Volumes are rolled up to the Product level and not NDC specific. Amount supplied represents the whole Product family. | |
| Rx0000090 | UCB, Inc | 04/30/2024 | FINTEPLA 2.2MG/ML, 360ML | 43376032236 | 2020 | 12/29/2038 | Single Source Drug | Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. Our Public Gross Sales Volumes are rolled up to the Product level and not NDC specific. Amount supplied represents the whole Product family. | |
| Rx0000090 | UCB, Inc | 04/30/2024 | KEPPRA 1000MG-60 TABLETS | 50474059766 | 12/07/2031 | Innovator Multiple Source Drug | Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. Our Public Gross Sales Volumes are rolled up to the Product level and not NDC specific. Amount supplied represents the whole Product family. | ||
| Rx0000090 | UCB, Inc | 04/30/2024 | KEPPRA 250MG-120 TABLETS | 50474059440 | 12/07/2031 | Innovator Multiple Source Drug | Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. Our Public Gross Sales Volumes are rolled up to the Product level and not NDC specific. Amount supplied represents the whole Product family. | ||
| Rx0000090 | UCB, Inc | 04/30/2024 | KEPPRA 500 MG-120 TABLETS | 50474059540 | 12/07/2031 | Innovator Multiple Source Drug | Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. Our Public Gross Sales Volumes are rolled up to the Product level and not NDC specific. Amount supplied represents the whole Product family. | ||
| Rx0000090 | UCB, Inc | 04/30/2024 | KEPPRA 750MG-120 TABLETS | 50474059640 | 12/07/2031 | Innovator Multiple Source Drug | Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. Our Public Gross Sales Volumes are rolled up to the Product level and not NDC specific. Amount supplied represents the whole Product family. | ||
| Rx0000090 | UCB, Inc | 04/30/2024 | KEPPRA IV-1ML INJECTION FOR INTRAVENOUS USE 500mg5mL 10 VIALS | 50474000263 | Innovator Multiple Source Drug | Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. Our Public Gross Sales Volumes are rolled up to the Product level and not NDC specific. Amount supplied represents the whole Product family. | |||
| Rx0000090 | UCB, Inc | 04/30/2024 | KEPPRA ORAL SOLUTION-100MG-473ML | 50474000148 | Innovator Multiple Source Drug | Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. Our Public Gross Sales Volumes are rolled up to the Product level and not NDC specific. Amount supplied represents the whole Product family. | |||
| Rx0000090 | UCB, Inc | 04/30/2024 | KEPPRA XR (LEVETIRACETAM) 500MG-60 TABLETS | 50474059866 | 09/17/2028 | Innovator Multiple Source Drug | Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. Our Public Gross Sales Volumes are rolled up to the Product level and not NDC specific. Amount supplied represents the whole Product family. | ||
| Rx0000090 | UCB, Inc | 04/30/2024 | KEPPRA XR 750MG (LEVETIRACETAM)-60 TABLETS | 50474059966 | 09/17/2028 | Innovator Multiple Source Drug | Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. Our Public Gross Sales Volumes are rolled up to the Product level and not NDC specific. Amount supplied represents the whole Product family. | ||
| Rx0000090 | UCB, Inc | 04/30/2024 | NAYZILAM 5 MG NASAL SPRAY-0.2ML | 50474050015 | 01/18/2028 | Single Source Drug | Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. Our Public Gross Sales Volumes are rolled up to the Product level and not NDC specific. Amount supplied represents the whole Product family. | ||
| Rx0000090 | UCB, Inc | 04/30/2024 | NEUPRO 1MG/24HR-30 TRANSDERMAL SYSTEM | 50474080103 | 12/22/2030 | Single Source Drug | Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. Our Public Gross Sales Volumes are rolled up to the Product level and not NDC specific. Amount supplied represents the whole Product family. | ||
| Rx0000090 | UCB, Inc | 04/30/2024 | NEUPRO 2MG/24HR-30 TRANSDERMAL SYSTEM | 50474080203 | 12/22/2030 | Single Source Drug | Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. Our Public Gross Sales Volumes are rolled up to the Product level and not NDC specific. Amount supplied represents the whole Product family. | ||
| Rx0000090 | UCB, Inc | 04/30/2024 | NEUPRO 3MG/24HR-30 TRANSDERMAL SYSTEM | 50474080303 | 12/22/2030 | Single Source Drug | Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. Our Public Gross Sales Volumes are rolled up to the Product level and not NDC specific. Amount supplied represents the whole Product family. | ||
| Rx0000090 | UCB, Inc | 04/30/2024 | NEUPRO 4MG/24HR-30 TRANSDERMAL SYSTEM | 50474080403 | 12/22/2030 | Single Source Drug | Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. Our Public Gross Sales Volumes are rolled up to the Product level and not NDC specific. Amount supplied represents the whole Product family. | ||
| Rx0000090 | UCB, Inc | 04/30/2024 | NEUPRO 6MG/24HR-30 TRANSDERMAL SYSTEM | 50474080503 | 12/22/2030 | Single Source Drug | Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. Our Public Gross Sales Volumes are rolled up to the Product level and not NDC specific. Amount supplied represents the whole Product family. | ||
| Rx0000090 | UCB, Inc | 04/30/2024 | NEUPRO 8MG/24HR-30 TRANSDERMAL SYSTEM | 50474080603 | 12/22/2030 | Single Source Drug | Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. Our Public Gross Sales Volumes are rolled up to the Product level and not NDC specific. Amount supplied represents the whole Product family. | ||
| Rx0000090 | UCB, Inc | 04/30/2024 | VIMPAT 100MG UD-60 TABLETS | 00131247860 | Single Source Drug | Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. Our Public Gross Sales Volumes are rolled up to the Product level and not NDC specific. Amount supplied represents the whole Product family. | |||
| Rx0000090 | UCB, Inc | 04/30/2024 | VIMPAT 100MG-60 TABLETS | 00131247835 | Single Source Drug | Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. Our Public Gross Sales Volumes are rolled up to the Product level and not NDC specific. Amount supplied represents the whole Product family. | |||
| Rx0000090 | UCB, Inc | 04/30/2024 | VIMPAT 150MG UD-60 TABLETS | 00131247960 | Single Source Drug | Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. Our Public Gross Sales Volumes are rolled up to the Product level and not NDC specific. Amount supplied represents the whole Product family. | |||
| Rx0000090 | UCB, Inc | 04/30/2024 | VIMPAT 150MG-60 TABLETS | 00131247935 | Single Source Drug | Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. Our Public Gross Sales Volumes are rolled up to the Product level and not NDC specific. Amount supplied represents the whole Product family. | |||
| Rx0000090 | UCB, Inc | 04/30/2024 | VIMPAT 200MG UD-60 TABLETS | 00131248060 | Single Source Drug | Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. Our Public Gross Sales Volumes are rolled up to the Product level and not NDC specific. Amount supplied represents the whole Product family. | |||
| Rx0000090 | UCB, Inc | 04/30/2024 | VIMPAT 200MG-60 TABLETS | 00131248035 | Single Source Drug | Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. Our Public Gross Sales Volumes are rolled up to the Product level and not NDC specific. Amount supplied represents the whole Product family. | |||
| Rx0000090 | UCB, Inc | 04/30/2024 | VIMPAT 50MG UD-60 TABLETS | 00131247760 | Single Source Drug | Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. Our Public Gross Sales Volumes are rolled up to the Product level and not NDC specific. Amount supplied represents the whole Product family. | |||
| Rx0000090 | UCB, Inc | 04/30/2024 | VIMPAT 50MG-60 TABLETS | 00131247735 | Single Source Drug | Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. Our Public Gross Sales Volumes are rolled up to the Product level and not NDC specific. Amount supplied represents the whole Product family. | |||
| Rx0000090 | UCB, Inc | 04/30/2024 | VIMPAT INJECTION FOR INTRAVENOUS USE 200MG/20ML 10 VIALS | 00131181067 | Single Source Drug | Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. Our Public Gross Sales Volumes are rolled up to the Product level and not NDC specific. Amount supplied represents the whole Product family. | |||
| Rx0000090 | UCB, Inc | 04/30/2024 | VIMPAT ORAL SOLUTION 10MG-200ML | 00131541072 | Single Source Drug | Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. Our Public Gross Sales Volumes are rolled up to the Product level and not NDC specific. Amount supplied represents the whole Product family. | |||
| Rx0000262 | Ultragenyx Pharmaceuticals Inc. | 04/03/2024 | Dojolvi .96 g/mL Oral Liquid 1 Carton | 69794005050 | 04/28/2029 | Single Source Drug | |||
| Rx0000036 | United Therapeutics | 03/31/2024 | ORENITRAM ER .125 MG Oral Tablet 10 Pack | 66302030010 | 08/11/2031 | Single Source Drug | |||
| Rx0000036 | United Therapeutics | 03/31/2024 | ORENITRAM ER .125 MG Oral Tablet 100 Pack | 66302030001 | 08/11/2031 | Single Source Drug | |||
| Rx0000036 | United Therapeutics | 03/31/2024 | ORENITRAM ER .25 MG Oral Tablet 10 Pack | 66302030210 | 08/11/2031 | Single Source Drug | |||
| Rx0000036 | United Therapeutics | 03/31/2024 | ORENITRAM ER .25 MG Oral Tablet 100 Pack | 66302030201 | 08/11/2031 | Single Source Drug | |||
| Rx0000036 | United Therapeutics | 03/31/2024 | ORENITRAM ER 1 MG Oral Tablet 10 Pack | 66302031010 | 08/11/2031 | Single Source Drug | |||
| Rx0000036 | United Therapeutics | 03/31/2024 | ORENITRAM ER 1 MG Oral Tablet 100 Pack | 66302031001 | 08/11/2031 | Single Source Drug | |||
| Rx0000036 | United Therapeutics | 03/31/2024 | ORENITRAM ER 2.5 MG Oral Tablet 10 Pack | 66302032510 | 08/11/2031 | Single Source Drug | |||
| Rx0000036 | United Therapeutics | 03/31/2024 | ORENITRAM ER 2.5 MG Oral Tablet 100 Pack | 66302032501 | 08/11/2031 | Single Source Drug | |||
| Rx0000036 | United Therapeutics | 03/31/2024 | ORENITRAM ER 5 MG Oral Tablet 100 Pack | 66302035001 | 08/11/2031 | Single Source Drug | |||
| Rx0000036 | United Therapeutics | 03/31/2024 | ORENITRAM ER 5 MG Pack Oral Tablet 10 Pack | 66302035010 | 08/11/2031 | Single Source Drug | |||
| Rx0000036 | United Therapeutics | 03/31/2024 | Unituxin Intravenous Solution 17.5 MG/5ML 1 Vial in 1 Carton | 66302001401 | Single Source Drug | ||||
| Rx0000443 | USWM, LLC | 04/10/2024 | LUCEMYRA .18mg 36 Tablet | 78670005036 | Single Source Drug | ||||
| Rx0000443 | USWM, LLC | 04/10/2024 | LUCEMYRA .18mg 96 Tablet | 78670005096 | Single Source Drug | ||||
| Rx0000450 | Vericel Corporation | 10/23/2024 | MACI; (Autologous Cultured Chondrocytes on Porcine Collagen Membrane) 1 BAG in 1 BOX (69866-1030-5) > 1 BOTTLE, PLASTIC in 1 BAG (69866-1030-4) > 1 IMPLANT in 1 BOTTLE, PLASTIC (69866-1030-3) | 69866103005 | 11/25/2033 | Single Source Drug | Please note that while Vericel acquired MACI in 2014, the product was not launched until 06/27/2017, under the NDC # 69866-1030-01. The product was relabeled and given a new NDC # 69866-1030-05 with a market entry date 05/10/2021. | ||
| Rx0000450 | Vericel Corporation | 10/23/2024 | MACI; (Autologous Cultured Chondrocytes on Porcine Collagen Membrane) 2 BAG in 1 BOX > 1 BOTTLE, PLASTIC in 1 BAG (69866-1030-7) > 1 IMPLANT in 1 BOTTLE, PLASTIC (69866-1030-6) | 69866103008 | 11/25/2033 | Single Source Drug | Please note that while Vericel acquired MACI in 2014, the product was not launched until 06/27/2017, under the NDC # 69866-1030-02. The product was relabeled and given a new NDC # 69866-1030-08 with a market entry date 05/10/2021. | ||
| Rx0000155 | Vertical Pharmaceuticals, LLC | 04/24/2024 | Corvite 150 Oral Tablet - package size 30 | 68025005230 | 04/21/2029 | Non-innovator Multiple Source Drug | Drug Developed by Vertical Pharmaceuticals | ||
| Rx0000155 | Vertical Pharmaceuticals, LLC | 04/24/2024 | Corvite FE package size 30 | 68025006030 | 04/27/2029 | Non-innovator Multiple Source Drug | Drug Developed by Vertical Pharmaceuticals | ||
| Rx0000155 | Vertical Pharmaceuticals, LLC | 04/24/2024 | Dsuvia - sublingual sufentanil citrate tablet 30 mcg, package size 1 | 61621043001 | 2019 | 02/02/2038 | Single Source Drug | ||
| Rx0000155 | Vertical Pharmaceuticals, LLC | 04/24/2024 | Dsuvia - sublingual sufentanil citrate tablet 30 mcg, package size 10 | 61621043011 | 2019 | 02/02/2038 | Single Source Drug | ||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Caduet Tabs 10mg/10mg 30s | 00069781030 | Innovator Multiple Source Drug | This NDC is a result of an NDC change for previous product (00069-2160-30). 00069-2160-30 is a discontinued NDC effective August 31, 2022 and does not appear on Viatris analysis for NDCs to report ashe product was off market and not subject to this price change. Viatris is reporting this NDC on this report in an abundance of caution and in the interest of supporting Californias Drug Price Transparency Program. Viatris reserves the right on future reports to reassess this reporting obligation for NDC changes.This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Caduet Tabs 10mg/20mg 30s-New NDC | 00069723230 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Caduet Tabs 10mg/20mg 30s-Old NDC | 00069218030 | Innovator Multiple Source Drug | 00069-2180-30 is a discontinued NDC effective April 30, 2023 and would typically not appear on Viatris analysis for NDCs to report. Viatris is reporting this NDC on this report in an abundance of caution and in the interest of supporting Californias Drug Price Transparency Program. Viatris reserves the right on future reports to reassess this reporting obligation for discontinued NDCs. This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Caduet Tabs 10mg/40mg 30s-New NDC | 00069765430 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Caduet Tabs 10mg/40mg 30s-Old NDC | 00069225030 | Innovator Multiple Source Drug | 00069-2250-30 is a discontinued NDC effective July 31, 2023 and would typically not appear on Viatris analysis for NDCs to report. Viatris is reporting this NDC on this report in an abundance of caution and in the interest of supporting Californias Drug Price Transparency Program. Viatris reserves the right on future reports to reassess this reporting obligation for discontinued NDCs. This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Caduet Tabs 10mg/80mg 30s-New NDC | 00069747630 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Caduet Tabs 10mg/80mg 30s-Old NDC | 00069227030 | Innovator Multiple Source Drug | 00069-2270-30 is a discontinued NDC effective April 30, 2023 and would typically not appear on Viatris analysis for NDCs to report. Viatris is reporting this NDC on this report in an abundance of caution and in the interest of supporting Californias Drug Price Transparency Program. Viatris reserves the right on future reports to reassess this reporting obligation for discontinued NDCs. This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Caduet Tabs 5mg/10mg 30s-New NDC | 00069618030 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Caduet Tabs 5mg/10mg 30s-Old NDC | 00069215030 | Innovator Multiple Source Drug | 00069-2150-30 is a discontinued NDC effective April 30, 2023 and would typically not appear on Viatris analysis for NDCs to report. Viatris is reporting this NDC on this report in an abundance of caution and in the interest of supporting Californias Drug Price Transparency Program. Viatris reserves the right on future reports to reassess this reporting obligation for discontinued NDCs. This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Caduet Tabs 5mg/20mg 30s-New NDC | 00069632330 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Caduet Tabs 5mg/20mg 30s-Old NDC | 00069217030 | Innovator Multiple Source Drug | 00069-2170-30 is a discontinued NDC effective April 30, 2023 and would typically not appear on Viatris analysis for NDCs to report. Viatris is reporting this NDC on this report in an abundance of caution and in the interest of supporting Californias Drug Price Transparency Program. Viatris reserves the right on future reports to reassess this reporting obligation for discontinued NDCs. This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Caduet Tabs 5mg/40mg 30s-New NDC | 00069656530 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Caduet Tabs 5mg/40mg 30s-Old NDC | 00069219030 | Innovator Multiple Source Drug | 00069-2190-30 is a discontinued NDC effective April 30, 2023 and would typically not appear on Viatris analysis for NDCs to report. Viatris is reporting this NDC on this report in an abundance of caution and in the interest of supporting Californias Drug Price Transparency Program. Viatris reserves the right on future reports to reassess this reporting obligation for discontinued NDCs. This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Caduet Tabs 5mg/80mg 30s-New NDC | 00069674730 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Caduet Tabs 5mg/80mg 30s-Old NDC | 00069226030 | Innovator Multiple Source Drug | 00069-2260-30 is a discontinued NDC effective April 30, 2023 and would typically not appear on Viatris analysis for NDCs to report. Viatris is reporting this NDC on this report in an abundance of caution and in the interest of supporting Californias Drug Price Transparency Program. Viatris reserves the right on future reports to reassess this reporting obligation for discontinued NDCs. This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Cardura Tabs 1mg 100s | 00049241010 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Cardura Tabs 2mg 100s | 00049251210 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Cardura Tabs 4mg 100s | 00049261410 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Cardura Tabs 8mg 100s-New NDC | 00049271610 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Cardura Tabs 8mg 100s-Old NDC | 00049278066 | Innovator Multiple Source Drug | 00049-2780-66 is a discontinued NDC effective September 30, 2023 and would typically not appear on Viatris analysis for NDCs to report. Viatris is reporting this NDC on this report in an abundance of caution and in the interest of supporting Californias Drug Price Transparency Program. Viatris reserves the right on future reports to reassess this reporting obligation for discontinued NDCs. This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Cardura XL Tabs 4mg 30s | 00049204010 | Single Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Cardura XL Tabs 8mg 30s-New NDC | 58151007993 | Single Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Cardura XL Tabs 8mg 30s-Old NDC | 00049208010 | Single Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Celebrex Caps 100mg 100s | 00025152031 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Celebrex Caps 100mg 500s | 00025152051 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Celebrex Caps 100mg UD100 | 00025152034 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Celebrex Caps 200mg 100s-New NDC | 58151008401 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Celebrex Caps 200mg 100s-Old NDC | 00025152531 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Celebrex Caps 200mg 500s | 00025152551 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Celebrex Caps 200mg UD100 | 00025152534 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Celebrex Caps 400mg 60s-New NDC | 58151008591 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Celebrex Caps 400mg 60s-Old NDC | 00025153002 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Celebrex Caps 400mg UD100-New NDC | 58151008588 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Celebrex Caps 400mg UD100-Old NDC | 00025153001 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Celebrex Caps 50mg 60s-New NDC | 58151008291 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Celebrex Caps 50mg 60s-Old NDC | 00025151501 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Dilantin ER Caps 100mg 1000s | 00071036932 | Non-innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Dilantin ER Caps 100mg 100s | 00071036924 | Non-innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Dilantin ER Caps 100mg UD100 | 00071036940 | Non-innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Dilantin ER Caps 30mg 100s | 00071374066 | Non-innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Dilantin Infatabs 50mg 100s | 00071000724 | Non-innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Dilantin Infatabs 50mg UD100 | 00071000740 | Non-innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Dilantin-125 Oral Suspension 125mg/5mL 237mL | 00071221435 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Effexor XR Caps 150mg 30s | 00008083621 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Effexor XR Caps 150mg 90s | 00008083622 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Effexor XR Caps 37.5mg 30s | 00008083721 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Effexor XR Caps 37.5mg 90s | 00008083722 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Effexor XR Caps 75mg 30s | 00008083321 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Effexor XR Caps 75mg 90s | 00008083322 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Geodon Caps 20mg 60s | 00049035260 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Geodon Caps 40mg 60s-New NDC | 00049035460 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Geodon Caps 40mg 60s-Old NDC | 00049005460 | Innovator Multiple Source Drug | 00049-0054-60 is a discontinued NDC effective January 31, 2024 and would typically not appear on Viatris analysis for NDCs to report. Viatris is reporting this NDC on this report in an abundance of caution and in the interest of supporting Californias Drug Price Transparency Program. Viatris reserves the right on future reports to reassess this reporting obligation for discontinued NDCs. This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Geodon Caps 60mg 60s | 00049035660 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Geodon Caps 80mg 60s | 00049035860 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Geodon Injection 20mg/mL SDV 10PK | 00049392083 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Inspra Tabs 25mg 30s | 00025171001 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Inspra Tabs 50mg 30s | 00025172003 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Lyrica Caps 100mg 90s | 00071101568 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Lyrica Caps 100mg UD100 | 00071101541 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Lyrica Caps 150mg 90s | 00071101668 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Lyrica Caps 150mg UD100 | 00071101641 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Lyrica Caps 200mg 90s | 00071101768 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Lyrica Caps 225mg 90s | 00071101968 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Lyrica Caps 25mg 90s | 00071101268 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Lyrica Caps 300mg 90s | 00071101868 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Lyrica Caps 50mg 90s | 00071101368 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Lyrica Caps 50mg UD100 | 00071101341 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Lyrica Caps 75mg 90s | 00071101468 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Lyrica Caps 75mg UD100 | 00071101441 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Lyrica CR Tabs 165mg 30s | 00071102701 | 05/02/2027 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | ||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Lyrica CR Tabs 330mg 30s | 00071102901 | 05/02/2027 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | ||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Lyrica CR Tabs 82.5mg 30s | 00071102601 | 05/02/2027 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | ||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Neurontin Caps 100mg 100s | 00071080324 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Neurontin Caps 300mg 100s | 00071080524 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Neurontin Caps 400mg 100s | 00071080624 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Neurontin Tabs 600mg 100s | 00071051324 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Neurontin Tabs 800mg 100s | 00071040124 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Nitrostat Sublingual Tabs 0.3mg 100s | 00071041724 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Nitrostat Sublingual Tabs 0.4mg 100s | 00071041824 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Nitrostat Sublingual Tabs 0.4mg 100s (Convenience Pack) | 00071041813 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Nitrostat Sublingual Tabs 0.6mg 100s | 00071041924 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Norvasc Tabs 10mg 90s | 00069154068 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Norvasc Tabs 10mg UD100 | 00069154041 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Norvasc Tabs 2.5mg 90s | 00069152068 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Norvasc Tabs 5mg 300s | 00069153072 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Norvasc Tabs 5mg 90s | 00069153068 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Norvasc Tabs 5mg UD100 | 00069153041 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Relpax Tabs 20mg 6s | 00049233045 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Relpax Tabs 40mg 12s | 00049234005 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Relpax Tabs 40mg 6s | 00049234045 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Revatio Injection 0.8mg/mL 12.5mL | 00069033801 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Revatio Tabs 20mg 90s | 00069419068 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Xalatan Ophthalmic Drops 0.005% 2.5mL | 00013830304 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Xanax Tabs 0.25mg 100s | 00009002901 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Xanax Tabs 0.25mg 500s | 00009002902 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Xanax Tabs 0.5mg 100s | 00009005501 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Xanax Tabs 0.5mg 500s | 00009005503 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Xanax Tabs 1mg 100s | 00009009001 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Xanax Tabs 1mg 500s | 00009009004 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Xanax Tabs 2mg 100s | 00009009401 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Xanax XR Tabs 0.5mg 60s | 00009005707 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Xanax XR Tabs 1mg 60s | 00009005907 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Xanax XR Tabs 2mg 60s | 00009006607 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Xanax XR Tabs 3mg 60s | 00009006807 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Zoloft Tabs 100mg 30s | 00049491030 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Zoloft Tabs 100mg UD100 | 00049491041 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Zoloft Tabs 25mg 30s | 00049496030 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Zoloft Tabs 50mg 30s | 00049490030 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000502 | Viatris Specialty LLC | 04/30/2024 | Zoloft Tabs 50mg UD100 | 00049490041 | Innovator Multiple Source Drug | This product does not meet the definition of a product acquisition as this product was included as part of the combination of Pfizers Upjohn business and Mylan to form Viatris. Viatris was formed through a Reverse Morris Trust transaction, pursuant to which Upjohn Inc. was spun off to Pfizer's stockholders by way of a pro rata distribution and immediately thereafter combined with Mylan effective on November 16, 2020, at which time the combined company was renamed Viatris. (see https://newsroom.viatris.com/2020-10-30-Mylan-and-Pfizer-Receive-Clearance-from-the-U-S-Federal-Trade-Commission-for-Proposed-Combination-of-Mylan-and-Upjohn) | |||
| Rx0000066 | ViiV Healthcare | 03/31/2024 | DOVATO TAB 50-300MG 30 Tablets per BOTTLE | 49702024613 | 01/24/2031 | Single Source Drug | Note on Patent Expiration Date: Pursuant to Sec. 96070(d), if the drug is under patent, the patent expiration date is provided. The date provided is the latest expiration date of all patents listed with the USFDA under 21 CFR 314.53. Note on Acquisition Fields: This drug was developed by ViiV Healthcare, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, WAC_YEAR_PRIOR_TO_ACQ, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. | ||
| Rx0000066 | ViiV Healthcare | 03/31/2024 | JULUCA TAB 50-25MG 30 Tablets per BOTTLE | 49702024213 | 01/24/2031 | Single Source Drug | Note on Patent Expiration Date: Pursuant to Sec. 96070(d), if the drug is under patent, the patent expiration date is provided. The date provided is the latest expiration date of all patents listed with the USFDA under 21 CFR 314.53. Note on Acquisition Fields: This drug was developed by ViiV Healthcare, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, WAC_YEAR_PRIOR_TO_ACQ, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. | ||
| Rx0000066 | ViiV Healthcare | 03/31/2024 | RUKOBIA TAB 600MG ER 60 Tablets per BOTTLE | 49702025018 | 11/19/2027 | Single Source Drug | Note on Patent Expiration Date: Pursuant to Sec. 96070(d), if the drug is under patent, the patent expiration date is provided. The date provided is the latest expiration date of all patents listed with the USFDA under 21 CFR 314.53. Note on Acquisition Fields: This drug was developed by ViiV Healthcare, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, WAC_YEAR_PRIOR_TO_ACQ, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. | ||
| Rx0000066 | ViiV Healthcare | 03/31/2024 | TIVICAY PD TAB 5MG 60 Tablets per BOTTLE | 49702025537 | 06/08/2030 | Single Source Drug | Note on Patent Expiration Date: Pursuant to Sec. 96070(d), if the drug is under patent, the patent expiration date is provided. The date provided is the latest expiration date of all patents listed with the USFDA under 21 CFR 314.53. Note on Acquisition Fields: This drug was developed by ViiV Healthcare, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, WAC_YEAR_PRIOR_TO_ACQ, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. | ||
| Rx0000066 | ViiV Healthcare | 03/31/2024 | TIVICAY TAB 50MG 30 Tablets per BOTTLE | 49702022813 | 06/08/2030 | Single Source Drug | Note on Patent Expiration Date: Pursuant to Sec. 96070(d), if the drug is under patent, the patent expiration date is provided. The date provided is the latest expiration date of all patents listed with the USFDA under 21 CFR 314.53. Note on Acquisition Fields: This drug was developed by ViiV Healthcare, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, WAC_YEAR_PRIOR_TO_ACQ, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. | ||
| Rx0000066 | ViiV Healthcare | 03/31/2024 | TRIUMEQ TAB 600-50-300MG 30 Tablets per BOTTLE | 49702023113 | 06/08/2030 | Single Source Drug | Note on Patent Expiration Date: Pursuant to Sec. 96070(d), if the drug is under patent, the patent expiration date is provided. The date provided is the latest expiration date of all patents listed with the USFDA under 21 CFR 314.53. Note on Acquisition Fields: This drug was developed by ViiV Healthcare, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, WAC_YEAR_PRIOR_TO_ACQ, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. | ||
| Rx0000223 | Woodward Pharma Services LLC | 03/31/2024 | Lovaza (omega-3-acid ethyl esters) Capsules, 1g, 120 CT | 69784042012 | 2016 | Innovator Multiple Source Drug | |||
| Rx0000380 | Xeris Pharmaceuticals, INC. | 03/31/2024 | Keveyis Oral Tablet 50 MG, | 72065000101 | Single Source Drug | Keveyis was relabeled from 71090-0001-01 to 72065-0001-01 with an effective date of 12/15/2022. 72065-0001-01 is the NDC that will be used moving forward. | |||
| Rx0000380 | Xeris Pharmaceuticals, INC. | 03/31/2024 | Keveyis Oral Tablet 50 MG, Dichlorphenamide Tab 50 MG, 100 Each, Bottle | 71090000101 | Single Source Drug | Keveyis was relabeled from 71090-0001-01 to 72065-0001-01 with an effective date of 12/15/2022. 72065-0001-01 is the NDC that will be used moving forward. | |||
| Rx0000380 | Xeris Pharmaceuticals, INC. | 10/09/2024 | Recorlev Oral Tablet 150 MG 50 per bottle | 72065000301 | 03/02/2040 | Single Source Drug | |||
| Rx0000163 | Zyla Life Sciences | 07/29/2024 | Sprix (ketorolac tromethamine) 15.75mg/1 Spray, 8 Sprays / Bottle (1 Bottle) | 69344014463 | Innovator Multiple Source Drug | Product not acquired in last 5 years. | |||
| Rx0000163 | Zyla Life Sciences | 07/29/2024 | Sprix (ketorolac tromethamine) 15.75mg/1 Spray, 8 Sprays per Bottle (5 Bottles per Carton) | 69344014443 | Innovator Multiple Source Drug | Product not acquired in last 5 years. | |||
| None | None | None | None | None | None |